Plenary Session:

R. T. Oliver, G. M. Mead, P. J. Fogarty, S. P. Stenning, and MRC TE19 and EORTC 30982 trial collaborators

Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214)
J Clin Oncol (Meeting Abstracts) 2008 26: 1. [Abstract]  

E. Van Cutsem, I. Lang, G. D'haens, V. Moiseyenko, J. Zaluski, G. Folprecht, S. Tejpar, O. Kisker, C. Stroh, and P. Rougier

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
J Clin Oncol (Meeting Abstracts) 2008 26: 2. [Abstract]  

R. Pirker, A. Szczesna, J. von Pawel, M. Krzakowski, R. Ramlau, K. Park, U. Gatzemeier, E. Bajeta, M. Emig, and J. R. Pereira

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
J Clin Oncol (Meeting Abstracts) 2008 26: 3. [Abstract]  

M. Gnant, B. Mlineritsch, W. Schippinger, G. Luschin-Ebengreuth, S. Poestlberger, C. Menzel, R. Jakesz, E. Kubista, C. Marth, R. Greil on behalf of the ABCSG

Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12
J Clin Oncol (Meeting Abstracts) 2008 26: LBA4. [Abstract]  

Breast Cancer–Local-Regional and Adjuvant Therapy:

J. R. Bernard, Jr., L. A. Vallow, E. R. DePeri, D. G. Feigel, S. Amar, S. J. Buskirk, and E. A. Perez

Mammographically occult contralateral breast carcinoma detected by magnetic resonance imaging in the elderly
J Clin Oncol (Meeting Abstracts) 2008 26: 500. [Abstract]  

J. L. Grabinski, G. Chisholm, L. S. Smith, R. L. Drengler, S. Kalter, G. Rodriguez, A. Garner, J. Cooper, B. Pollock, and J. Kuhn

ER alpha genotypes and breast cancer recurrence
J Clin Oncol (Meeting Abstracts) 2008 26: 501. [Abstract]  

M. J. Ellis, Y. Tao, J. Luo, J. Hoog, M. Watson, D. C. Allred, P. S. Bernard, T. O. Nielsen, C. M. Perou, J. Olson, and Neoadjuvant Letrozole Study Group

A poor prognosis ER and HER2-negative, nonbasal, breast cancer subtype identified through postneoadjuvant endocrine therapy tumor profiling
J Clin Oncol (Meeting Abstracts) 2008 26: 502. [Abstract]  

B. K. Rack, C. Schindlbeck, A. Schneeweiss, J. Hilfrich, R. Lorenz, M. W. Beckmann, K. Pantel, W. Lichtenegger, H. L. Sommer, and W. J. Janni

Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: The German SUCCESS-Trial
J Clin Oncol (Meeting Abstracts) 2008 26: 503. [Abstract]  

L. Gianni, W. Eiermann, L. Pusztai, V. F. Semiglazov, B. Hoegel, A. Koehler, G. Manikhas, M. Bates, P. Valagussa, and J. Baselga

Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)
J Clin Oncol (Meeting Abstracts) 2008 26: 504. [Abstract]  

C. J. Poole, L. Hiller, H. C. Howard, J. A. Dunn, P. Canney, A. M. Wardley, M. J. Kennedy, R. E. Coleman, R. C. Leonard, H. M. Earl, and tAnGo trial collaborators

tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 506. [Abstract]  

H. B. Muss, D. L. Berry, C. Cirrincione, M. Theodoulou, A. Mauer, H. Cohen, A. H. Partridge, L. Norton, C. A. Hudis, E. P. Winer, and North American Breast Cancer Intergroup

Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907
J Clin Oncol (Meeting Abstracts) 2008 26: 507. [Abstract]  

F. J. Gilbert, S. M. Astley, M. G. Gillan, O. F. Agbaje, M. G. Wallis, J. James, C. R. Boggis, S. W. Duffy, and CADET II group

CADET II: A prospective trial of computer-aided detection (CAD) in the UK Breast Screening Programme
J Clin Oncol (Meeting Abstracts) 2008 26: 508. [Abstract]  

R. Katipamula, T. L. Hoskin, J. C. Boughey, A. C. Degnim, C. S. Grant, K. R. Brandt, C. L. Loprinzi, S. Pruthi, and M. P. Goetz

Trends in mastectomy rates at the Mayo Clinic Rochester: Effect of surgical year and preoperative MRI
J Clin Oncol (Meeting Abstracts) 2008 26: 509. [Abstract]  

M. C. Cheang, D. Voduc, S. Tyldesley, K. A. Gelmon, M. J. Ellis, P. S. Bernard, C. M. Perou, T. O. Nielsen, and H. F. Kennecke

Breast cancer molecular subtypes and locoregional recurrence
J Clin Oncol (Meeting Abstracts) 2008 26: 510. [Abstract]  

P. J. Goodwin, M. Ennis, K. I. Pritchard, J. Koo, and N. Hood

Frequency of vitamin D (Vit D) deficiency at breast cancer (BC) diagnosis and association with risk of distant recurrence and death in a prospective cohort study of T1–3, N0–1, M0 B
J Clin Oncol (Meeting Abstracts) 2008 26: 511. [Abstract]  

C. L. Shapiro, S. Halabi, G. Gibson, D. J. Weckstein, J. Kirshner, W. M. Sikov, E. P. Winer, C. A. Hudis, C. Isaacs, D. Weckstein, R. L. Schilsky, and E. Paskett

Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980
J Clin Oncol (Meeting Abstracts) 2008 26: 512. [Abstract]  

R. G. Gray, D. W. Rea, K. Handley, A. Marshall, M. G. Pritchard, P. Perry, H. M. Earl, C. J. Poole, A. Salman, M. Lee, and aTTom Collaborators

aTTom (adjuvant Tamoxifen—To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—Preliminary results
J Clin Oncol (Meeting Abstracts) 2008 26: 513. [Abstract]  

U. Nitz, J. B. Huober, B. Lisboa, N. Harbeck, H. Fischer, V. Moebus, G. Hoffmann, D. Augustin, E. Weiss, W. Kuhn, and West German Study Group /AGO-Mamma

Interim results of Intergroup EC-Doc Trial: A randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1–3 positive lymph nodes
J Clin Oncol (Meeting Abstracts) 2008 26: 515. [Abstract]  

L. Del Mastro, M. Costantini, A. Durando, A. Michelotti, S. Danese, E. Aitini, N. Olmeo, P. Pronzato, M. Venturini, and Gruppo Oncologico Nord Ovest - Mammella Intergruppo

Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group
J Clin Oncol (Meeting Abstracts) 2008 26: 516. [Abstract]  

M. Untch, P. A. Fasching, I. Bauerfeind, U. Conrad, O. Camara, W. Fett, W. Kuzeder, H. Lück, S. Loibl, and G. Von Minckwitz

PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery
J Clin Oncol (Meeting Abstracts) 2008 26: 517. [Abstract]  

C. T. Dang, N. U. Lin, D. Lake, M. N. Dickler, S. Modi, A. D. Seidman, R. M. Steingart, L. Norton, E. P. Winer, and C. A. Hudis

Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
J Clin Oncol (Meeting Abstracts) 2008 26: 518. [Abstract]  

E. L. Mayer, K. D. Miller, H. S. Rugo, J. M. Peppercorn, L. A. Carey, N. Ryabin, K. Josephs, E. P. Winer, and H. J. Burstein

A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 519. [Abstract]  

K. D. Miller, A. O'Neill, E. A. Perez, A. D. Seidman, and G. W. Sledge

Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104)
J Clin Oncol (Meeting Abstracts) 2008 26: 520. [Abstract]  

D. Mavroudis, N. Malamos, P. Papakotoulas, A. Adamou, C. Christophyllakis, N. Ziras, K. Syrigos, S. Kakolyris, C. Kouroussis, and V. Georgoulias

Randomized phase III trial comparing the sequential administration of docetaxel followed by epirubicin plus cyclophosphamide versus FE₇₅C as adjuvant chemotherapy in axillary lymph node-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 521. [Abstract]  

R. T. Chlebowski, G. L. Blackburn, M. K. Hoy, C. A. Thomson, A. E. Giuliano, P. McAndrew, C. A. Hudis, J. Butler, A. Shapiro, R. M. Elashoff, and Women's Intervention Nutrition Study

Survival analyses from the Women's Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome
J Clin Oncol (Meeting Abstracts) 2008 26: 522. [Abstract]  

R. Ismail-Khan, S. Minton, C. Cox, I. Sims, M. Lacevic, M. Gross-King, P. Xu, B. Carter, and P. N. Munster

Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 524. [Abstract]  

S. L. Hines, B. A. Mincey, J. A. Sloan, S. P. Thomas, E. G. Chottiner, C. L. Loprinzi, P. J. Atherton, M. D. Carlson, M. Salim, and E. A. Perez

N02C1: A phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 525. [Abstract]  

W. J. Tester, M. Valsecchi, S. Pomerantz, and R. Jaslow

Reduced risk of bone metastases in breast cancer patients treated with Cox-2 inhibitors
J Clin Oncol (Meeting Abstracts) 2008 26: 526. [Abstract]  

L. Pusztai, C. Hatzis, F. Cardoso, C. Sotiriou, V. Lazar, M. Piccart-Gebhart, G. N. Hortobagyi, L. van't Veer, and W. F. Symmans

Combined use of genomic prognostic and treatment response predictors in breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 527. [Abstract]  

S. Jiralerspong, S. H. Giordano, F. Meric-Bernstam, C. M. Barnett, S. Kau, M. C. Hung, G. N. Hortobagyi, and A. M. Gonzalez-Angulo

The effects of metformin on pathologic complete response (pCR) rates in diabetic breast cancer (BC) patients receiving neoadjuvant systemic therapy (NST)
J Clin Oncol (Meeting Abstracts) 2008 26: 528. [Abstract]  

A. Moreno-Aspitia, A. C. Dueck, W. L. Lingle, L. Kutteh, K. Tenner, N. E. Davidson, S. Martino, P. Kaufman, W. P. Carney, and E. A. Perez

Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2+BC): Results from the NCCTG adjuvant Intergroup trial N9831
J Clin Oncol (Meeting Abstracts) 2008 26: 529. [Abstract]  

J. Baselga, P. A. van Dam, R. Greil, H. Gardner, R. Bandaru, B. Molloy, J. Steinseifer, P. Phillips, J. M. Dixon, and H. S. Rugo

Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 530. [Abstract]  

M. N. Pollak, J. W. Chapman, K. I. Pritchard, J. E. Krook, H. S. Dhaliwal, T. A. Vandenberg, B. D. Norris, T. J. Whelan, C. F. Wilson, and L. E. Shepherd

NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 532. [Abstract]  

K. I. Pritchard, J. Julian, D. McCready, C. Holloway, K. Gulenchyn, N. Hodgson, P. Lovrics, N. Down, R. George, and M. N. Levine

A prospective study evaluating ¹⁸F-Fluorodeoxyglucose (¹⁸FDG) positron emission tomography (PET) in the assessment of axillary nodal spread in women undergoing sentinel lymph node biopsy (SLNB) for breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 533. [Abstract]  

A. L. Kong, K. K. Hunt, M. Yi, K. Weatherspoon, I. Bedrosian, W. Tereffe, R. Hwang, M. I. Ross, T. A. Buchholz, and F. Meric-Bernstam

The impact of IMC nodal drainage on primary breast cancer outcome
J Clin Oncol (Meeting Abstracts) 2008 26: 534. [Abstract]  

R. A. Freedman, Y. He, E. P. Winer, and N. L. Keating

Racial disparity trends in definitive primary therapy of early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 535. [Abstract]  

L. J. Pierce, K. A. Griffith, S. Buys, D. Gaffney, B. Haffty, M. Moran, M. Ben-David, J. Garber, S. D. Merajver, A. Meirovitz, and S. Domchek

Outcomes following breast conservation versus mastectomy in BRCA1/2 carriers with early-stage breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 536. [Abstract]  

T. B. Julian, S. R. Land, Y. Wang, F. Vicini, D. Arthur, E. P. Mamounas, J. P. Costantino, and N. Wolmark

Is boost therapy necessary in the treatment of DCIS?
J Clin Oncol (Meeting Abstracts) 2008 26: 537. [Abstract]  

A. Goyal, F. MacNeill, M. Keshtgar, K. Horgan, M. Kissin, G. Layer, G. Wishart, D. Brown, A. Purusotham, R. E. Mansel, and NEW START steering group

Injection of radioactive colloid and blue dye at the peri-areolar edge in the tumor quadrant for sentinel lymph node biopsy in breast cancer: Results of the UK NEW START training program
J Clin Oncol (Meeting Abstracts) 2008 26: 538. [Abstract]  

M. O. Meyers, N. Klauber-Demore, D. W. Ollila, E. C. Dees, B. F. Calvo, D. T. Moore, W. G. Cance, C. I. Sartor, and L. A. Carey

Locoregional control in locally advanced breast cancer using neoadjuvant chemotherapy followed by breast conservation
J Clin Oncol (Meeting Abstracts) 2008 26: 539. [Abstract]  

T. R. Evans, A. Yellowlees, I. Devine, H. M. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, J. P. Crown, R. C. Leonard, and J. L. Mansi

5-year outcome for women randomised in a phase III trial comparing doxorubicin (A) and cyclophosphamide (C) with doxorubicin and docetaxel (D) as primary medical therapy of breast cancer: An Anglo-Celtic Cooperative Oncology Group Study
J Clin Oncol (Meeting Abstracts) 2008 26: 540. [Abstract]  

W. F. Symmans, C. Hatzis, C. Liedtke, C. Desmedt, V. Valero, H. M. Kuerer, G. N. Hortobagyi, M. Piccart- Gebhart, L. Pusztai, and C. Sotiriou

Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 541. [Abstract]  

M. Martin, A. Iluch, M. Segui, A. Ruiz, M. Ramos, E. Adrover Cebrián, A. Rodriguez-Lescure, R. Grosse, L. Calvo Martínez, and A. Anton

Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial
J Clin Oncol (Meeting Abstracts) 2008 26: 542. [Abstract]  

M. R. Kell, J. Burke, and M. Morrow

Outcome following axillary staging in early breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 543. [Abstract]  

R. Hubbard, F. Peintinger, C. Liedtke, C. Hatzis, H. M. Kuerer, V. Valero, A. U. Buzdar, G. N. Hortobagyi, L. Pusztai, and W. F. Symmans

Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 544. [Abstract]  

V. Vinh-Hung, P. Truong, W. J. Janni, N. P. Nguyen, G. Vlastos, G. Cserni, M. E. Royce, W. A. Woodward, D. Promish, G. Storme, and C. Bouchardy

Effect of adjuvant radiation therapy on mortality according to primary tumor location in women with node-positive breast cancer: Is there a need to irradiate the internal mammary nodes?
J Clin Oncol (Meeting Abstracts) 2008 26: 545. [Abstract]  

G. K. Ellis, H. G. Bone, R. T. Chlebowski, D. Paul, S. Spadafora, J. Smith, M. Fan, and S. Jun

Subgroup analysis of a randomized, phase III study of the effect of denosumab in women with nonmetastatic breast cancer receiving aromatase inhibitor (AI) therapy
J Clin Oncol (Meeting Abstracts) 2008 26: 546. [Abstract]  

V. Lazar, F. André, C. Liedtke, B. Job, W. F. Symmans, A. Levy, S. Delaloge, P. Dessens, S. Michiels, and L. Pusztai

High resolution oligonucleotide array-CGH to identify therapeutic targets in breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 547. [Abstract]  

P. Hopwood, A. Ridolfi, S. Russell, C. Peckitt, J. M. Bliss, E. Hall, L. Johnson, P. Barrett-Lee, P. Ellis, D. A. Cameron on behalf of the TACT Trial Management Group

Impact on quality of life (QoL) of FEC-T compared with FEC or E-CMF: UK Taxotere as Adjuvant Chemotherapy Trial (TACT) 2-year follow-up
J Clin Oncol (Meeting Abstracts) 2008 26: 548. [Abstract]  

T. J. Vogl, R. Bauer, K. Eichler, and T. Gruber

Repeated transarterial chemoembolization (TACE) in the treatment of patients with liver metastases of breast cancer: Local tumor control and survival
J Clin Oncol (Meeting Abstracts) 2008 26: 549. [Abstract]  

M. J. Burnell, E. M. O'Connor, J. W. Chapman, M. N. Levine, K. I. Pritchard, P. S. O'Brien, K. J. Howarth, Z. Ding, T. J. Whelan, and L. E. Shepherd

Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial
J Clin Oncol (Meeting Abstracts) 2008 26: 550. [Abstract]  

W. J. Janni, E. Genss, H. L. Sommer, B. K. Rack, A. Schneeweiβ, M. Rezai, J. Hilfrich, A. Schneider, W. Lichtenegger, and M. W. Beckmann

The SUCCESS-Trial: Toxicity analysis of a phase III study evaluating the role of docetaxel and gemcitabine in the adjuvant therapy of breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 551. [Abstract]  

A. U. Buzdar and J. Cuzick

Is overall survival an appropriate endpoint in early breast cancer studies? Data from the ATAC study at 100-month median follow-up
J Clin Oncol (Meeting Abstracts) 2008 26: 552. [Abstract]  

T. P. Srokowski, S. Fang, G. N. Hortobagyi, and S. H. Giordano

Impact of diabetes mellitus on complications of chemotherapy and outcomes in older patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 553. [Abstract]  

J. Lester, D. Dodwell, O. P. Purohit, S. A. Gutcher, S. P. Ellis, R. Thorpe, J. M. Horsman, J. E. Brown, R. A. Hannon, and R. E. Coleman

Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study
J Clin Oncol (Meeting Abstracts) 2008 26: 554. [Abstract]  

I. H. Kunkler, U. Chetty, W. Jack, G. Kerr, J. Thomas, and J. M. Bartlett

Implications from long-term follow-up after breast-conserving therapy for patient selection and duration of follow-up: The Edinburgh experience
J Clin Oncol (Meeting Abstracts) 2008 26: 555. [Abstract]  

D. Azria, Y. Belkacemi, G. Romieu, S. Gourgou-Bourgade, K. Zaman, M. Gutowski, B. S. Rosenstein, C. Llacer Moscardo, C. Lemanski, and M. Ozsahin

Concurrent or sequential adjuvant hormonoradiotherapy after conservative surgery for early stage breast cancer: First results of the CO-HO-RT phase II randomized trial
J Clin Oncol (Meeting Abstracts) 2008 26: 556. [Abstract]  

L. J. Goldstein, R. J. Gray, R. Bugarini, S. Shak, S. S. Badve, F. L. Baehner, N. E. Davidson, G. W. Sledge, Jr., J. A. Sparano, and The North American Breast Cancer Intergroup

Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197
J Clin Oncol (Meeting Abstracts) 2008 26: 557. [Abstract]  

R. Yerushalmi, M. Kramer, S. Rizel, A. Sulkes, K. A. Gelmon, T. Granot, and S. M. Stemmer

Prospective evaluation of pulmonary function in patients with breast cancer on dose-dense chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 558. [Abstract]  

A. Y. Lin, J. W. Park, J. Scott, M. Melisko, A. Goga, M. M. Moasser, D. H. Moore, and H. S. Rugo

Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow
J Clin Oncol (Meeting Abstracts) 2008 26: 559. [Abstract]  

M. Zoubir, M. Mathieu, C. Liedtke, F. Bidard, S. Delaloge, L. Corley, M. Spielmann, L. Pusztai, F. André, and W. F. Symmans

Predictive biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue microarrays
J Clin Oncol (Meeting Abstracts) 2008 26: 560. [Abstract]  

A. Nichol, C. Bajdik, R. Yerushalmi, C. Speers, M. L'Esperance, S. Tyldesley, K. A. Gelmon, and I. Olivotto

Calculation of outcome estimates for synchronous bilateral breast cancer patients using Adjuvant!
J Clin Oncol (Meeting Abstracts) 2008 26: 561. [Abstract]  

S. A. Hurvitz, L. D. Bosserman, B. Leland-Jones, M. Thirwell, M. K. Allison, J. Barstis, D. Molthrop, E. Quan, G. Upadhyaya, and D. Slamon

A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or stage III breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 562. [Abstract]  

V. Roy, B. A. Pockaj, D. W. Northfelt, J. B. Allred, H. Liu, D. A. Nikcevich, B. I. Mattar, and E. A. Perez

N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 563. [Abstract]  

B. A. Mincey, T. Dentchev, J. A. Sloan, S. L. Hines, E. A. Perez, D. B. Johnson, P. L. Schaefer, H. Liu, S. P. Kahanic, and C. L. Loprinzi

N03CC—a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen
J Clin Oncol (Meeting Abstracts) 2008 26: 564. [Abstract]  

J. S. Vaidya, M. Baum, J. S. Tobias, S. Massarut, F. K. Wenz, B. Hilaris, T. Corica, U. Kraus-Tiefenbacher, M. Roncadin, M. Keshtgar, C. Saunders, and D. Joseph

Efficacy of targeted intraoperative radiotherapy (Targit) boost after breast-conserving surgery: Updated results
J Clin Oncol (Meeting Abstracts) 2008 26: 565. [Abstract]  

N. Mizuta, H. Nakajima, I. Fujiwara, K. Sakaguchi, and Y. Hachimine

Endoscopic skin-sparing breast-conserving surgery for breast cancer and immediate reconstruction with autologous tissue
J Clin Oncol (Meeting Abstracts) 2008 26: 566. [Abstract]  

I. B. Paz, S. Lau, C. Garberoglio, T. H. Luu, C. T. Chung, J. Mortimer, L. Wagman, J. Shen, P. Frankel, and G. Somlo

Nab-paclitaxel and carboplatin with or without trastuzumab (trast) as part of neoadjuvant chemotherapy (NCT) in patients (pts) with stage II-III breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 567. [Abstract]  

M. Miyashita, N. Kohno, S. Takao, K. Wakita, M. Konishi, I. Kokufu, H. Yoshimura, Y. Kasahara, S. Kohno, and Y. Minari

Randomized phase II clinical trial of comparison of epirubicin (E) plus cyclophosphamide (C) and weekly paclitaxel (P) as primary systemic therapy (PST) in patients (pts) with stages II and III breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 568. [Abstract]  

H. J. Kim, B. Keam, S. Im, H. S. Ham, D. Oh, J. Kim, W. S. Han, T. Kim, I. A. Park, and Y. J. Bang

Use of MDR1/ABCB1 single nucleotide polymorphism (SNP) as a prognostic factor for breast cancer patients receiving docetaxel + doxorubicin neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 569. [Abstract]  

S. Saha, S. J. Sirop, P. Fritz, S. Carpenter, K. Doan, D. Iddings, N. Krishnaiah, M. Ghanem, S. Seone, and D. Wiese

Comparative analysis of sentinel lymph node mapping in breast cancer by 1% lymphazurin vs. 1% methylene blue: A prospective study
J Clin Oncol (Meeting Abstracts) 2008 26: 570. [Abstract]  

C. Hatzis, W. F. Symmans, F. Lin, B. Zheng, K. Yan, D. J. Booser, Y. Gong, V. Valero, G. N. Hortobagyi, and L. Pusztai

Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancers
J Clin Oncol (Meeting Abstracts) 2008 26: 571. [Abstract]  

P. Hadji, M. Ziller, D. G. Kieback, W. Dornoff, H. Tessen, G. Weyer, and A. Hasenburg

Bone effects of exemestane versus tamoxifen within the TEAM Trial: Results of a prospective randomized bone substudy
J Clin Oncol (Meeting Abstracts) 2008 26: 572. [Abstract]  

S. Kulkarni, D. G. Hicks, N. Watroba, C. Murekeyisoni, R. Beck, B. Z. Ring, N. Estopinal, Jr., M. T. Schreeder, R. S. Seitz, and D. T. Ross

TLE3 as a biomarker for taxane sensitivity in breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 573. [Abstract]  

S. Delaloge, F. Bidard, Y. El Masmoudi, B. Bressac de Paillerets, O. Caron, C. Bourgier, J. Garbay, M. Spielmann, and F. André

BRCA1 germ-line mutation: Predictive of sensitivity to anthracyclin alkylating agents regimens but not to taxanes?
J Clin Oncol (Meeting Abstracts) 2008 26: 574. [Abstract]  

L. L. Hart, S. Badarinath, D. M. Waterhouse, B. Daniel, D. Raimondo, H. A. Burris, III, and D. A. Yardley

A multicenter study of 3 docetaxel regimens with bevacizumab as adjuvant therapy for breast cancer (BC): Preliminary results
J Clin Oncol (Meeting Abstracts) 2008 26: 575. [Abstract]  

F. Peintinger, C. Hatzis, J. Morkowski, R. Hubbard, C. T. Albarracin, G. Qureshi, L. Pusztai, and W. F. Symmans

Inter-pathologist agreement of residual cancer burden (rcb) assessment in breast cancer after treatment with preoperative chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 576. [Abstract]  

G. Frasci, G. D'Aiuto, P. Comella, R. Thomas, G. Iodice, G. Botti, M. Di Bonito, M. D'Aiuto, M. Rubulotta, and G. Comella

Weekly cisplatin-epirubicin-paclitaxel with G-CSF support in ER-negative large operable breast cancer. The NCI of Naples’ nine-year experience
J Clin Oncol (Meeting Abstracts) 2008 26: 577. [Abstract]  

J. Matro, C. Stankiewicz, M. Horn, W. Hwang, J. Green, I. Su, L. Velders, L. Sherman, and A. DeMichele

Clinical and genetic risk factors for bone loss in breast cancer survivors after adjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 578. [Abstract]  

I. Kuter, F. Sapunar, and P. McCormack

Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg: Results from the NEWEST study
J Clin Oncol (Meeting Abstracts) 2008 26: 579. [Abstract]  

V. Guarneri, A. Frassoldati, K. Cagossi, A. Bottini, A. Michelotti, L. Cavanna, G. Jovic, F. Piacentini, C. Oliva, and P. F. Conte

CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer—Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data
J Clin Oncol (Meeting Abstracts) 2008 26: 580. [Abstract]  

A. Mukherjee, M. Shehata, R. Sharma, E. Rakha, I. Ellis, G. Ball, B. M. Ball, and S. Chan

Predictive markers of response to neoadjuvant chemotherapy in locally advanced breast cancer (LAPC)
J Clin Oncol (Meeting Abstracts) 2008 26: 581. [Abstract]  

A. Haydaroglu, Y. Bolukbasi, S. Demirci, M. Esassolak, Z. Ozsaran, B. Aydin, and A. Aras

The prognostic impact of percentage of involved axillary lymph nodes for breast cancer patients treated with radiotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 582. [Abstract]  

V. R. Jacobs, M. Braun, N. Harbeck, S. Wagenpfeil, D. Sattler, R. Bernard, W. Kuhn, and A. Ihbe-Heffinger

Incremental costs of chemotherapy—Pharmacoeconomic results from the prospective adjuvant AGO-WSG intergroup EC->DOC trial comparing an anthracycline-docetaxel sequence to CMF in node-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 583. [Abstract]  

C. Bouchardy, E. Rapiti, M. Usel, S. Balmer-Majno, G. Vlastos, I. Neyroud-Caspar, H. Verkooijen, and V. Vinh-Hung

Important excess of cardiovascular mortality among breast cancer patients irradiated for inner quadrant tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 584. [Abstract]  

U. Rudloff, E. Brogi, J. P. Brockway, C. A. Wynveen, T. Nehhozina, A. Reiner, S. Patil, and K. J. Van Zee

Correlation of concurrent lobular neoplasia (LN) and ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ (DCIS) treated with breast-conserving therapy (BCT)
J Clin Oncol (Meeting Abstracts) 2008 26: 585. [Abstract]  

H. F. Kennecke, R. Yerushalmi, R. Woods, C. Speers, and K. A. Gelmon

Impact of multicentricity/multifocality on contralateral events and survival in invasive breast carcinoma
J Clin Oncol (Meeting Abstracts) 2008 26: 586. [Abstract]  

R. E. Coleman on behalf of the ATAC Trialists’ Group

Long-term effects of anastrozole on bone mineral density: Seven-year results from the ATAC trial
J Clin Oncol (Meeting Abstracts) 2008 26: 587. [Abstract]  

M. Zambetti, M. Mansutti, A. Llunch, C. Zamagni, E. De Benedictis, P. Gomez, L. Pavesi, C. Dittrich, P. Valagussa, and L. Gianni

First report of the European Cooperative Trial in Operable Breast Cancer II (ECTO II): Effects of primary chemo-endocrine therapy on local-regional disease in ER-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 588. [Abstract]  

M. R. Sierecki, H. S. Rugo, H. L. McArthur, T. A. Traina, M. Paulson, M. Rourke, L. Norton, A. D. Seidman, C. A. Hudis, and M. N. Dickler

Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 589. [Abstract]  

M. Brandi, Sr., S. Petroni, B. Stea, C. D'Amico, R. Necchia, R. Altieri, and F. Schittulli

Randomized study testing as adjuvant chemotherapy the same primary (neoadjuvant) epirubicin/vinorelbine (EN) regimen versus docetaxel (TXT) in inflammatory breast cancer (IBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 590. [Abstract]  

A. Lipton, J. W. Chapman, L. Demers, L. E. Shepherd, L. Han, C. F. Wilson, K. I. Pritchard, K. Leitzel, S. M. Ali, and M. N. Pollak

Use of elevated bone turnover to predict bone metastasis
J Clin Oncol (Meeting Abstracts) 2008 26: 591. [Abstract]  

P. Pedrazzoli, A. M. Gianni, G. Da Prada, A. Ballestrero, M. V. Martino, G. Rosti, M. Bregni, M. Aglietta, C. Bengala, and G. Martinelli

Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for breast cancer with > 9 positive nodes: 15-year results from the Italian registry
J Clin Oncol (Meeting Abstracts) 2008 26: 592. [Abstract]  

M. J. Martin, S. G. Chong, M. MacLochlainn-Row, N. Enright, A. Alaudin, D. S. Kamel, and A. M. Ibrahim

Contribution of estrogen and progesterone receptor status of carcinoma in situ to risk of subsequent development of invasive cancer and disease specific survival
J Clin Oncol (Meeting Abstracts) 2008 26: 593. [Abstract]  

G. Miolo, N. La Mura, M. D. Magri, D. Crivellari, S. Scalone, A. Freschi, R. Sorio, and A. Veronesi

Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a randomized study
J Clin Oncol (Meeting Abstracts) 2008 26: 594. [Abstract]  

K. Yamashita and K. Shimizu

Five axillary node groups beyond sentinel node observed by 3D-CT lymphography, evaluated for avoiding axillary dissection with sentinel node metastasis
J Clin Oncol (Meeting Abstracts) 2008 26: 595. [Abstract]  

J. Karnon, N. Mody-Patel, and S. Kaura

Reflecting time dependency in hazard rates to analyse the cost-effectiveness of letrozole or anastrozole versus tamoxifen as adjuvant therapies for early breast cancer in hormone receptor-positive (HR+) postmenopausal women: The U.S. perspective
J Clin Oncol (Meeting Abstracts) 2008 26: 596. [Abstract]  

G. M. Jacobson and B. J. Smith

A randomized trial of pentoxifylline and vitamin E versus standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter (TCM)
J Clin Oncol (Meeting Abstracts) 2008 26: 597. [Abstract]  

D. Berton-Rigaud, H. Roché, F. Penault-Llorca, N. Tubiana-Mathieu, J. Ferrero, B. Coudert, G. A. Milano, M. Mousseau, H. Homokos, and P. Fumoleau

Benefit of neoadjuvant capecitabine + epirubicin + cyclophosphamide (CEX) versus 5-FU + epirubicin + cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T)
J Clin Oncol (Meeting Abstracts) 2008 26: 598. [Abstract]  

A. Camerini, D. Amoroso, A. Capodanno, C. Graziani, S. Ricci, G. Bevilacqua, B. Faraglia, A. Cittadini, P. Collecchi, and A. Sgambato

Correlation of cyclin E expression with manganese superoxide dismutase expression and prediction of survival in early breast cancer patients receiving epirubicin-based adjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 600. [Abstract]  

H. Mukai, T. Watanabe, M. Mitsumori, H. Tsuda, S. Nakamura, N. Masuda, N. Yamamoto, T. Shibata, A. Sato, and K. Aogi

Safety and efficacy trial of preoperative sequential chemo-radiation therapy for the nonsurgical treatment (NST) in early breast cancer (EBC): Japan Clinical Oncology Group trial (JCOG0306)
J Clin Oncol (Meeting Abstracts) 2008 26: 601. [Abstract]  

L. M. Vargas-Roig, F. D. Cuello-Carrión, N. Fernández-Escobar, P. Daguerre, M. Leuzzi, J. Ibarra, F. E. Gago, S. B. Nadin, and D. R. Ciocca

Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 602. [Abstract]  

D. A. Yardley, R. C. Inhorn, D. Daniel, B. Daniel, Y. Naot, J. Zubkus, L. Simons, D. Knauer, V. Trieu, and N. Desai

Phase II study of neoadjuvant gemcitabine, epirubicin, and albumin-bound nab paclitaxel (GEA) in locally advanced breast cancer with SPARC tumor assessments
J Clin Oncol (Meeting Abstracts) 2008 26: 603. [Abstract]  

H. R. Chang, D. Slamon, J. A. Gornbein, and D. Chung

Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C)
J Clin Oncol (Meeting Abstracts) 2008 26: 604. [Abstract]  

N. Tagaya, A. Nakagawa, T. Kosuge, K. Hamada, K. Kubota, Y. Ishikawa, and T. Oyama

Sentinel lymph node identification using near-infrared fluorescence imaging and ultrasound in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 605. [Abstract]  

G. Cartei, L. Borgato, G. Lombardi, A. Cappetta, F. Bozza, S. Zovato, G. Zavagno, S. Mocellin, and G. Artioli

Phase II study of neoadjuvant gemcitabine (GC), pegylated liposomal doxorubicin (DX) and docetaxel (TT) in locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 606. [Abstract]  

K. Hisamatsu, W. Takiyama, R. Sakabe, Y. Satou, S. Saiki, H. Mukaida, Y. Yamashita, N. Hirabayashi, M. Kaneko, and T. Ono

Factors influencing 3D-MRI diagnosis in preoperative breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 607. [Abstract]  

F. Bidard, M. Mathieu, P. Chollet, I. Raoefils, C. Abrial, J. Dômont, M. Spielmann, S. Delaloge, F. André, and F. Penault-Llorca

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
J Clin Oncol (Meeting Abstracts) 2008 26: 608. [Abstract]  

J. A. Malmgren, M. K. Atwood, and H. G. Kaplan

Risk of local-regional and distant recurrence in triple-negative T1N0 breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 609. [Abstract]  

P. Garg, F. Rana, and T. H. Guthrie

Role of performance status and comorbidities as predictors of toxicity of adjuvant chemotherapy in elderly breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 610. [Abstract]  

R. H. Alvarez, S. Kau, E. A. Strom, A. A. Sahin, S. E. Singletary, D. J. Booser, M. Cristofanilli, F. J. Esteva, G. N. Hortobagyi, and V. Valero

Phase II study of primary systemic therapy (PST) with doxorubicin (D) and docetaxel (T), then surgery (S), and radiation (RT), followed by use of non-cross-resistant adjuvant chemotherapy (Adj CT) with CMF based on pathologic response, in patients (pts) with locally advanced breast cancer (LABC): Long-term results from study ID97–099, M. D. Anderson Cancer Center
J Clin Oncol (Meeting Abstracts) 2008 26: 611. [Abstract]  

C. Kurzeder, J. König, M. Wischnewsky, K. Koretz, P. Möller, T. Wiegel, H. J. Brambs, M. Blettner, and R. Kreienberg

Impact of guideline conform local-regional treatment on survival of breast cancer patients: An analyses of the BRENDA-study group
J Clin Oncol (Meeting Abstracts) 2008 26: 612. [Abstract]  

Y. Suh, C. Chun, S. Oh, B. Song, and S. Jung

Prevention of infection after TAC chemotherapy for node-positive breast cancer as an adjuvant therapy with or without ciprofloxacin
J Clin Oncol (Meeting Abstracts) 2008 26: 613. [Abstract]  

N. S. Bese, A. Y. Altinok, E. M. Ozsahin, S. Yildirim, N. Sut, T. Altug, A. Ober, and D. Azria

Aromatase inhibitors and radiation-induced lung fibrosis
J Clin Oncol (Meeting Abstracts) 2008 26: 614. [Abstract]  

S. Ohsumi, H. Inaji, Y. Ohashi, K. Suemasu, R. Nishimura, N. Masuda, S. Akashi-Tanaka, S. Murakami, T. Ikeda, T. Nishi, and Japanese Breast Conserving Treatment Study Group

Prospective study of wide local excision and endocrine therapy WithOut RadioTHerapy (WORTH) for node-negative, estrogen receptor-positive early breast cancer with negative histologic margins (WORTH trial, Protocol 1): Three-year interim results
J Clin Oncol (Meeting Abstracts) 2008 26: 615. [Abstract]  

R. Conforti, T. Boulet, G. Tomasic, M. Spielmann, S. Delaloge, R. Arriagada, A. S. Veillard, L. Zitvogel, S. Michiels, and F. André

Predictive value of MRP2, p53, bcl2 and topoisomerase II immunostainings for the efficacy of anthracyclines-based adjuvant chemotherapy in breast cancer: Results from two randomized trials
J Clin Oncol (Meeting Abstracts) 2008 26: 616. [Abstract]  

B. Lee, A. Lim, R. C. Leonard, J. Lewis, C. R. Coombes, and J. Stebbing

Indeterminate pulmonary nodules in breast cancer: Clinical significance and management
J Clin Oncol (Meeting Abstracts) 2008 26: 617. [Abstract]  

B. Arun, D. Atchley, J. Litton, L. Pusztai, V. Valero, G. N. Hortobagyi, and C. T. Albarracin

Response to neoadjuvant chemotherapy in BRCA1- and BRCA2-related breast cancers
J Clin Oncol (Meeting Abstracts) 2008 26: 618. [Abstract]  

W. Bal, M. Jarzab, E. Nowara, M. Kowalski, M. Kustra, and I. Cedrych

Breast cancer in young women (<35 years): The impact of age on the prognosis
J Clin Oncol (Meeting Abstracts) 2008 26: 619. [Abstract]  

S. J. Nicum, S. Sutherland, I. E. Smith, S. Ashley, and S. Johnston

Determination of the rates of neurological toxicity associated with the use of dose-dense (DD) paclitaxel-containing schedules in patients with early breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 620. [Abstract]  

Y. Suh, C. Chun, S. Oh, B. Song, and S. Jung

Comparison of one-day premedication for TAC chemotherapy with three-day regimen for node-positive breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 621. [Abstract]  

B. Keam, S. Im, J. Lim, D. Kim, D. Oh, J. Kim, T. Kim, I. A. Park, D. Noh, and Y. Bang

Comparison of axillary nodal ratios and absolute number of involved nodes as prognostic factors for stage II/III breast cancer treated with neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 622. [Abstract]  

A. Frassoldati, V. Guarneri, A. Bottini, K. Cagossi, L. Cavanna, G. Bisagni, G. Jovic, F. Piacentini, C. Oliva, and P. F. Conte

Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study
J Clin Oncol (Meeting Abstracts) 2008 26: 623. [Abstract]  

C. I. Sartor, R. J. Kimple, C. M. Kuzmiak, D. Pavic, J. Lian, X. S. Chang, D. T. Moore, R. F. Phipps, L. Esler, N. Klauber-Demore, and D. W. Ollila

Cosmetic outcomes following single-dose intraoperative radiotherapy for early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 624. [Abstract]  

A. Forero-Torres, J. Galleshaw, C. Jones, I. Percent, L. Nabell, J. Carpenter, C. Falkson, H. Krontiras, K. Bland, J. De Los Santos, and M. N. Saleh

A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 625. [Abstract]  

L. Livi, S. M. Magrini, I. Meattini, F. Paiar, S. Scoccianti, S. Bianchi, L. Cataliotti, and G. Biti

Risk factors for local-regional failure in patients with T1-T2 breast cancer after breast-conserving therapy. Indications for nodal irradiation
J Clin Oncol (Meeting Abstracts) 2008 26: 626. [Abstract]  

E. Raefsky, R. Castillo, A. Lahiry, D. S. Thompson, S. Hanson, C. Meng, D. Knauer, V. Trieu, N. Desai, and D. A. Yardley

Phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin-bound paclitaxel (nab paclitaxel) and carboplatin in HER2+ locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 627. [Abstract]  

A. Chan, D. Hastrich, D. Ingram, J. Anderson, T. Barham, A. van der Schaaf, D. Joseph, A. Redfern, A. Provis, and P. Willsher

Final results of XRP6976D: Preoperative TAC (docetaxel, doxorubicin, cyclophsophamide) in conjunction with the development of a standard protocol for the management of locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 628. [Abstract]  

M. Morrow, J. J. Graff, and S. J. Katz

Adoption of new breast cancer therapies: Is evidence important?
J Clin Oncol (Meeting Abstracts) 2008 26: 629. [Abstract]  

G. Welzel, E. Blank, U. Kraus-Tiefenbacher, A. Keller, F. Vorodi, C. Herskind, O. Tome, M. Sütterlin, and F. K. Wenz

The influence of the interval between IORT during breast-conserving surgery and external beam radiotherapy (EBRT) on late toxicity
J Clin Oncol (Meeting Abstracts) 2008 26: 630. [Abstract]  

A. M. Minisini, J. Menis, C. Andreetta, B. Alessi, G. Pascoletti, P. Driol, F. Valent, A. Piga, G. Fasola, and F. Puglisi

Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era
J Clin Oncol (Meeting Abstracts) 2008 26: 631. [Abstract]  

T. Delozier, J. P. Guastalla, E. C. Antoine, C. Roux, L. Mauriac, A. Fontana, and E. Vicaut

Long-term safety assessment of a cohort of postmenopausal women treated with anastrozole as adjuvant treatment for hormone-dependent breast cancer: Baseline data
J Clin Oncol (Meeting Abstracts) 2008 26: 632. [Abstract]  

K. Yamagami, T. Hashimoto, and M. Yamamoto

The efficacy of sentinel lymph node and lymphatic tracts detection using fluorescence navigation with indocyanine green in breast cancer: An analysis of 410 patients
J Clin Oncol (Meeting Abstracts) 2008 26: 633. [Abstract]  

E. Culakova, D. A. Wolff, M. S. Poniewierski, J. Crawford, D. C. Dale, and G. H. Lyman

Factors related to neutropenic events in early stage breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 634. [Abstract]  

S. De la Cruz, J. M. Aramendia, J. Espinós, O. Fernandez-Hidalgo, M. Santisteban, L. Arbea, J. Aristu, C. Garran, R. Martinez-Monge, F. Martinez-Regueira, and Y. Nieto

Phase II trial of sequential dose-dense epirubicin/cyclophosphamide (E/C) followed by docetaxel/capecitabine (D/X) as adjuvant or neoadjuvant chemotherapy for patients with HER2-negative breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 635. [Abstract]  

B. Kaufman, M. E. Trudeau, S. Johnston, A. Awada, K. L. Blackwell, T. Bachelot, V. Salazar, R. Westlund, M. Desilvio, and T. Zaks

Clinical activity of lapatinib monotherapy in patients with HER2+ relapsed/refractory inflammatory breast cancer (IBC): Final results of the expanded HER2+ cohort in EGF103009
J Clin Oncol (Meeting Abstracts) 2008 26: 636. [Abstract]  

P. G. Morris, M. N. Dickler, H. L. McArthur, T. A. Traina, B. Nulsen, R. M. Steingart, H. S. Rugo, L. Norton, C. A. Hudis, and C. T. Dang

Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 637. [Abstract]  

D. Rayson, J. I. Payne, P. J. Barnes, R. MacIntosh, M. Abdolell, T. Foley, T. Younis, and J. Caines

Clinical-pathologic characteristics of true interval and screen-detected breast cancer among participants in a Canadian breast screening program: A nested case-control study
J Clin Oncol (Meeting Abstracts) 2008 26: 638. [Abstract]  

T. Hashem, K. Kamal Eldin, H. Metwaly, and E. Elkholy

Prophylactic cranial irradiation (PCI) in high-risk breast cancer patients: Preliminary data
J Clin Oncol (Meeting Abstracts) 2008 26: 11501. [Abstract]  

M. Ignatiadis, M. Perraki, S. Apostolaki, N. Xenidis, E. Stathopoulos, E. Lianidou, M. E. Buyse, C. Sotiriou, V. Georgoulias, and D. Mavroudis

Circulating tumor cells (CTCs) monitoring in HER2-negative early breast cancer: Implications for secondary anti-HER2 adjuvant treatment strategies
J Clin Oncol (Meeting Abstracts) 2008 26: 11502. [Abstract]  

R. M. Layman, D. G. Thomas, M. S. Sabel, K. A. Griffith, D. El-Ashry, and A. F. Schott

Assessment of estrogen receptor expression by automated quantitative analysis in core biopsy and surgical specimens in ER negative, HER-2 positive breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11503. [Abstract]  

C. Farrell, A. M. Wardley, H. Mitchell, A. McGurk, V. Lau, B. Magee, J. Loncaster, A. Stewart, G. Wilson, P. Burt, and Christie Hospital Breast Disease Orientated Group

Analysis of a single institution series of 155 patients treated with adjuvant trastuzumab
J Clin Oncol (Meeting Abstracts) 2008 26: 11504. [Abstract]  

M. S. Raza, J. Younus, and S. Welch

Delivered relative dose intensity and febrile neutropenia rate with common adjuvant chemotherapy regimens: A review
J Clin Oncol (Meeting Abstracts) 2008 26: 11505. [Abstract]  

G. S. Sidhu, D. Bristol, N. Palanisamy, T. Lewis, N. Patel, B. Adamson, and A. S. Braverman

Omission of post-tumorectomy radiation (RT) for patients treated for invasive breast cancer in Caribbean nations
J Clin Oncol (Meeting Abstracts) 2008 26: 11506. [Abstract]  

R. Bollina, C. Cozzi, G. Beretta, and A. Corsini

Clinico-experimental correlations of triptorelin (TPR) based adjuvant treatment in premenopausal breast cancer patients (PBCP)
J Clin Oncol (Meeting Abstracts) 2008 26: 11507. [Abstract]  

A. Ferro, A. Caldara, R. Triolo, M. Barbareschi, E. Leonardi, O. Caffo, M. Pellegrini, M. Frisinghelli, D. Bernardi, and E. Galligioni

Microinvasive breast cancer (Tmic): A descriptive mono-institutional report
J Clin Oncol (Meeting Abstracts) 2008 26: 11508. [Abstract]  

J. Iturbe, J. P. Leone, A. O. Zwenger, J. A. Lacava, C. T. Vallejo, R. R. Scuteri, P. Cabaleiro, J. Castro, and B. A. Leone

Treatment of stage I breast cancer (T1N0M0): A long-term follow-up study
J Clin Oncol (Meeting Abstracts) 2008 26: 11509. [Abstract]  

M. Margelí, B. Cirauqui, E. Castellà, G. Tapia, C. Costa, A. Gimenez-Capitan, O. Etxaniz, A. Ariza, M. Tarón, and R. Rosell

Use of BRCA1 mRNA expression levels to predict survival in breast cancer patients (p) treated with neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 11510. [Abstract]  

R. Gingrich, A. Thomas, B. J. Smith, and M. Silverman

Autologous stem cell transplantation (ASCT) for locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC): University of Iowa (UI) experience 1992–2007
J Clin Oncol (Meeting Abstracts) 2008 26: 11511. [Abstract]  

T. Vidaurre, M. Olivera, H. Gómez, J. Pinto, F. Doimi, R. Velarde, J. Abugattas, J. Leon, L. Mas, and C. Vigil

Effect of dose intensity and overexpression of topoisomerase iia on survival in patients with locally advanced breast cancer treated with anthracyclines
J Clin Oncol (Meeting Abstracts) 2008 26: 11512. [Abstract]  

G. Atalay Basaran, D. Cabuk, M. Teomete, B. Gulluoglu, H. Kaya, F. Dane, P. F. Yumuk, and N. S. Turhal

Benefit from adjuvant anthracyclines according to hormone receptor status
J Clin Oncol (Meeting Abstracts) 2008 26: 11513. [Abstract]  

J. G. Mata, S. Antolín, J. R. Mel, M. Ramos, A. García-Palomo, M. C. Almanza, L. De Paz, L. Calvo Martínez, E. Álvarez, and A. González-Quintas

Neoadyuvant therapy with dose-dense (DD) docetaxel (T) and doxorubicin/cyclophosphamide (AC) in locally advanced breast cancer (LABC)
J Clin Oncol (Meeting Abstracts) 2008 26: 11514. [Abstract]  

V. Massard, G. MacGrogan, M. Debled, C. Tunon de Lara, and L. Mauriac

Prognosis and survival of patients with T1a breast carcinoma: A single center retrospective study
J Clin Oncol (Meeting Abstracts) 2008 26: 11515. [Abstract]  

P. Chollet, C. Abrial, X. Durando, M. Mouret-Reynier, O. Tacca, R. Delva, B. Coudert, B. Leduc, E. Villeneuve, and H. Curé

Sequential addition of a semi-intensive anthracycline-based regimen (TNCF) to docetaxel as neoadjuvant treatment of operable breast cancer: An update at five years
J Clin Oncol (Meeting Abstracts) 2008 26: 11516. [Abstract]  

M. Keshtgar, J. S. Tobias, J. S. Vaidya, N. Williams, C. Stacey, M. Metaxas, M. Douek, C. Brew-Graves, and M. Baum

Breast cancer patients treated with intra-operative radiotherapy [IORT] alone when conventional external beam radiation therapy [EBRT] was not possible
J Clin Oncol (Meeting Abstracts) 2008 26: 11517. [Abstract]  

E. Morgenfeld, F. Tognelli, N. Gercovich, C. García Gerardi, S. Carnaval, E. Gil Deza, E. J. Rivarola, and F. G. Gercovich

Second and third primary tumors in early breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 11518. [Abstract]  

A. Espinoza, L. E. Damon, J. L. Wolf, H. S. Rugo, E. O. Gold, C. A. Ries, and C. A. Linker

High-dose chemotherapy and autologous hematopoietic stem cell transplant for women with breast cancer and 10 or more involved axillary lymph nodes: Long-term follow-up
J Clin Oncol (Meeting Abstracts) 2008 26: 11519. [Abstract]  

M. Caleffi, M. C. Biesdorf-Pretto, J. P. Viegas-Butzke, R. A. Ribeiro, and M. S. Graudenz

Sentinel node pathology analysis in patients with breast cancer and clinical positive axilla
J Clin Oncol (Meeting Abstracts) 2008 26: 11520. [Abstract]  

S. Chumsri, S. C. Jeter, L. K. Jacobs, J. R. Lange, N. E. Davidson, L. A. Emens, J. H. Fetting, E. Gabrielson, Z. Zhang, and V. Stearns

Pathologic complete response (pCR) to preoperative sequential doxorubicin/cyclophosphamide (AC) and taxane (AC-T) or AC followed by paclitaxel and trastuzumab (AC-TH) in stage II-III HER2-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11521. [Abstract]  

D. Wadhwa, N. Fallah-Rad, D. Grenier, M. Krahn, T. Fang, R. Ahmadie, D. Lister, R. C. Arora, I. Barac, A. Morris, and D. S. Jassal

Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: A real world population-based study
J Clin Oncol (Meeting Abstracts) 2008 26: 11522. [Abstract]  

M. R. Guerra, J. R. Duarte-Cintra, M. T. Bustamante-Teixeira, and C. Domenge

Adjuvant chemotherapy for invasive nonmetastatic breast cancer in limited-resource countries: Evidence-based guidelines therapies versus allocation of resources matter
J Clin Oncol (Meeting Abstracts) 2008 26: 11523. [Abstract]  

F. E. Petracci, Sr. and R. D. Chacón

Invasive breast carcinoma in women 35 years: Clinical features, prognostic factors and clinical outcome related to hormone receptor status and Her2/neu expression
J Clin Oncol (Meeting Abstracts) 2008 26: 11524. [Abstract]  

H. Harputluoglu, O. Dizdar, F. Unsal Malas, L. Ozcakar, N. Bulut, Y. Ozisik, and K. Altundag

Aromatase inhibitor-associated arthralgia: Prevalence, clinical and serum parameters among Turkish postmenopausal breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 11525. [Abstract]  

D. Cabuk, G. Basaran, H. Kaya, B. Gulluoglu, M. Teomete, F. Dane, P. F. Yumuk, and N. S. Turhal

Clinical outcome of triple-negative (TN) breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 11526. [Abstract]  

H. A. Azim, Jr., R. A. Malek, I. Elattar, D. Elkheshen, and H. Azim

The relation between hormone receptor status and disease-free survival in adjuvant breast cancer: A multivariate analysis
J Clin Oncol (Meeting Abstracts) 2008 26: 11527. [Abstract]  

T. Saphner and S. Triest-Robertson

Non-alcoholic steatohepatitis (NASH) in patients with breast cancer and association with tamoxifen
J Clin Oncol (Meeting Abstracts) 2008 26: 11528. [Abstract]  

R. A. Somer, R. Dougherty, M. Koch, E. Rodler, K. Sharan, and G. Grana

Neoadjuvant treatment for operable breast cancer in the community: Applications of cooperative group trials
J Clin Oncol (Meeting Abstracts) 2008 26: 11529. [Abstract]  

A. Balmanoukian, Z. Zhang, S. C. Jeter, T. N. Tsangaris, A. C. Wolff, D. K. Armstrong, J. H. Fetting, M. Fackler, E. Gabrielson, V. Stearns, and Breast Cancer Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Outcomes of African American (AA) versus caucasian (CA) women with triple-negative (TN) breast cancer following preoperative anthracycline and taxane-based chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 11530. [Abstract]  

E. Hedayati, A. Schedin, H. Nyman, M. Albertsson, and B. I. Nilsson

The effects of breast cancer treatment on cognitive functions
J Clin Oncol (Meeting Abstracts) 2008 26: 11531. [Abstract]  

Z. Nadeem, A. Shaharyar, M. Hafeez, and S. Tahir

Gemcitabine-cisplatin-anastrozole concomitant chemo-hormonal treatment in locally advanced breast cancer in postmenopausal women
J Clin Oncol (Meeting Abstracts) 2008 26: 11532. [Abstract]  

H. A. McCarty, F. Green, J. I. Clarke, J. J. McAleer, and A. J. Clayton

Implementation of adjuvant trastuzumab in Northern Ireland: Patient selection and treatment tolerability
J Clin Oncol (Meeting Abstracts) 2008 26: 11533. [Abstract]  

M. E. Trudeau, L. Yeung, R. Iyer, S. Hertz, S. Gavura, and C. Sawka

Trends in trastuzumab utilization in Ontario: A single payer system
J Clin Oncol (Meeting Abstracts) 2008 26: 11534. [Abstract]  

A. Veerapaneni, M. Boisvert, A. Choi, and A. Aggarwal

Capecitabine and ABI-007 chemotherapy as neoadjuvant treatment of locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11535. [Abstract]  

H. Jinno, T. Ikeda, M. Mukai, and Y. Kitagawa

A phase II trial of capecitabine and docetaxel followed by 5-FU/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11536. [Abstract]  

S. Chabaud, O. Tredan, I. Treilleux, V. Bourdes, T. Gargi, D. Pérol, and T. Bachelot

Pathologic node involvement as a prognostic factor in HER2-amplified primary breast cancer (BC) patients (pts) treated without trastuzumab
J Clin Oncol (Meeting Abstracts) 2008 26: 11537. [Abstract]  

E. Tapen, F. E. Halberg, L. A. Champion, B. Davis CRA, S. C. Dutton, and S. A. Rosenthal

Treatment of locally recurrent or high-risk carcinoma of the breast with radiation therapy and weekly docetaxel given as a radiosensitizer
J Clin Oncol (Meeting Abstracts) 2008 26: 11538. [Abstract]  

A. Deptala, I. Cedrych, A. Polakiewicz-Gilowska, E. Nowara, and I. Domin

Male breast cancer: An analysis of clinical features, disease outcome and treatment efficacy
J Clin Oncol (Meeting Abstracts) 2008 26: 11539. [Abstract]  

Z. Tomasevic, Z. Rakocevic, S. Milosevic, Z. Tomasevic, Z. Zdrale, S. Vasovic, M. Matijasevic, N. Borojevic, and V. Lukic

Patterns of relapse during adjuvant trastuzumab therapy
J Clin Oncol (Meeting Abstracts) 2008 26: 11540. [Abstract]  

F. Recchia, G. Candeloro, S. Necozione, M. Sureda, M. Bratta, R. Bisegna, and S. Rea

Total estrogen blockade (TEB) plus adjuvant chemotherapy in high-risk estrogen receptor-positive (ER+) premenopausal breast cancer: Long term results of an ovarian protection study
J Clin Oncol (Meeting Abstracts) 2008 26: 11541. [Abstract]  

M. A. Cobleigh, K. L. Griem, and K. P. Siziopikou

Long term disease-free survival after stopping trastuzumab in trastuzumab-sensitive metastatic breast cancer patients treated with local-regional therapy
J Clin Oncol (Meeting Abstracts) 2008 26: 11542. [Abstract]  

P. G. Vigneri, G. L. Banna, G. Novello, N. Restuccia, E. Salomone, G. Privitera, S. Gangi, F. Ferraù, and C. Buscarino

Short course dose-dense (dd) epirubicin (E) and cyclophosphamide (C) as neo-adjuvant chemotherapy for stage II-IIIA breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 11543. [Abstract]  

P. Khosravi-Shahi, M. Mendez, R. Quiben, I. Palomero, Y. Izarzugaza, J. Belon, P. Garcia-Alfonso, and G. Perez-Manga

Phase II study of neoadjuvant treatment with docetaxel, doxorubicin and capecitabine (ATX) in locally advanced or inflammatory breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11544. [Abstract]  

A. Ghavamzadeh and S. Nadjar Najafi

Comparing doxorubicin plus cyclophosphamide (four courses) and CMF (three more courses) with doxorubicin plus cyclophosphamide (four courses) and paclitaxel plus epirubicin (three courses) as adjuvant therapy for operable breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11545. [Abstract]  

L. R. Henry, S. A. Prindiville, S. M. Swain, R. Cordes, and P. W. Soballe M.D.

The influence of a gene expression profile on breast cancer decisions
J Clin Oncol (Meeting Abstracts) 2008 26: 11546. [Abstract]  

C. E. Woodall, III, N. P. Reuter, C. R. Scoggins, R. C. Martin, II, K. M. McMasters, J. B. Hargis, and A. B. Chagpar

Use of adjuvant chemotherapy in young women with node-negative ER+ breast cancer: Refining the use of recurrence score—A decision analysis
J Clin Oncol (Meeting Abstracts) 2008 26: 11547. [Abstract]  

S. O. Ramalho, O. Martucci, G. Redi, A. Garcia, and J. Oliveira

Invasive ductal carcinoma (IDC), triple negative (TN) and inflammatory breast cancer (IBC): A Brazilian single institution experience
J Clin Oncol (Meeting Abstracts) 2008 26: 11548. [Abstract]  

S. Snow, D. Rayson, P. J. Barnes, M. Sellon, K. Thompson, and T. Younis

Does Her2/neu status affect adjuvant chemotherapy utilization? A population based analysis
J Clin Oncol (Meeting Abstracts) 2008 26: 11549. [Abstract]  

A. K. Swayampakula, A. Schwartzman, A. Saad, C. Dillis, J. Schreiman, G. Hobbs, and J. Abraham

Breast cancer tumor size in MRI versus surgical pathological specimen: A correlative study
J Clin Oncol (Meeting Abstracts) 2008 26: 11550. [Abstract]  

J. S. Nunes, A. T. Tsunoda, L. S. Viana, F. H. Souza, N. Castro, J. Hohmann, and S. V. Serrano

Analysis of response to neoadjuvant chemotherapy (NCT) with doxorubicin plus cyclophosphamide followed by paclitaxel (AC- T) in triple negative locally advanced breast cancer (LABC) in Brazil
J Clin Oncol (Meeting Abstracts) 2008 26: 11551. [Abstract]  

D. S. Wells, A. Morales, R. Gallegos, V. Uttamsingh, G. Bridson, C. Cheng, C. Masse, S. Harbeson, R. Zelle, and R. Tung

The effect of CTP-347 on CYP2D6-mediated tamoxifen metabolism
J Clin Oncol (Meeting Abstracts) 2008 26: 11552. [Abstract]  

A. t. Brown, L. C. Thanasoulis, and T. G. Frazier

Comparison of infrared sentinel breastscan (SBS) and bilateral MRI for detection of occult breast cancer: Can this modality assist in surgical planning?
J Clin Oncol (Meeting Abstracts) 2008 26: 11553. [Abstract]  

C. Umay, N. S. Bese, S. Serdengecti, N. Kepil, C. Karaca, N. Sut, T. Altug, and A. Ober

The effects of concurrent or sequential administration of trastuzumab on radiation-induced pulmonary fibrosis in rats
J Clin Oncol (Meeting Abstracts) 2008 26: 11554. [Abstract]  

N. L. Sroka, L. Sclafani, M. Stempel, S. Devore, and L. Montgomery

Percutaneous core biopsy in patients with a history of LCIS
J Clin Oncol (Meeting Abstracts) 2008 26: 11555. [Abstract]  

M. Kalder and P. Hadji

Bone health in postmenopausal women (PMW) with hormone-sensitive breast cancer (HSBC) receiving adjuvant aromatase inhibitor (AI) therapy
J Clin Oncol (Meeting Abstracts) 2008 26: 11556. [Abstract]  

M. Kadivar, N. Shayanfar, M. Bahraminejad, A. Sadeghipour, and P. Askarzadeh

Interpretation of immunohistochemistry results of HER2/neu expression in invasive breast cancer: Evaluation of interobserver and intraobserver agreement in Iran
J Clin Oncol (Meeting Abstracts) 2008 26: 11557. [Abstract]  

G. A. Wernicke, P. Parhar, M. Rasca, P. Christos, A. Fischer, and D. Nori

Assessment of inter-observer and intra-observer variability in measuring compliance of breast tissue with the Tissue Compliance Meter in healthy volunteers: Implications for studying fibrosis in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 11558. [Abstract]  

D. Crivellari, G. Miolo, D. Lombardi, S. Massarut, T. Perin, S. Venturini, V. Di Lauro, R. Dolcetti, S. Tumolo, and A. Veronesi

HER2 guided neoadjuvant treatment of advanced breast cancer: Clinico-biological correlations
J Clin Oncol (Meeting Abstracts) 2008 26: 11559. [Abstract]  

M. Aun and T. N. Ansari

Response of brain metastases to simulation whole brain and topotecan
J Clin Oncol (Meeting Abstracts) 2008 26: 11560. [Abstract]  

C. R. Villegas Mejia, Sr., J. P. Cardona Arcila, Sr, T. Sanchez Villegas, Sr, and J. A. Chacon Cardona, Sr

Epidemic profile of breast cancer at the Instituto Oncologico ION S.A. in Manizales in a developing country
J Clin Oncol (Meeting Abstracts) 2008 26: 11561. [Abstract]  

B. Knight, K. A. Gelmon, D. J. Renouf, H. F. Kennecke, T. Thomson, and G. Naus

Comparison of immunostaining for estrogen receptor in breast cancer using the rabbit monoclonal antibody SP1 or the mouse monoclonal antibody 6F-11
J Clin Oncol (Meeting Abstracts) 2008 26: 11562. [Abstract]  

Y. Eralp, B. Sakallioglu, S. Kucucuk, S. Tuzlali, P. Saip, A. Igci, M. Muslumanoglu, A. Aydiner, and E. Topuz

Impact of adjuvant chemotherapy with respect to level of hormone receptor expression in patients with hormone responsive breast cancer: Implications for endocrine resistance
J Clin Oncol (Meeting Abstracts) 2008 26: 11563. [Abstract]  

I. Jiveliouk, B. Corn, M. J. Inbar, and O. Merimsky

Ductal carcinoma in situ (DCIS) of the breast in Israeli women treated by radiation therapy following breast-conserving surgery
J Clin Oncol (Meeting Abstracts) 2008 26: 11564. [Abstract]  

N. I. Usoro, M. A. Inyama, G. A. Ebughe, and I. U. Ilori

A protocol for blood conservation in breast cancer care in a resource-poor setting
J Clin Oncol (Meeting Abstracts) 2008 26: 11565. [Abstract]  

X. Huang, J. Tang, J. Feng, L. Zhang, L. Pan, J. Chen, and J. Qin

A comparison of regimens for preoperative chemotherapy in a group of Chinese breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 11566. [Abstract]  

A. E. Borello, Sr., L. Figueroa, A. Basquiera, P. Calafat, A. Diller, A. E. Sturich, N. Rossi, J. J. García, and E. Palazzo

Comparison of immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) to determine the presence of Gen HER-2Neu in breast carcinoma
J Clin Oncol (Meeting Abstracts) 2008 26: 11567. [Abstract]  

M. R. Cruz, J. C. Prestes, and M. F. Fanelli

Fertility preservation in breast cancer women undergoing adjuvant chemotherapy: A systematic review
J Clin Oncol (Meeting Abstracts) 2008 26: 11568. [Abstract]  

R. S. Mehta

In vivo response-adapted dose-dense (dd) doxorubicin and cyclophosphamide (AC) -> weekly carboplatin and albumin- bound paclitaxel (nab-TC) plus trastuzumab (H) or bevacizumab (B) in patients with large and inflammatory breast cancer (BC): A phase II study
J Clin Oncol (Meeting Abstracts) 2008 26: 11569. [Abstract]  

U. Bohn, J. Aguiar Morales, D. Aguiar Bujanda, S. Saura, and C. A. Rodríguez

Ablative chemotherapy and stem cell transplant in patients with breast cancer. Thirteen years of follow-up
J Clin Oncol (Meeting Abstracts) 2008 26: 11570. [Abstract]  

S. Goyle, S. Karmarkar, I. Ambulkar, A. Borker, G. Ingle, and S. H. Advani

Presentation trends of breast cancer patients at a single cancer institute in India
J Clin Oncol (Meeting Abstracts) 2008 26: 11571. [Abstract]  

N. M. Abd El-Bary, A. F. El-Kased, and H. Aiad

Does neoadjuvant chemotherapy in operable breast cancer increase breast conservation?
J Clin Oncol (Meeting Abstracts) 2008 26: 11572. [Abstract]  

J. A. Chacon Cardona, C. R. Villegas Mejia, T. Sanchez Villegas, and J. P. Cardona Arcila

Inflammatory breast cancer in Manizales from a developing country like Colombia
J Clin Oncol (Meeting Abstracts) 2008 26: 11573. [Abstract]  

D. Donat, J. Pesic, J. Trifunovic, L. Muzikravic, S. Tesanovic, D. D. Donat, and T. Pesic

Development of distant metastases during adjuvant therapy with trastuzumab (H) in premenopausal patients with HER2-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11574. [Abstract]  

M. A. Alrefae, D. Roberge, and L. Panasci

High rate of complete pathologic response using neoadjuvant trastuzumab in women with human epidermal growth factor 2 positive stage III breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11575. [Abstract]  

R. Villalobos, G. Hernández, and M. Martinez-Prieto

Clinical behavior of a cohort of patients with triple negative breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11576. [Abstract]  

J. Zhang and Y. Liu

A retrospective and prospective study of response to aromatase inhibitors and TAM in HER2-overexpressed postmenopausal breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 11577. [Abstract]  

S. Goyal, T. Puri, G. Saini, D. N. Sharma, P. K. Julka, and G. K. Rath

Radiation delivery practices in nonmetastatic breast cancer at a regional cancer center in India
J Clin Oncol (Meeting Abstracts) 2008 26: 11578. [Abstract]  

E. Gocen, A. Mayadagli, S. K. Gul, F. Oruc, and C. Parlak

Our experiences in cases with breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11579. [Abstract]  

O. Karakoyun Celik, Y. Turan, Z. Kocaaga, A. Gürgan, and A. Duransoy

Bone mineral density in women with breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11580. [Abstract]  

R. L. Elliott, M. M. DeLand, J. F. Head, and M. C. Elliott

Accelerated partial breast irradiation: Preliminary experience with the IntraBeam System
J Clin Oncol (Meeting Abstracts) 2008 26: 11581. [Abstract]  

P. Hadjii, M. Blettner, R. Haidiner, N. Harbeck, C. Jackisch, H. Lück, R. R. Martin, A. Rexrodt v. Fircks, J. Torode, and R. Kreienberg

Patient’s Anastrozole Compliance to Therapy Programme (PACT): Influence of the addition of a standardized information and reminder service on compliance in comparison to standard clinical care alone in women with early-stage breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11582. [Abstract]  

S. Imoto, N. Wada, N. Sakemura, Y. Murata, and T. Hasebe

Feasibility study on radiofrequency ablation therapy followed by partial mastectomy for stage I breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 11583. [Abstract]  

J. L. Marti and K. Hiotis

Excision of 13 phyllodes bilateral breast tumors in one patient
J Clin Oncol (Meeting Abstracts) 2008 26: 11584. [Abstract]  

C. Liu, Jr. and J. B. Li

Comparison of displacement of the silver clips in the cavity determined by KV-plain film and cone-beam computed tomography for the breast cancer patients treated by three-dimensional conformal external-beam partial breast irradiation assisted by active breathing control
J Clin Oncol (Meeting Abstracts) 2008 26: 11585. [Abstract]  

M. Xu, J. B. Li, J. M. Yu, J. Xing, Y. J. Zhang, S. Y. Tian, C. Q. Liang, Q. Shao, T. Y. Fan, and L. Jie

Measurement of the width and the depth of internal mammary lymph nodes according to internal mammary artery and vein on CT simulition in breast cancer post-surgery
J Clin Oncol (Meeting Abstracts) 2008 26: 11586. [Abstract]  

M. Y. Choi, K. E. Lee, H. J. Chang, S. H. Sung, B. I. Moon, H. Y. Choi, H. S. Suh, E. M. Nam, Y. C. Mun, C. M. Seong, and S. N. Lee

Prognostic significance of triple-negative phenotype in breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11587. [Abstract]  

S. Wu

Breast cancer in elder women in China
J Clin Oncol (Meeting Abstracts) 2008 26: 11588. [Abstract]  

F. Giovanardi, F. Gibertoni, L. Scaltriti, K. Cagossi, G. Di Carlo, F. Artioli, L. Cavanna, and G. Giovanardi

One day surgery in breast cancer patients: Safe and feasible procedure
J Clin Oncol (Meeting Abstracts) 2008 26: 11589. [Abstract]  

D. G. Tiezzi, J. M. Andrade, A. H. Macchetti, W. S. Clagnan, H. R. Marana, F. E. Zola, and F. M. Peria

Docetaxel and anthracycline-based neoadjuvant chemotherapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11590. [Abstract]  

J. B. Li, T. Fan, J. Lu, and Z. Ma

Clinical application of three-dimensional conformal partial breast external-beam irradiation after breast-conserving surgery in China
J Clin Oncol (Meeting Abstracts) 2008 26: 11591. [Abstract]  

F. D’Halluin, P. Tas, S. Rouquette, C. Bendavid, and H. Mesbah

Role of intraoperative imprint cytology for evaluation of surgical margins in breast cancer: A prospective controlled study of about 400 lumpectomies
J Clin Oncol (Meeting Abstracts) 2008 26: 11592. [Abstract]  

A. V. Bakshi, R. Bharath, S. Gupta, R. Nair, T. Shet, N. S. Ghadyalpatil, R. Kaushal, K. Gaikwad, S. Kannan, and P. M. Parikh

Evaluation of efficacy and safety of neoadjuvant chemotherapy with weekly paclitaxel in patients with locally advanced and large operable breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11593. [Abstract]  

D. G. Generali, M. C. Garassino, S. Lonardi, A. Bettini, R. Rossello, O. Martelli, E. Collova, I. Rampinelli, A. Mancuso, C. Saggia, and V. Torri

Retrospective analysis of patients with male breast cancer: Report from O.R.I.O.N. collaborative group
J Clin Oncol (Meeting Abstracts) 2008 26: 11594. [Abstract]  

S. Demirci, J. Nam, J. L. Hubbs, and L. B. Marks

The reported rate of radiation-induced cardiac toxicity in patients with breast cancer: Impact of treatment era and follow-up duration
J Clin Oncol (Meeting Abstracts) 2008 26: 11595. [Abstract]  

N. Siddiqui, M. K. Siddique, I. A. Muazzam, R. Faiz, N. Anwar, and F. Badar

Breast cancer in very young Pakistani women at a cancer hospital in Lahore
J Clin Oncol (Meeting Abstracts) 2008 26: 11596. [Abstract]  

R. Yelamanchili, T. Koru-Sengul, V. Pavlova, C. Phillips, A. Ali, and B. Dhesy

Patterns of adjuvant systemic therapy in elderly with breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 11597. [Abstract]  

P. Eroles, J. Furriol, J. Ferrer, B. Bermejo, A. Bosch, and A. Lluch

Relation of activation of NFkB family members and clinical-pathological factors in breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11598. [Abstract]  

S. Lee, K. Min, S. Kim, S. Kim, K. Lee, E. A. Kim, Y. Kwon, H. Kang, J. Ro, and E. Lee

Effect of preoperative chemotherapy on the rate of breast conserving surgery in Korean patients with advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11599. [Abstract]  

K. R. Basarakodu, J. A. Linebaugh, B. K. Barrett, and M. C. Perry

Efficacy of neoadjuvant weekly docetaxel in locally advanced or inflammatory breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 11600. [Abstract]  

Breast Cancer–Metastatic Breast Cancer:

R. MacFarlane, C. Speers, H. Masoudi, and S. Chia

Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series
J Clin Oncol (Meeting Abstracts) 2008 26: 1000. [Abstract]  

K. Broglio, S. L. Moulder, L. Hsu, S. Kau, L. Pusztai, W. F. Symmans, G. N. Hortobagyi, A. M. Gonzalez-Angulo, and C. Liedtke

Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1001. [Abstract]  

K. Leitzel, A. Lipton, W. Koestler, E. Fuchs, S. M. Ali, J. Weidler, Y. Wu, J. Sperinde, W. Huang, and M. Bates

Use of total HER2 and HER2 homodimer levels to predict response to trastuzumab
J Clin Oncol (Meeting Abstracts) 2008 26: 1002. [Abstract]  

F. André, M. Campone, S. A. Hurvitz, L. Vittori, I. Pylvaenaeinen, T. Sahmoud, and R. M. O'Regan

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab
J Clin Oncol (Meeting Abstracts) 2008 26: 1003. [Abstract]  

I. E. Krop, K. D. Miller, R. T. Zon, S. Isakoff, C. J. Schneider, M. Yu, C. Johnson, L. G. Vaughn, O. O. Shonukan, and G. W. Sledge, Jr.

A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane-containing regimen: HOG BRE05–97
J Clin Oncol (Meeting Abstracts) 2008 26: 1004. [Abstract]  

S. M. Shreeve, D. Palmieri, M. M. Johnson, K. D. Aldape, S. Davis, P. S. Meltzer, G. L. Davis, C. M. Hoffmann, S. M. Steinberg, and P. S. Steeg

Correlation of hexokinase-2 expression with overall survival and potential as a therapeutic target in the treatment of breast cancer brain metastases
J Clin Oncol (Meeting Abstracts) 2008 26: 1005. [Abstract]  

R. B. Livingston, L. Downey, A. Di Leo, M. Koehler, M. Arbushites, L. Williams, and M. F. Press

Evaluation of chromosome 17 (Chr-17) polysomy in HER2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib
J Clin Oncol (Meeting Abstracts) 2008 26: 1006. [Abstract]  

M. F. Press, R. S. Finn, A. Di Leo, D. A. Cameron, C. E. Geyer, A. Martin, B. Newstat, R. Gagnon, M. Arbushites, and M. Koehler

Correlation of HER2 gene amplification, HER2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1007. [Abstract]  

S. Yi, J. Uhm, E. Cho, S. Lee, M. Park, H. Jun, Y. Park, J. Ahn, Y. Im, W. Kang, and K. Park

Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 1008. [Abstract]  

L. A. Carey, H. S. Rugo, P. K. Marcom, W. Irvin, Jr, M. Ferraro, E. Burrows, X. He, C. M. Perou, E. P. Winer on behalf of the Translational Breast Cancer Research Consortium

TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1009. [Abstract]  

F. Heitz, P. Harter, A. Traut, H. J. Lueck, B. Beutel, and A. du Bois

Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 1010. [Abstract]  

D. Miles, A. Chan, G. Romieu, L. Y. Dirix, J. Cortes, X. Pivot, P. Tomczak, T. Taran, N. Harbeck, and G. G. Steger

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.
J Clin Oncol (Meeting Abstracts) 2008 26: LBA1011. [Abstract]  

M. Cristofanilli, V. Valero, A. Mangalik, I. Rabinowitz, F. P. Arena, J. F. Kroener, E. Curcio, C. Watkins, and P. Magill

A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1012. [Abstract]  

P. Cortazar, J. R. Johnson, R. Justice, and R. Pazdur

Metastatic breast cancer (MBC): FDA approval overview
J Clin Oncol (Meeting Abstracts) 2008 26: 1013. [Abstract]  

M. Bontenbal, C. Seynaeve, J. Stouthard, M. Bos, H. Braun, F. L. Erdkamp, G. van Deijk, P. Schmitz, I. Van der Stelt-Frissen, P. Hamberg, and J. Klijn

Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study)
J Clin Oncol (Meeting Abstracts) 2008 26: 1014. [Abstract]  

J. O'Shaughnessy, K. L. Blackwell, H. Burstein, A. M. Storniolo, G. Sledge, J. Baselga, M. Koehler, S. Laabs, A. Florance, and D. Roychowdhury

A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy
J Clin Oncol (Meeting Abstracts) 2008 26: 1015. [Abstract]  

D. Slamon, H. L. Gomez, F. F. Kabbinavar, O. Amit, M. Richie, L. Pandite, and V. Goodman

Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1016. [Abstract]  

R. S. Finn, R. Gagnon, A. Di Leo, M. F. Press, M. Arbushites, and M. Koehler

Lapatinib and paclitaxel in HER2-negative, extracellular domain (ECD) positive metastatic breast cancer (MBC) in a randomized phase III study
J Clin Oncol (Meeting Abstracts) 2008 26: 1017. [Abstract]  

S. S. Dawood, B. Kristine, G. N. Hortobagyi, and S. H. Giordano

Prognosis of women with stage IV breast cancer by HER2 status and trastuzumab treatment: An institutional based review
J Clin Oncol (Meeting Abstracts) 2008 26: 1018. [Abstract]  

R. Duchnowska, J. Jassem, M. A. Thorat, A. Morimiya, G. W. Sledge, L. Li, W. Biernat, C. Szczylik, P. S. Steeg, and S. S. Badve

Gene expression analysis for prediction of early brain metastasis (BM) in HER2-positive (HER2+) breast cancer patients (pts)
J Clin Oncol (Meeting Abstracts) 2008 26: 1019. [Abstract]  

A. Lucci, Jr., S. Krishnamurthy, K. Mosalpuria, I. Bedrosian, F. Meric-Bernstam, J. M. Reuben, B. Singh, W. A. Woodward, and M. Cristofanilli

Global evaluation of minimal residual disease in primary breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 1020. [Abstract]  

R. Aft, M. Watson, L. Ylagan, M. Chavez-MacGregor, K. Trinkaus, J. Zhai, M. Naughton, and K. Weilbaecher

Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1021. [Abstract]  

R. E. Ellsworth, C. Heckman, J. Seebach, L. A. Field, B. Love, J. A. Hooke, and C. D. Shriver

Identification of a gene expression breast cancer nodal metastasis profile
J Clin Oncol (Meeting Abstracts) 2008 26: 1022. [Abstract]  

A. B. Jensen, N. Olmeo, C. Wynne, G. Ramirez, A. Lebrecht, A. Mehta, W. He, Y. Song, Y. Berd, and A. Lombardi

Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial
J Clin Oncol (Meeting Abstracts) 2008 26: 1023. [Abstract]  

L. A. Costa, I. Alho, S. Casimiro, A. G. Oliveira, I. Luís, A. Fernandes, M. Bicho, S. M. Ali, K. Leitzel, L. Demers, and A. Lipton

Markers of bone turnover (ICTP, NTX) and serum matrix metalloproteinase 1 (MMP1) as prognostic markers in breast cancer patients (BC) with bone metastases (BM) treated with bisphosphonates (BP)
J Clin Oncol (Meeting Abstracts) 2008 26: 1024. [Abstract]  

G. Von Minckwitz, C. Zielinski, E. Maarteense, P. Vogel, M. Schmidt, H. Eidtmann, T. Cufer, F. E. de Jongh, M. Kaufmann, and S. Loibl

Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05)
J Clin Oncol (Meeting Abstracts) 2008 26: 1025. [Abstract]  

K. A. Gelmon, P. Fumoleau, S. Verma, A. M. Wardley, P. F. Conte, D. Miles, L. Gianni, V. A. McNally, G. Ross, and J. Baselga

Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy
J Clin Oncol (Meeting Abstracts) 2008 26: 1026. [Abstract]  

S. Modi, S. Sugarman, A. Stopeck, H. Linden, W. Ma, K. Kersey, R. G. Johnson, N. Rosen, A. L. Hannah, and C. A. Hudis

Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1027. [Abstract]  

M. Beeram, H. A. Burris, III, S. Modi, M. Birkner, S. Girish, J. Tibbitts, S. N. Holden, S. G. Lutzker, and I. E. Krop

A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1028. [Abstract]  

S. N. Holden, M. Beeram, I. E. Krop, H. A. Burris, III, M. Birkner, S. Girish, J. Tibbitts, S. G. Lutzker, and S. Modi

A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1029. [Abstract]  

J. Thery, J. Picquenot, M. Cornic, C. Lamarche, V. Raillot, S. Laberge-Le-couteulx, C. Veyret, J. Basuyau, and E. Blot

Comparison of HER2 extra cellular domain (ECD) serum level at the time of metastasis with HER2 status modification between primary breast cancers and their respective metastases
J Clin Oncol (Meeting Abstracts) 2008 26: 1030. [Abstract]  

S. Gori, V. Ludovini, M. Colozza, L. Pistola, F. R. Tofanetti, A. Flacco, J. Foglietta, E. Minenza, L. Stocchi, V. De Angelis, and L. Crinò

HER2, EGFR, PIK3CA mutations in HER2+ metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response
J Clin Oncol (Meeting Abstracts) 2008 26: 1031. [Abstract]  

N. W. Peacock, J. R. Infante, D. A. Yardley, H. A. Burris, III, F. A. Greco, C. Farley, C. Webb, D. R. Spigel, and J. D. Hainsworth

Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1032. [Abstract]  

J. Kash, W. E. Barlow, K. S. Albain, J. R. Gralow, D. Lew, L. E. Flaherty, M. E. Royce, G. N. Hortobagyi, and R. B. Livingston

Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1033. [Abstract]  

M. Mansutti, G. Cavazzini, V. Lorusso, C. Boni, M. Occelli, F. Puglisi, L. Del Mastro, and M. Venturini

Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1034. [Abstract]  

H. Joensuu, L. Sailas, T. Alanko, K. Sunela, R. Huuhtanen, M. Utriainen, R. Kokko, P. Bono, M. Hahka-Kemppinen, and P. Kellokumpu-Lehtinen

Single-agent docetacel (D) versus docetaxel alternating with single-agent gemcitabine (G) as treatments of patients (pts) with advanced breast cancer (ABC): Final analysis of a randomized trial
J Clin Oncol (Meeting Abstracts) 2008 26: 1035. [Abstract]  

B. J. Klencke, S. Bhattacharya, M. K. Samant, J. R. Gralow, M. N. Dickler, M. A. Cobleigh, E. A. Perez, T. N. Shenkier, N. E. Davidson, and K. D. Miller

Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1036. [Abstract]  

M. G. Mack, K. Eichler, S. Zangos, T. Lehnert, and T. J. Vogl

Long-term results of MR-guided laser ablation (LITT) of liver metastases of breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1037. [Abstract]  

R. Le Scodan, D. Stevens, M. Tubiana-Hulin, B. De La Lande, C. Cohen-Solal, E. Brain, M. Gutierrez, A. Boudinet, F. Spyratos, J. Munck, and A. Labib

Breast cancer with synchronous metastases: Impact of locoregional radiotherapy (LRR) on survival
J Clin Oncol (Meeting Abstracts) 2008 26: 1038. [Abstract]  

M. L. Johnson, T. Nehhozina, A. K. Conlin, M. Hsu, S. Patil, K. Jhaveri, C. A. Hudis, E. Brogi, and A. D. Seidman

Clinical and pathologic correlates in breast cancer (BC) brain metastasis (BM): Tissue microarray (TMA) studies
J Clin Oncol (Meeting Abstracts) 2008 26: 1039. [Abstract]  

N. K. Ibrahim, B. Abdulkarim, F. Huguet, Z. Gabos, L. Hsu, O. Marpeau, S. Uzan, L. Pusztai, E. A. Strom, G. N. Hortobagyi, and R. Rouzier

A nomogram to predict subsequent brain metastasis in metastatic breast cancer (MBC) patients
J Clin Oncol (Meeting Abstracts) 2008 26: 1040. [Abstract]  

G. Viale, B. Del Curto, E. Orvieto, and E. Maiorano

Analysis of HER1 and HER2 status in CNS metastases from patients (pts) with breast carcinoma (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1041. [Abstract]  

H. S. Rugo, S. Franco, P. Munster, A. Stopeck, W. Ma, J. Lyandres, S. Lahiri, M. Arbushites, M. Koehler, and M. N. Dickler

A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1042. [Abstract]  

J. W. Gray, D. Das, N. Wang, W. Kuo, M. F. Press, A. Di Leo, C. Ellis, M. Arbushites, L. Williams, and M. Koehler

Identification of a 6 gene molecular predictor of lapatinib related benefit: From breast cancer cell lines to a phase III trial
J Clin Oncol (Meeting Abstracts) 2008 26: 1043. [Abstract]  

F. Triebel, C. Brignone, C. Grygar, M. Marcu, and M. Gutierez

IMP321 and weekly paclitaxel as first-line chemoimmunotherapy for metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1045. [Abstract]  

B. P. Schneider, M. Karwal, L. Laufman, L. Sylvester, M. A. Taylor, C. Sidor, A. Hannah, J. Arnott, and K. D. Miller

A phase II study of oral MKC-1 for metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1046. [Abstract]  

A. D. Seidman, A. K. Conlin, A. Bach, A. M. Brufsky, M. N. Saleh, D. Lake, M. N. Dickler, G. D'Andrea, T. A. Traina, and C. A. Hudis

Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1047. [Abstract]  

P. Grell, M. Svoboda, P. Fabian, L. Radova, M. Dziechciarkova, M. Palacova, R. Nenutil, M. Hajduch, and R. Vyzula

The impact of signaling pathways stimulated by HER2 receptor on prediction of clinical outcome in metastatic breast cancer patients treated with trastuzumab
J Clin Oncol (Meeting Abstracts) 2008 26: 1048. [Abstract]  

T. Bachelot, E. Luporsi, A. Bajard, J. Provencal, D. Coefic, C. Platini, D. Dramais, C. Oprea, R. Ferri-Dessens, and D. Pérol

Randomized trial of first-line docetaxel + capecitabine (XT) versus docetaxel + epirubicin (ET) for metastatic breast cancer (MBC): Efficacy results of ERASME-4/CAPEDOC-EPIDOC
J Clin Oncol (Meeting Abstracts) 2008 26: 1049. [Abstract]  

Y. Beldjilali, M. Yamouni, K. A. Benhadji, H. Khellafi, A. Abdelaoui, and L. Djellali

A comparative study of gemcitabine/doxorubicin and cyclophosphamide/doxorubicin combinations in first-line metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1050. [Abstract]  

B. Sirohi, M. Arnedos, S. Popat, S. Ashley, A. Nerurkar, G. Walsh, S. Johnston, and I. E. Smith

Platinum-based chemotherapy in triple-negative (TN) breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1051. [Abstract]  

C. Simmons, N. Miller, W. Geddie, D. Gianfelice, M. Oldfield, and M. Clemons

Changes in breast tumour receptor status with time: A prospective study assessing the impact of obtaining confirmatory biopsy at metastatic recurrence on patient management
J Clin Oncol (Meeting Abstracts) 2008 26: 1052. [Abstract]  

H. Han, J. Kim, S. Im, J. Park, S. Oh, D. Oh, J. Kim, K. Lee, T. Kim, and Y. Bang

Magnitude of HER2 amplification as a predictive factor for HER2-overexpressing metastatic breast cancer treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 1053. [Abstract]  

W. Freier, H. J. Stemmler, H. Tessen, G. Gitsch, W. Jonat, W. Brugger, E. Kettner, H. Tesch, W. Abenhardt, and V. Heinemann

Randomised trial comparing gemcitabine plus vinorelbine (Gem/Vin), gemcitabine plus cisplatin (Gem/Cis), and gemcitabine plus capecitabine (Gem/Cap) in pretreated metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1054. [Abstract]  

R. L. Capizzi, L. A. Roman, S. Tjulandin, I. Smirnova, A. Manikhas, J. S. Paterson, A. Major, A. S. Lundberg, and P. Fumoleau

Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1055. [Abstract]  

A. Niwinska and M. Murawska

Brain metastases in breast cancer patients: Differences in survival depending on biological subtype and RPA RTOG prognostic class
J Clin Oncol (Meeting Abstracts) 2008 26: 1056. [Abstract]  

G. H. Jerusalem, V. Dieras, F. Cardoso, J. Bergh, A. Fasolo, A. Rorive, C. Manlius, I. Pylvaenaeinen, T. Sahmoud, and L. Gianni

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab
J Clin Oncol (Meeting Abstracts) 2008 26: 1057. [Abstract]  

H. H. Roché, M. Zambetti, F. Dalenc, S. Govi, L. Gladieff, B. Mudenda, I. Lainas, L. Iacono, and L. Gianni

Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1058. [Abstract]  

R. Baffa, B. O'Hara, M. Fassan, C. Liu, S. Volinia, J. P. Palazzo, C. M. Croce, and A. L. Rosenberg

MicroRNA expression profiling of human metastatic cancers
J Clin Oncol (Meeting Abstracts) 2008 26: 1059. [Abstract]  

R. Bartsch, B. Mlineritsch, M. Gnant, T. Niernberger, U. Pluschnig, R. Greil, M. Pober, P. Sevelda, J. Thaler, and G. G. Steger

The Austrian Fulvestrant Registry: Results from a prospective observation of fulvestrant in postmenopausal patients
J Clin Oncol (Meeting Abstracts) 2008 26: 1060. [Abstract]  

D. Laessig, U. Vehling-Kaiser, H. D. Harich, A. Welt, B. Heinrich, R. Pihusch, C. Ziske, G. Deutsch, S. Hegewisch-Becker, and V. Heinemann

Oral and intravenous vinorelbine plus trastuzumab for 1st-line treatment of HER2-overexpressing metastatic breast cancer (MBC). A trial of the german AIO breast cancer group
J Clin Oncol (Meeting Abstracts) 2008 26: 1061. [Abstract]  

S. Ménard on behalf of the Demetra Group

Observational Demetra study: Survival of metastatic breast carcinoma patients after treatment with trastuzumab
J Clin Oncol (Meeting Abstracts) 2008 26: 1062. [Abstract]  

D. W. Northfelt, J. B. Allred, H. Liu, T. J. Hobday, M. W. Rodacker, A. P. Lyss, T. R. Fitch, and E. A. Perez

Phase II trial of paclitaxel polyglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1063. [Abstract]  

M. Nelson, D. S. Blum, J. R. Gralow, F. Cardoso, C. Grande, F. M. Palmieri, M. C. Kirk, and C. Eagan

Oncologist and patient roles in assessing current and future treatment for metastatic breast cancer: Results of an observational linguistic study
J Clin Oncol (Meeting Abstracts) 2008 26: 1064. [Abstract]  

N. Fersis, D. Koliogiannis, L. Sisic, M. Aggarwal, and S. Kaul

Embedded tumor cell calibrators (ETC) for normalized quantitative multi-gene expression analysis of micrometastatic cells in blood and bone marrow of cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 1065. [Abstract]  

M. Beer, L. Lenaz, D. Amadori, and Ortataxel Study Group

Phase II study of ortataxel in taxane-resistant breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1066. [Abstract]  

A. Gennari, M. Sormani, P. Bruzzi, N. Wilcken, O. Nanni, M. Fornier, and M. R. Stockler

A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1067. [Abstract]  

C. Andreetta, F. Valent, G. Pascoletti, R. Sottile, A. M. Minisini, S. Russo, G. Fasola, S. Pizzolitto, C. Di Loreto, and F. Puglisi

Determinants of capecitabine efficacy in metastatic breast cancer: The role of thymidine phosphorylase
J Clin Oncol (Meeting Abstracts) 2008 26: 1068. [Abstract]  

D. Hawes, M. Patel, K. K. Hunt, A. E. Giuliano, and R. J. Cote

Prevalence of putative breast cancer stem cells (BCSC) in lymph node occult metastases (LNOM) of patients with node-negative (LN-) breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1069. [Abstract]  

V. Dieras, P. Viens, C. Veyret, G. Romieu, A. Awada, E. Lidbrink, H. Bonnefoi, D. Mery-Mignard, F. Dalenc, and H. Roché

Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label study
J Clin Oncol (Meeting Abstracts) 2008 26: 1070. [Abstract]  

G. Metro, A. Fabi, D. Giannarelli, D. Gemma, M. Ciccarese, G. Lanzetta, P. Papaldo, V. Lorusso, E. Magnolfi, and F. Cognetti

Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER2-positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1071. [Abstract]  

I. Ertl, V. Heinemann, I. Bauerfeind, M. Untch, D. Laessig, D. Nagel, D. Seidel, and P. Stieber

Utility of tumor markers for the early detection of metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1072. [Abstract]  

N. J. Robert, P. R. Conkling, P. R. Kuefler, K. J. McIntyre, F. Zhan, L. Asmar, Y. Wang, O. O. Shonukan, and J. O'Shaughnessy

Results of a phase II study of pemetrexed as first-line chemotherapy for advanced or metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1073. [Abstract]  

C. Falkson, J. F. Rossman, L. Nabell, J. Carpenter, M. N. Saleh, J. O'Malley, and A. Forero

A phase II trial investigating if bevacizumab in combination with hormone therapy will reverse acquired estrogen independence in metastatic breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 1074. [Abstract]  

M. A. Danso, J. L. Blum, N. J. Robert, L. Krekow, R. Rotche, D. A. Smith, P. Richards, T. Anderson, D. A. Richards, and J. O'Shaughnessy

Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1075. [Abstract]  

M. Knauer, A. Rottenfusser, R. Bartsch, K. Dieckmann, C. Wenzel, S. Fromm, H. Eiter, G. G. Steger, C. C. Zielinski, and A. de Vries

Analysis of risk factors predicting time to development of brain metastases
J Clin Oncol (Meeting Abstracts) 2008 26: 1076. [Abstract]  

V. J. Harvey, K. Sharples, R. Isaacs, M. B. Jameson, M. Jeffery, B. McLaren, S. Pollard, G. Riley, A. Simpson, and M. P. Findlay

A randomized phase II study comparing capecitabine (C) with C plus oral cyclophosphamide (CCy) in patients (pts) with advanced breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1077. [Abstract]  

N. U. Lin, H. H. Roché, V. Dieras, D. Skarlos, H. J. Stemmler, M. Liu, B. Dharan, D. Zembryki, K. Stepewski, and S. D. Rubin

A physician-reported neurological signs and symptoms worksheet (NSS WS) in EGF105084: A phase II study of lapatinib (lap) for pts with recurrent brain metastases (BM) from HER2+ breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1078. [Abstract]  

P. J. Wysocki, K. Korski, K. Lamperska, J. Zaluski, and A. Mackiewicz

Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations
J Clin Oncol (Meeting Abstracts) 2008 26: 1079. [Abstract]  

M. Ruiz, J. Salvador, J. Bayo, M. Lomas, A. Moreno, M. Valero, R. Bernabé, D. Vicente, J. Jimenez, and A. López-Ladrón

Multicenter study of weekly trastuzumab, paclitaxel, and carboplatin followed by a week of rest every 28 days in patients with HER2+ metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1080. [Abstract]  

T. J. Hobday, P. J. Stella, T. R. Fitch, A. Jaslowski, B. LaPlant, M. M. Ames, M. P. Goetz, and E. A. Perez

N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy
J Clin Oncol (Meeting Abstracts) 2008 26: 1081. [Abstract]  

S. J. Vukelja, J. O'Shaughnessy, D. Krasnojon, S. V. Cheporov, A. Makhson, G. Manikhas, P. Bhar, and W. Gradishar

Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1082. [Abstract]  

M. Ryberg, D. L. Nielsen, J. S. Johansen, and F. Bach

Cerebrospinal fluid concentration of HER2, IL-6, and YKL40 in breast cancer patients with meningeal carcinomatosis or brain metastasis
J Clin Oncol (Meeting Abstracts) 2008 26: 1083. [Abstract]  

L. T. Vahdat, C. Twelves, M. K. Allison, J. A. Cortes, M. Campone, D. E. Shuster, J. Wanders, F. Fang, R. D. Gurnani, and J. L. Blum

Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy
J Clin Oncol (Meeting Abstracts) 2008 26: 1084. [Abstract]  

W. Khodari, A. Vataire, S. Delaloge, F. André, C. Uzan, J. Garbay, A. Dunant, R. Arriagada, H. Marsiglia, and C. Bourgier

The role of radiation therapy as part of local-regional treatment in breast cancer patients with metastatic disease at diagnosis
J Clin Oncol (Meeting Abstracts) 2008 26: 1085. [Abstract]  

A. K. Conlin, G. D'Andrea, C. A. Hudis, M. E. Robson, P. Drullinsky, M. Theodoulou, E. Lis, T. Y. Kang, D. M. Peereboom, and A. D. Seidman

Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT)
J Clin Oncol (Meeting Abstracts) 2008 26: 1086. [Abstract]  

P. Carlini, E. Bria, F. Cuppone, I. Sperduti, V. Vaccaro, C. Nistico, C. Nuzzo, F. Cognetti, E. Terzoli, and D. Giannarelli

Should non-anthracycline-based chemotherapy (Non-A) substitute anthracycline-based (A) when combined with taxanes (T) as 1st-line chemotherapy (CT) for advanced breast cancer (ABC)? Meta-analysis of randomized clinical trials (RCTs) balancing efficacy and toxicity
J Clin Oncol (Meeting Abstracts) 2008 26: 1087. [Abstract]  

V. Huyge, P. Flamen, P. Bergmann, L. Ameye, B. Vanderlinden, C. Garcia, J. Alexiou, M. Lemort, A. Awada, and J. Body

Whole body PET(CT) with FDG for treatment monitoring of patients with bone metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1088. [Abstract]  

S. Gluck, C. Lobo, I. Reis, G. Lopes, C. Carmody, K. Tukia, J. Hurley, P. Seo, O. Silva, J. Slingerland, and C. Welsh

Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1089. [Abstract]  

D. M. Waterhouse, M. Mainwaring, J. Barton, C. Webb, T. M. Markus, D. R. Spigel, J. R. Infante, J. D. Hainsworth, F. A. Greco, and D. A. Yardley

Phase II pilot results of imatinib mesylate with weekly docetaxel in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1090. [Abstract]  

A. Agrawal, L. Winterbottom, J. F. Robertson, and K. L. Cheung

Goserelin plus anastrozole (G+A) as first-line systemic therapy for premenopausal estrogen receptor positive (ER+) advanced breast cancer (ABC)— clinical and endocrine data
J Clin Oncol (Meeting Abstracts) 2008 26: 1091. [Abstract]  

M. Warm, A. Thomas, K. Ziegler, C. Moers, R. Kates, and N. Harbeck

Results of the German IPEP study evaluating tolerability, efficacy and acceptance of fulvestrant under routine clinical conditions in advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1092. [Abstract]  

V. Kyritsis, M. de Lemos, C. Speers, and J. Barnett

Survival analysis of sequential use of first-line tamoxifen versus aromatase inhibitors for estrogen-positive metastatic breast cancer in postmenopausal women
J Clin Oncol (Meeting Abstracts) 2008 26: 1093. [Abstract]  

F. Boccardo, B. Kaufman, J. Baselga, V. Dieras, J. Link, M. A. Casey, A. Fittipaldo, C. Oliva, D. Zembryki, and S. D. Rubin

Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU)
J Clin Oncol (Meeting Abstracts) 2008 26: 1094. [Abstract]  

A. M. Brufsky, K. L. Hoelzer, M. R. Keaton, J. T. Beck, E. Krill-Jackson, Y. Wang, S. Hu, L. G. Vaughn, and O. O. Shonukan

A phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer (MBC): Interim safety results
J Clin Oncol (Meeting Abstracts) 2008 26: 1095. [Abstract]  

A. Brunello, S. Monfardini, D. Crivellari, F. Puglisi, O. Nascimben, G. Scattolin, A. Molino, G. Mustacchi, M. Beda, and U. Basso

Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women ( 70 years)
J Clin Oncol (Meeting Abstracts) 2008 26: 1096. [Abstract]  

M. S. Rosati, C. Raimondi, S. Quadrini, R. De Sanctis, L. Stumbo, B. Gori, E. Del Signore, M. P. Poleggi, and M. Di Seri

WALT trial (Phase I-II): Weekly non-pegylated liposomal anthracycline and taxane combination in first-line breast cancer chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 1097. [Abstract]  

F. Vicini, N. S. Goldstein, M. Wallace, L. Kestin, and S. Schell

Molecular evidence demonstrating that local treatment failure is the source of distant metastases in some patients treated for breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1098. [Abstract]  

A. T. Perez, H. S. Shaw, G. F. Fleming, D. L. Hershman, S. Franco, C. L. Shapiro, K. Neal, I. Cohen, M. Tagliaferri, and D. Tripathy

A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1099. [Abstract]  

S. Nathan, P. Patel, M. Gaddh, B. Yim, V. Zayat, K. Ferrer, M. Sekosan, and J. Samuel

Clinical presentation characteristics and prognosis of urban, minority patients presenting with triple-negative breast cancer: An observational 5-year case review
J Clin Oncol (Meeting Abstracts) 2008 26: 1100. [Abstract]  

T. A. Traina, M. Theodoulou, U. Dugan, K. Feigin, S. Patil, C. Edwards, L. Norton, and C. A. Hudis

A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study
J Clin Oncol (Meeting Abstracts) 2008 26: 1101. [Abstract]  

C. Lévy, O. Switsers, J. Ollivier, D. Allouache, C. Delcambre, J. Génot, K. Gunzer, F. Toudic-Emily, C. Segura, and T. Delozier

Prognostic factors for survival of metastatic breast cancer (MBC): A retrospective study from 4,233 women treated in a single institution
J Clin Oncol (Meeting Abstracts) 2008 26: 1102. [Abstract]  

M. Melisko, J. Lyandres, J. Scott, J. W. Park, and H. S. Rugo

Phase II study of irinotecan (irin) and temozolomide (TMZ) in breast cancer patients with brain metastases that have progressed after stereotactic radiosurgery (SRS) or whole brain radiation (WBRT)
J Clin Oncol (Meeting Abstracts) 2008 26: 1103. [Abstract]  

A. Guerrero, A. Rodriguez-Lescure, S. Servitja, L. Calvo Martínez, S. del Barco, A. Llombart, V. Pons, G. Gutierrez, J. Gayo, and I. Tusquets

Phase I-II study of IV vinorelbine (NVB) and oxaliplatin (OXP) every two weeks (q2w) in metastatic breast cancer (MBC): Interim results of the phase II trial
J Clin Oncol (Meeting Abstracts) 2008 26: 1104. [Abstract]  

A. Anton, A. Lluch, A. Casado, M. Provencio, M. Muñoz, J. Lao, B. Bermejo, A. B. Paules, J. Gayo, and M. Martin

Phase I-II study of oral vinorelbine (NVBO ) and capecitabine (X) in metastatic breast cancer (MBC): Results of the phase I trial
J Clin Oncol (Meeting Abstracts) 2008 26: 1105. [Abstract]  

A. Tomova, T. Brodowicz, V. Tzekova, C. Timcheva, C. Wiltschke, D. A. Gerges, J. Pawlega, S. Spanik, M. J. Inbar, and C. C. Zielinski

Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine
J Clin Oncol (Meeting Abstracts) 2008 26: 1106. [Abstract]  

M. Solh, H. Bu ALI, V. Mittal, and K. Bergsman

Synchronous versus metachronous breast cancer: Characteristics of the second tumor
J Clin Oncol (Meeting Abstracts) 2008 26: 1107. [Abstract]  

F. Clatot, M. Ouvrier, C. Guillemet, C. Veyret, and E. Blot

Correlation of normalization of cerebrospinal fluid cytology (CSFC) with survival in breast cancer-related malignant meningitis (BMM)
J Clin Oncol (Meeting Abstracts) 2008 26: 1108. [Abstract]  

A. A. Elsaid, Y. Elkerm, and K. El-Shami

Trastuzumab plus gemcitabine and cisplatin chemotherapy for HER2/neu-overexpressing breast cancer with visceral metastasis
J Clin Oncol (Meeting Abstracts) 2008 26: 1109. [Abstract]  

P. Vici, A. Fabi, D. Sergi, S. Carpano, L. Di Lauro, P. Foggi, P. Papaldo, D. Giannarelli, F. Cognetti, and M. Lopez

Phase I-II trial of prolonged gemcitabine (G) infusion in combination with paclitaxel (P) in heavily-pretreated advanced breast cancer (ABC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2008 26: 1110. [Abstract]  

J. Lee and S. Ahn

Correlation between HER2/neu status with immunohistochemical analysis and serum HER2 concentration with ADVIA Cencaur automated immunoassay in breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1111. [Abstract]  

S. Roncella, Sr., P. Ferro, B. Bacigalupo, P. Pronzato, M. Franceschini, L. Pratticò, A. Carletti, P. Canessa, V. Fontana, M. Pistillo, and F. Fedeli

Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions
J Clin Oncol (Meeting Abstracts) 2008 26: 1112. [Abstract]  

E. Takeuchi, K. E. Anderson, G. D. Hall, T. J. Perren, and J. A. Spencer

Utility of image-guided peritoneal core biopsy and radiological findings in women with prior breast cancer and a new diagnosis of peritoneal carcinomatosis
J Clin Oncol (Meeting Abstracts) 2008 26: 1113. [Abstract]  

V. Lorusso, R. Forcignanò, S. Leo, M. Ciccarese, V. Chiuri, G. Santacroce, G. Romano, S. Romano, and C. Manca

Vinorelbine plus capecitabine in salvage therapy of breast cancer. Comparison of intravenous vs oral administration of vinorelbine
J Clin Oncol (Meeting Abstracts) 2008 26: 1114. [Abstract]  

A. A. Ranade, P. P. Bapsy, S. Nag, D. Raghunadharao, V. Raina, S. H. Advani, S. K. Mishra, S. Tyagi, A. C. Burman, and P. M. Parikh

A novel, cremophor-free, polymeric nanoparticle paclitaxel (do/ndr/02) multicenter study in advanced/ metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1115. [Abstract]  

C. Schem, Z. Li, N. Maass, W. Jonat, D. Medina, Y. H. Shi, and M. Zhang

Correlation of COX2 expression with tumor-induced osteoclastic lesions in breast cancer bone metastasis
J Clin Oncol (Meeting Abstracts) 2008 26: 1116. [Abstract]  

T. Ishida, T. Kiba, M. Takeda, K. Matsuyama, S. Teramukai, N. Masuda, Y. Takatsuka, S. Noguchi, M. Fukushima, and N. Ohuchi

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2-overexpressing metastatic breast cancers after failure of both anthracyclines and taxanes
J Clin Oncol (Meeting Abstracts) 2008 26: 1117. [Abstract]  

B. Mirtsching, T. Cosgriff, G. Harker, M. Keaton, T. Chidiac, and M. Min

Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04–012)
J Clin Oncol (Meeting Abstracts) 2008 26: 1118. [Abstract]  

M. Ghosn, F. S. Farhat, J. G. Kattan, C. Hanna, F. Younes, N. Haddad, P. Aftimos, F. Nasr, W. Moukadem, and G. Chahine

Navcap (vinorelbine and capecitabine) versus navcap followed by weekly docetaxel as first-line treatment in metastatic breast cancer patients: A randomized multicenter phase II trial
J Clin Oncol (Meeting Abstracts) 2008 26: 1119. [Abstract]  

M. E. Trinkaus, C. Simmons, J. Myers, G. Dranitsaris, and M. Clemons

Skeletal related events (SREs) in patients with bone metastases from breast cancer treated with intravenous (i.v.) bisphosphonates (BPs) in the non-trial setting
J Clin Oncol (Meeting Abstracts) 2008 26: 1120. [Abstract]  

F. Kassam, K. Enright, R. Dent, C. Flynn, J. Myers, M. Fralick, R. Kumar, and M. Clemons

Outcomes for metastatic triple-negative (TN) breast cancer: Impact for clinical practice and trial design
J Clin Oncol (Meeting Abstracts) 2008 26: 1121. [Abstract]  

I. Fujiwara, H. Nakajima, N. Mizuta, K. Sakaguchi, and Y. Hachimine

Prognosis of Japanese breast cancer based on hormone receptor and HER2 expression determined by immunohistochemical staining
J Clin Oncol (Meeting Abstracts) 2008 26: 1122. [Abstract]  

M. Kashiwaba

Phase I study of capecitabine in combination with CPT-11 for metastatic breast cancer (MBC) pre-treated with anthracycline and taxanes
J Clin Oncol (Meeting Abstracts) 2008 26: 1123. [Abstract]  

A. Cavazzana, A. Camerini, R. Prosperi Porta, F. De Luca, N. Decarli, M. Rondini, C. Puccetti, O. Siclari, G. Tartarelli, and D. Amoroso

Correlation of HER2 overexpression evaluated by fluorescence in situ hybridization with response to docetaxel-based first-line chemotherapy in advanced breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 1124. [Abstract]  

H. Elghazaly, H. Tawfik, M. Mahrous, M. M. Meshref, A. Sakr, and N. Haddad

Vinorelbine and capecitabine combination as first-line treatment in patients with metastatic breast cancer: Final results of a multicentric trial in Egypt
J Clin Oncol (Meeting Abstracts) 2008 26: 1125. [Abstract]  

M. Siva, P. Correa, S. Skaria, and P. Canney

Capecitabine in advanced breast cancer: Predictive factors for response
J Clin Oncol (Meeting Abstracts) 2008 26: 1126. [Abstract]  

A. Zaniboni, F. Meriggi, A. Rizzi, L. Rota, C. Codignola, B. Di Biasi, M. Mazzocchi, and S. Mutti

Navelbine (N), leucovorin (L), and fluorouracil (5-FU) (FLN) for triple-negative metastatic breast cancer (TNBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1127. [Abstract]  

J. A. Cnossen, V. Heinemann, D. Laessig, and H. J. Stemmler

Long-term survival with metastatic breast cancer (MBC): Results of a retrospective, single-centre analysis from 2000–2005
J Clin Oncol (Meeting Abstracts) 2008 26: 1128. [Abstract]  

S. Saji, M. Hirose, H. Iwase, Y. Yamaguchi, M. Toi, S. Hayashi, and K. Kuroi

Rationale for salvage therapy with high-dose selective estrogen receptor modulator after treatment failure of aromatase inhibitors in breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1129. [Abstract]  

L. Di Scala, I. Pylvänäinen, B. Molloy, C. Manlius, L. Vittori, T. Sahmoud, D. Lebwohl, and E. P. Zuber

A novel Bayesian dose-escalation phase Ib design investigating safety of combination of RAD001 with chemotherapy plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab
J Clin Oncol (Meeting Abstracts) 2008 26: 1130. [Abstract]  

C. S. Ferdous, T. M. Islam, and L. A. Meza

Review of inflammatory breast cancer: A meta-analysis
J Clin Oncol (Meeting Abstracts) 2008 26: 1131. [Abstract]  

C. Serrano, E. Muñoz, I. Braña, P. Martínez, C. Saura, I. R. Quispe, F. Atzori, P. Gómez, E. Calvo-Aller, and J. A. Cortes

Evaluation of clinical cardiotoxicity of nonpegylated liposomal doxorubicin in the treatment of patients with metastatic breast cancer (MBC) who had received prior adjuvant anthracyclines
J Clin Oncol (Meeting Abstracts) 2008 26: 1132. [Abstract]  

G. Carillio, G. Scandurra, R. Aiello, E. Taibi, A. Mazzola, M. Alì, S. Bagnato, G. Fallica, M. Chiarenza, and M. Caruso

Fulvestrant in metastatic breast cancer: Safety, efficacy, and role as mainteinance therapy for heavily pretreated patients
J Clin Oncol (Meeting Abstracts) 2008 26: 1133. [Abstract]  

S. J. Stanway, A. Purohit, R. Ward, C. Palmieri, C. R. Coombes, and M. J. Reed

Effect of aromatase inhibitor or tamoxifen therapy on steroid sulfatase activity and DHEA-DHEAS concentrations in postmenopausal women with breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1134. [Abstract]  

M. Gil-Delgado, M. Rocher, E. Boostandoost, and D. Khayat

First step of oral vinorelbine and capecitabine combination in advanced breast cancer patients: Feasability study
J Clin Oncol (Meeting Abstracts) 2008 26: 1135. [Abstract]  

J. Stewart, G. Berman, V. F. Semiglazov, H. L. Gomez, A. De La Cruz Vargas, S. Falcon, L. I. Akhmadullina, A. Guerrero, M. Varela, and C. Martin

5,10 methylenetetrahydrofolic acid with fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase II study
J Clin Oncol (Meeting Abstracts) 2008 26: 1136. [Abstract]  

K. Bethel, R. Scuderi, D. Marrinucci, J. M. Fisher, N. Lazarus, D. Lazar, and P. Kuhn

Morphologic assessment of peripheral blood smears in patients with circulating tumor cells (CTCs)
J Clin Oncol (Meeting Abstracts) 2008 26: 1137. [Abstract]  

K. Shojima, E. Suzuki, K. Saito, S. Sekine, D. Kitagawa, T. Aruga, S. Saji, and K. Kuroi

Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1138. [Abstract]  

J. B. Huober, W. Fett, A. Nusch, M. Neise, M. Schmidt, A. Wischnik, S. Gerhard, T. Goehler, and A. Rost

A multicentric observational trial with metastatic breast cancer (MBC) patients on pegylated liposomal doxorubicin (PLD) regimen
J Clin Oncol (Meeting Abstracts) 2008 26: 1139. [Abstract]  

J. Pierga, K. I. Pritchard, H. Cortes-Funes, L. Biganzoli, C. Thomssen, F. A. Franke, I. E. Smith, N. Bogdanova, and D. Stroyakovskiy

MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1140. [Abstract]  

D. Wiederkehr, S. Kaura, N. Mody-Patel, A. Ogbonnaya, and L. Stern

Cost associated with distant, contralateral, and local-regional breast cancer recurrence in a vertically integrated health care system
J Clin Oncol (Meeting Abstracts) 2008 26: 1141. [Abstract]  

M. Philco, S. Falcon, H. Gomez, R. Escandon, K. Saikali, and A. Wolff

A phase I-II open-label trial of ispinesib on an alternate dosing schedule in chemotherapy-naive patients with locally advanced or metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 1143. [Abstract]  

R. Ratti, Z. Coccorullo, D. Guarneri, G. Addamo, G. Colloca, A. Venturino, and E. Campora

Fulvestrant in heavily pretreated ER-positive postmenopausal metastatic breast cancer patients: A phase II study
J Clin Oncol (Meeting Abstracts) 2008 26: 1144. [Abstract]  

F. M. Peria, L. G. Brito, D. G. Tiezzi, F. E. Zola, T. C. Motta, H. H. Carrara, and J. M. Andrade

Sub-group analysis of response, overall survival, and quality of life (QoL) with gemcitabine-cisplatin (G-C) in anthracycline and taxane pretreated metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12000. [Abstract]  

J. Espinós, C. Olier-Garate, J. M. Aramendia, O. Fernandez Hidalgo, C. Reyna, S. De la Cruz, A. del Barrio, and J. García-Foncillas

Efficacy of the combination of irinotecan and bevacizumab in heavely pretreated metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12001. [Abstract]  

A. M. Carella

Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12002. [Abstract]  

I. Carreca, F. Bellomo, M. Brizzi, G. Bronte, S. Burgio, D. Piazza, S. Rizzo, S. Russo, and L. Balducci

Efficacy and safety of a combined treatment schedule with fulvestrant (F) and capecitabine (C) in elderly advanced breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 12003. [Abstract]  

A. Bensalem and K. Bouzid

Gemcitabine-vinorelbine as first-line treatment for metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12004. [Abstract]  

M. Gusella, U. Basso, F. Pasini, E. Ferrazzi, and A. Bononi

The effect of bi-weekly pegylated liposomal doxorubicin pharmacokinetics in elderly women with metastatic breast carcinoma
J Clin Oncol (Meeting Abstracts) 2008 26: 12005. [Abstract]  

F. Giotta, A. Latorre, G. Monticelli, S. Oliva, D. Albano, and G. Colucci

Lapatinib as salvage therapy in metastatic breast cancer: Preliminary results from an expanded access program
J Clin Oncol (Meeting Abstracts) 2008 26: 12006. [Abstract]  

M. Hafeez, A. Shaharyar, A. I. Masood, M. Zikria, A. Usman, K. Shabbir, Z. Nadeem, and S. Tahir

Low dose sequential docetaxel-capecitabine chemotherapy as first-line treatment of metastatic breast cancer (mbc)
J Clin Oncol (Meeting Abstracts) 2008 26: 12007. [Abstract]  

M. Sarti, O. Pagani, F. Bertoni, S. Longhi, C. Cafaro, R. Graffeo, F. Di Costanzo, and A. Goldhirsch

Retinal metastases treated with lapatinib (L) in a young HER2-positive breast cancer patient: Case report
J Clin Oncol (Meeting Abstracts) 2008 26: 12008. [Abstract]  

S. Labidi, T. Bachelot, I. L. Ray Coquard, B. Favier, G. Galy, and J. Guastalla

Bevacizumab and paclitaxel for breast cancer patients with CNS metastases
J Clin Oncol (Meeting Abstracts) 2008 26: 12009. [Abstract]  

N. Harbeck, S. Saupe, A. Kerber, H. J. Lueck, C. Jackisch, M. Untch, M. Schmidt, E. Jäger, and S. Al-Batran

Interim safety analysis of a randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line chemotherapy for metastatic breast cancer (MBC): The PELICAN study
J Clin Oncol (Meeting Abstracts) 2008 26: 12010. [Abstract]  

D. Errante, D. Bernardi, M. Stefani, M. Ramello, A. Bianco, and L. Salvagno

Prospective evaluation of liposomal doxorubicin (LD) in patients (pts) with metastatic breast cancer (MBC) pretreated with conventional anthracyclines
J Clin Oncol (Meeting Abstracts) 2008 26: 12011. [Abstract]  

V. Raina, K. Medhi, S. V. Deo, N. K. Shukla, and G. K. Rath

Pattern of relapse in 412 cases of locally advanced breast cancer (LABC) from a single centre in India
J Clin Oncol (Meeting Abstracts) 2008 26: 12012. [Abstract]  

N. Battelli, R. Giampieri, M. Squadroni, L. Zepponi, R. R. Silva, and S. Cascinu

Efficacy and toxicity of a low dose regimen of capecitabine and oral vinorelbine
J Clin Oncol (Meeting Abstracts) 2008 26: 12013. [Abstract]  

M. Romani, M. Cilli, C. Neumaier, G. Baio, and F. Piccardi

Evaluation of temozolomide (TMZ) activity in a mouse model of brain metastases (BM) from breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 12014. [Abstract]  

T. Hashem, K. Kamal al-Din, N. Mobarek, T. Al-Said, and S. Al-Hassanin

Cisplatin navelbine versus cisplatin capecitabine in the treatment of metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12015. [Abstract]  

C. G. Gennatas, V. Michalaki, S. Gennatas, and J. Psychogios

Capecitabine in combination with docetaxel in the management of metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12016. [Abstract]  

J. P. Cardona Arcila, J. A. Chacon Cardona, T. Sanchez Villegas, and C. R. Villegas Mejia

Breast cancer stage IV from a specific city in a developing country like Colombia
J Clin Oncol (Meeting Abstracts) 2008 26: 12017. [Abstract]  

B. Xu, L. Zhao, J. Wang, and P. Yuan

Docetaxel and cisplatin combination chemotherapy in Chinese patients with anthracycline-resistant advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12018. [Abstract]  

A. Jain, P. P. Bapsy, L. Dasappa, G. Babu, U. Batra, K. V. Sajeevan, K. Saini, T. Singh, and S. Attili

Nail changes induced by weekly paclitaxel as a surrogate marker for response assessment in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12019. [Abstract]  

M. Sandera and D. Hadlock

Significance of sentinel lymph node micrometastases on treatment of breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12020. [Abstract]  

M. S. Fayaz, S. M. Samir, H. G. Amanguno, and A. O. Adesina

Myoepithelioma (myoepithelial carcinoma) of the breast: Case report
J Clin Oncol (Meeting Abstracts) 2008 26: 12021. [Abstract]  

S. E. Waintraub and V. Tuchman

The role of maintenance bevacizumab in patients with metastatic breast cancer treated with chemotherapy and bevacizumab upon achieving complete response or maximal radiologic response with stable disease
J Clin Oncol (Meeting Abstracts) 2008 26: 12022. [Abstract]  

K. S. Velu

Study showing the efficacy of aromasin in metastatic CA breast in postmenopausal women
J Clin Oncol (Meeting Abstracts) 2008 26: 12023. [Abstract]  

P. J. Catanzaro

Evolution of sub-clinical metastases in breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12024. [Abstract]  

D. Bernardi, D. Errante, M. Stefani, M. Ramello, A. Bianco, and L. Salvagno

Prospective evaluation of liposomal doxorubicin (LD) in patients with metastatic breast cancer previously treated with conventional anthracyclines
J Clin Oncol (Meeting Abstracts) 2008 26: 12025. [Abstract]  

G. Valmadre, R. Epis, A. Pastorini, and C. Castello

Bone marrow involvement in breast cancer with pancytopenia: A case of good target selection
J Clin Oncol (Meeting Abstracts) 2008 26: 12026. [Abstract]  

J. K. Jueckstock, B. Strobl, M. Heinrigs, W. J. Janni, H. L. Sommer, and K. Friese

Locoregional hyperthermia in combination with chemotherapy for metastatic breast cancer patients: The Mammatherm- trial
J Clin Oncol (Meeting Abstracts) 2008 26: 12027. [Abstract]  

A. Özet Sr., D. Uncu, O. Kuzhan, F. Arpaci, M. Öztürk, S. Komurcu, and B. Ozturk

Evaluation of effect of oral capecitabine and oral cyclophosphamide in metastatic breast cancer patients with anhracyclin and taxan resistance
J Clin Oncol (Meeting Abstracts) 2008 26: 12028. [Abstract]  

X. J. Wang, D. Mitchell, and T. J. Lewis

Primary clinical use of sonodynamic therapy (SDT) for advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12029. [Abstract]  

J. Wang and B. Xu

The clinical characteristics and potential prognostic factors of patients with liver metastasis from breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 12030. [Abstract]  

Cancer Prevention:

C. K. Kuhl, S. Schrading, S. Weigelt, B. Arand, D. Nordhoff, R. Koenig, M. Reiser, and H. Schild

Management recommendations for women at increased familial risk for breast cancer: Results of a prospective national multimodality cohort study
J Clin Oncol (Meeting Abstracts) 2008 26: 1500. [Abstract]  

E. S. Kim, W. K. Hong, J. J. Lee, L. Mao, R. C. Morice, D. D. Liu, C. A. Jimenez, G. A. Eapen, I. I. Wistuba, and J. M. Kurie

A randomized double-blind study of the biological effects of celecoxib as a chemopreventive agent in current and former smokers
J Clin Oncol (Meeting Abstracts) 2008 26: 1501. [Abstract]  

J. A. Zell, C. E. McLaren, E. W. Gerner, and F. L. Meyskens, Jr.

Ornithine decarboxylase (Odc)-1 gene polymorphism effects on baseline tissue polyamine levels and adenoma recurrence in a randomized phase III adenoma prevention trial of DFMO + sulindac versus placebo
J Clin Oncol (Meeting Abstracts) 2008 26: 1502. [Abstract]  

A. Decensi, C. Robertson, A. Guerrieri-Gonzaga, D. Serrano, M. Cazzaniga, M. Gulisano, H. Johansson, E. Cassano, S. Moroni, K. Johnson, and B. Bonanni

A randomized double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention of high-risk premenopausal women
J Clin Oncol (Meeting Abstracts) 2008 26: 1503. [Abstract]  

L. Lashinger, L. Malone, E. Daniels, N. Smith, A. Pavone, J. K. Colby, S. Perkins, S. M. Fischer, and S. D. Hursting

Reduced levels of IGF-1 decrease tumor burden in an orthotopic mouse model of pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1504. [Abstract]  

T. O. Ogundiran, D. Huo, C. A. Adebamowo, A. A. Adenipekun, O. B. Campbell, and O. I. Olopade

Case-control study of height, weight and BMI and breast cancer risk in Nigerian women
J Clin Oncol (Meeting Abstracts) 2008 26: 1506. [Abstract]  

S. Schrading, A. Gnatzy, E. Wardelmann, M. Braun, H. Schild, and C. K. Kuhl

Magnetic resonance imaging versus mammography for diagnosing ductal carcinoma in-situ (DCIS) around invasive breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1507. [Abstract]  

R. V. van Klaveren, M. Oudkerk, W. Mali, E. Scholten, K. Nackaerts, E. Thunnissen, and H. J. de Koning

Baseline and second round results from the population based Dutch-Belgian randomized lung cancer screening trial (NELSON)
J Clin Oncol (Meeting Abstracts) 2008 26: 1508. [Abstract]  

T. Zander, S. Debey-Pascher, D. Eggle, A. Staratschek-Jox, E. Stoelben, J. Linseisen, G. Nagel, P. Boffetta, J. Schultze, and J. Wolf

Predictive value of transcriptional changes in peripheral blood for future clinical onset of lung cancer in asymptomatic smokers
J Clin Oncol (Meeting Abstracts) 2008 26: 1509. [Abstract]  

A. R. Bradbury, L. Patrick-Miller, M. Feigon, K. Pawlowski, B. Egleston, C. Ibe, C. B. Sands, S. Cummings, O. I. Olopade, and C. K. Daugherty

Should genetic testing for BRCA1/2 be permitted for minors? Opinions of parents who completed BRCA1/2 testing
J Clin Oncol (Meeting Abstracts) 2008 26: 1511. [Abstract]  

A. L. Law, W. Ng, C. W. Choi, T. K. Yau, and A. W. Lee

Screening for family members of patients with nasopharyngeal carcinoma—does early detection improve outcome?
J Clin Oncol (Meeting Abstracts) 2008 26: 1512. [Abstract]  

S. Sheinfeld Gorin, R. Franco, C. Westhoff, and New York Physicians against Cancer Study Group

HPV vaccinations one year post FDA approval
J Clin Oncol (Meeting Abstracts) 2008 26: 1513. [Abstract]  

T. M. Prowell, M. Fackler, P. Argani, N. F. Khouri, A. L. Blackford, K. Shahverdi, A. C. Wolff, N. E. Davidson, S. Sukumar, V. Stearns, and Breast Cancer Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

A prospective study of adjuvant anastrozole and gene promoter methylation in the contralateral breast of high-risk women
J Clin Oncol (Meeting Abstracts) 2008 26: 1514. [Abstract]  

T. Bao, K. Shahverdi, A. L. Blackford, T. Prowell, S. C. Jeter, P. Powers, L. Wright, C. F. Snyder, V. Stearns, and K. Visvanathan

Quality of life (QOL) changes in breast cancer patients participating in an anastrozole secondary prevention trial
J Clin Oncol (Meeting Abstracts) 2008 26: 1515. [Abstract]  

P. S. Grimison, Australian New Zealand Breast Cancer Trials Group, A. S. Coates, J. F. Forbes, J. Cuzick, C. Furnival, P. S. Craft, R. D. Snyder, R. M. Thornton, D. F. Lindsay, and R. J. Simes

Tamoxifen (TAM) for the prevention of breast cancer: Importance of specific aspects of health-related quality of life (HRQL) to global health status in the ANZ BCTG substudy of IBIS-1 (ANZ 92P1)
J Clin Oncol (Meeting Abstracts) 2008 26: 1516. [Abstract]  

H. Liang, S. S. Lo, F. Ye, J. P. Costantino, A. Hudson, and V. G. Vogel

Correlation of serum sex hormone levels with the Gail model risk of breast cancer in postmenopausal women
J Clin Oncol (Meeting Abstracts) 2008 26: 1517. [Abstract]  

M. Gamulin, A. Znaor, and A. Fucic

Increase of hormone-dependent cancer incidence in population under the age of forty
J Clin Oncol (Meeting Abstracts) 2008 26: 1518. [Abstract]  

B. S. Mann, P. Cortazar, J. R. Johnson, K. He, R. Sridhara, A. T. Farrell, R. Justice, and R. Pazdur

Differences in prior estrogen exposure may explain the difference in magnitude of breast cancer risk reduction observed in raloxifene breast cancer prevention trials
J Clin Oncol (Meeting Abstracts) 2008 26: 1519. [Abstract]  

A. Im, V. G. Vogel, G. Ahrendt, S. Lloyd, S. Garte, C. Ragin, and E. Taioli

Urinary estrogen metabolites in patients at high risk for breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1520. [Abstract]  

S. Gupta and A. Desai

Can lipophilic statins affect Her2/neu expression in breast cancer?
J Clin Oncol (Meeting Abstracts) 2008 26: 1521. [Abstract]  

C. W. Bayer, S. G. Gabram, R. J. Hendry, N. Sellers, M. B. Lund, W. Thompson, B. Vidakovic, and B. Mizaikoff

Breath analysis as a method for breast cancer early detection
J Clin Oncol (Meeting Abstracts) 2008 26: 1522. [Abstract]  

A. B. Weitberg

The antioxidant effect of lovastatin and vitamin E on phagocyte-induced DNA damage
J Clin Oncol (Meeting Abstracts) 2008 26: 1523. [Abstract]  

M. Moreno, E. Sarti, N. Herrera, J. Ramirez, V. Robles, and R. Tapia

Steroid metabolism gene CYP17, CYP1A1*2B, CYP1A1*2C and risk of breast cancer in Mexican women
J Clin Oncol (Meeting Abstracts) 2008 26: 1524. [Abstract]  

J. A. Lubinski, J. Gronwald, A. Pijpe, T. Byrski, T. Huzarski, M. Stawicka, C. Cybulski, F. van Leeuwen, and S. A. Narod

Early radiation exposures and BRCA1-associated breast cancer in young women from Poland
J Clin Oncol (Meeting Abstracts) 2008 26: 1525. [Abstract]  

U. Nawaz, J. B. Charles, A. V. Hajdenberg, N. Cohen, and J. Hajdenberg

Prospective evaluation of atorvastatin in patients with PSA relapse after definitive treatment for prostate cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1526. [Abstract]  

L. J. Peppone, K. B. Moysich, M. E. Reid, G. R. Morrow, and A. Hyland

Colorectal cancer risk from cigarette smoking increases over 5 decades
J Clin Oncol (Meeting Abstracts) 2008 26: 1527. [Abstract]  

K. M. Field, K. Phillips, M. A. Jenkins, J. McKinley, P. Weideman, M. Price, M. Friedlander, S. McLachlan, G. Lindeman, and P. Butow

Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
J Clin Oncol (Meeting Abstracts) 2008 26: 1528. [Abstract]  

M. Terenziani, G. Scaperrotta, P. Lepera, C. Meazza, M. Podda, L. Gandola, M. Greco, G. Trecate, F. Spreafico, and M. Gennaro

Specific breast-screening programme for childhood cancer survivors following exposure to ionizing radiation
J Clin Oncol (Meeting Abstracts) 2008 26: 1529. [Abstract]  

G. M. Strauss, A. Jemal, M. B. McKenna, J. A. Strauss, and K. M. Cummings

Lung cancer (LC) survival in relation to histologic subtype: Implications for LC prevention and early detection
J Clin Oncol (Meeting Abstracts) 2008 26: 1530. [Abstract]  

S. Waheed and T. A. Linthacum

Role of adjuvant HPV testing and continued Pap smear screening in women over age 6
J Clin Oncol (Meeting Abstracts) 2008 26: 1531. [Abstract]  

L. Chen, B. Crawford, J. McLennan, E. S. Hwang, R. Foster, and C. B. Powell

Combining risk-reducing salpingo-oophorectomy with mastectomy and reconstructive surgery in BRCA1 and BRCA2 mutation carrier
J Clin Oncol (Meeting Abstracts) 2008 26: 1532. [Abstract]  

H. T. Lynch, C. Snyder, J. F. Lynch, S. Ghate, S. A. Narod, and G. Gong

FIS impact upon BRCA testing uptake and prophylactic oophorectomy/mastectomy among HBOC attendees
J Clin Oncol (Meeting Abstracts) 2008 26: 1533. [Abstract]  

S. Verma, S. F. Dent, L. Paquet, and L. Bitonti

When the BRCA test is negative—Prevention strategies in women who have no detectable mutation (BRCA-) compared to women harboring positive BRCA mutations (BRCA+)
J Clin Oncol (Meeting Abstracts) 2008 26: 1534. [Abstract]  

M. Futagami

Necessity of screening for uterine cervical cancer in women younger than age 3
J Clin Oncol (Meeting Abstracts) 2008 26: 1535. [Abstract]  

K. Kamposioras, A. Valachis, I. Cortinovis, V. Karampoiki, N. P. Polyzos, G. Koukourakis, D. Tzachanis, D. Pectasides, G. Casazza, and D. Mauri

Cancer screening practice and misplaced priorities in Greece
J Clin Oncol (Meeting Abstracts) 2008 26: 1536. [Abstract]  

L. A. Keogh, K. Philips, D. Rosenthal, and J. L. Hopper

Australian clinicians and chemoprevention for women at high familial risk for breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1537. [Abstract]  

C. Saura, D. Fortuny, T. Ramon y Cajal, A. Torres, B. Graña, E. Darder, J. Sanz, J. Brunet, J. Baselga, J. Balmaña, and IMASS Collaborative Group

Cancer screening practices (CSP) among women at risk of hereditary breast and ovarian cancer syndrome (HBOS) before genetic testing in Spain
J Clin Oncol (Meeting Abstracts) 2008 26: 1538. [Abstract]  

A. B. Chagpar and K. M. McMasters

Trends in adherence to cancer screening guidelines: Are we moving in the right direction?
J Clin Oncol (Meeting Abstracts) 2008 26: 1539. [Abstract]  

A. Fontaine, K. A. Gelmon, J. M. Connors, and K. J. Savage

Secondary breast cancer in patients treated for Hodgkin lymphoma: Adherence to screening recommendations in a high-risk population
J Clin Oncol (Meeting Abstracts) 2008 26: 1540. [Abstract]  

A. Savarese, C. Vigna, F. M. Sega, B. Marozzo, I. Sperduti, F. Cognetti, and A. Caruso

Risk perception in genetic counselling for hereditary breast/ovarian cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 1541. [Abstract]  

M. E. Rader, J. Chun, A. Abraido-Lanza, A. Komorowski, J. S. Anker, and F. Schnabel

Breast cancer risk perception in a high-risk population
J Clin Oncol (Meeting Abstracts) 2008 26: 1542. [Abstract]  

G. Suneja, J. Diaz, M. Roberts, and W. Rakowski

Language and utilization of women's cancer screening: The association of Spanish language with receipt of mammography and Pap smear testing
J Clin Oncol (Meeting Abstracts) 2008 26: 1543. [Abstract]  

R. Massenburg, I. Safika, and E. A. Calhoun

Neighborhood strain and adaptation factors as multilevel predictors of mammography use among African American and Latina women across Chicago neighborhoods
J Clin Oncol (Meeting Abstracts) 2008 26: 1544. [Abstract]  

T. M. Islam and C. S. Ferdous

Inflammatory versus grade III and IV breast cancer and effect of mammogram
J Clin Oncol (Meeting Abstracts) 2008 26: 1545. [Abstract]  

M. M. Oken, T. R. Church, S. Inampudi, S. C. Oancea, G. D. Watt, M. Plunkett, G. Marquez, and The Minnesota PLCO Program and The NCI

Sensitivity of computer-aided diagnosis among participants at one center in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)
J Clin Oncol (Meeting Abstracts) 2008 26: 1546. [Abstract]  

S. M. van de Ven, M. A. van den Bosch, A. Kwong, J. Rosenberg, A. Kamaya, G. Lo, and D. M. Ikeda

Reproducibility of scoring systems used for breast density and breast parenchymal pattern assessment on X-ray mammography
J Clin Oncol (Meeting Abstracts) 2008 26: 1547. [Abstract]  

D. Rosner, A. Meschcheryakov, V. Bogatyrev, V. Sokolova, A. Hutson, G. Korzhenkova, J. Yeh, and M. Davydov

Limitation of the Gail score and mammographic density in recruiting candidate for prevention of breast cancer in high-risk women with precancerous lesions
J Clin Oncol (Meeting Abstracts) 2008 26: 1548. [Abstract]  

N. Seki, K. Eguchi, M. Kaneko, H. Ohmatsu, R. Kakinuma, E. Matsui, M. Kusumoto, T. Tsuchida, H. Nishiyama, and N. Moriyama

Individualizing the benefit of repeated screening with low-dose helical CT for lung cancer: Update of Anti-Lung Cancer Association project
J Clin Oncol (Meeting Abstracts) 2008 26: 1549. [Abstract]  

Central Nervous System Tumors:

A. Hormigo, S. V. Shmelkov, A. T. Hooper, J. Butler, D. Lyden, and S. Rafii

Expression of CD133+ in the brain of a mouse model with a lacZ reporter knock-in at the CD133 locus
J Clin Oncol (Meeting Abstracts) 2008 26: 2000. [Abstract]  

F. F. Lang, J. Gumin, T. Amano, N. Hata, A. B. Heimberger, F. Marini, M. Andreeff, K. D. Aldape, E. Sulman, and H. Colman

Tumor-derived mesenchymal stem cells in human gliomas: Isolation and biological properties
J Clin Oncol (Meeting Abstracts) 2008 26: 2001. [Abstract]  

A. Wong, S. Mitra, C. A. Del Vecchio, and S. Skirboll

Expression of EGFRvIII in brain tumor stem cells
J Clin Oncol (Meeting Abstracts) 2008 26: 2002. [Abstract]  

H. Colman, K. Sai, S. Wang, S. Popoff, K. D. Aldape, F. F. Lang, C. A. Conrad, T. Madden, A. Yung, and W. Priebe

Effect of a small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells
J Clin Oncol (Meeting Abstracts) 2008 26: 2003. [Abstract]  

G. L. Banna, R. Pallini, L. Ricci-Vitiani, M. Signore, M. Todaro, M. V. Martini, G. Maira, D. Giuffrida, L. M. Larocca, and R. De Maria

Prognostic value of cancer stem cell expression and growth in glioblastoma
J Clin Oncol (Meeting Abstracts) 2008 26: 2004. [Abstract]  

H. A. Fine, V. K. Puduvalli, M. C. Chamberlain, A. F. Carpentier, L. Cher, W. P. Mason, M. J. van den Bent, S. Hong, D. Thornton, and W. Wick

Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study
J Clin Oncol (Meeting Abstracts) 2008 26: 2005. [Abstract]  

E. G. Shaw, M. Wang, S. Coons, D. Brachman, J. C. Buckner, K. Stelzer, G. Barger, P. D. Brown, M. R. Gilbert, and M. P. Mehta

Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG)
J Clin Oncol (Meeting Abstracts) 2008 26: 2006. [Abstract]  

W. Wick Wolfgang, M. Weller o. Neurooncology Working Group of the German Cancer S

Randomized phase III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide: NOA-04
J Clin Oncol (Meeting Abstracts) 2008 26: LBA2007. [Abstract]  

E. Quant, A. D. Norden, J. Drappatz, A. Ciampa, L. Doherty, D. LaFrankie, S. Kesari, and P. Y. Wen

Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen
J Clin Oncol (Meeting Abstracts) 2008 26: 2008. [Abstract]  

E. di Tomaso, M. P. Frosch, P. K. Auluck, D. Cahill, D. G. Duda, S. R. Plotkin, J. S. Loeffler, A. G. Sorensen, T. T. Batchelor, and R. K. Jain

Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment
J Clin Oncol (Meeting Abstracts) 2008 26: 2009. [Abstract]  

J. R. Perry, W. P. Mason, K. Belanger, P. Kavan, D. Fulton, J. Easaw, S. Kirby, D. Macdonald, C. Shields, and J. Pouliot

The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma
J Clin Oncol (Meeting Abstracts) 2008 26: 2010. [Abstract]  

T. F. Cloughesy, M. D. Prados, P. Y. Wen, T. Mikkelsen, L. E. Abrey, D. Schiff, W. K. Yung, Z. Maoxia, I. Dimery, and H. S. Friedman

A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)
J Clin Oncol (Meeting Abstracts) 2008 26: 2010b. [Abstract]  

J. H. Sampson, G. E. Archer, D. D. Bigner, T. Davis, H. S. Friedman, T. Keler, D. A. Mitchell, D. A. Reardon, R. Sawaya, and A. B. Heimberger

Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM
J Clin Oncol (Meeting Abstracts) 2008 26: 2011. [Abstract]  

A. B. Heimberger, W. Sun, L. Kong, M. Abou-Ghazal, J. Wei, J. Gumin, H. Colman, W. Priebe, and F. F. Lang, Jr.

Glioblastoma stem cells mediate immune suppression that can be inhibited with Jak2/Stat3 blockade
J Clin Oncol (Meeting Abstracts) 2008 26: 2012. [Abstract]  

R. L. Derr, X. Ye, M. Islas, S. Desideri, and S. A. Grossman

The effect of hyperglycemia on survival in patients with glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2008 26: 2013. [Abstract]  

S. A. Grossman, X. Ye, M. C. Chamberlain, T. Mikkelsen, T. T. Batchelor, S. Desideri, S. Piantadosi, and H. A. Fine

Phase II trial of talampanel in conjunction with standard radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM)
J Clin Oncol (Meeting Abstracts) 2008 26: 2014. [Abstract]  

R. Stupp, A. Tosoni, W. Taal, P. Hau, M. Campone, J. Gijtenbeek, M. P. Frenay, T. Gorlia, D. Lacombe, A. A. Brandes on behalf of the EORTC Brain Tumor Group

Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: Initial report of the EORTC study 26061
J Clin Oncol (Meeting Abstracts) 2008 26: 2015. [Abstract]  

P. D. Brown, S. Krishnan, J. Sarkaria, W. Wu, P. Mischel, W. H. Yong, R. Arusell, R. B. Jenkins, J. C. Buckner, and C. Giannini

A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2008 26: 2016. [Abstract]  

B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J. F. Baurain, L. D'Hondt, C. Chaskis, A. Michotte, and J. De Greve

A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma
J Clin Oncol (Meeting Abstracts) 2008 26: 2017. [Abstract]  

U. Bogdahn, P. Hau, V. Olyushin, A. K. Mahapatra, V. Parfenov, N. K. Venkataramana, H. Wassmann, S. Ludwig, H. Heinrichs, and K. H. Schlingensiepen

Targeted therapy with AP 12009 in recurrent or refractory glioblastoma patients: Results of a phase Iib study
J Clin Oncol (Meeting Abstracts) 2008 26: 2018. [Abstract]  

R. Soffietti, R. Rudà, E. Trevisan, E. Laguzzi, D. Guarneri, C. Bomprezzi, M. Caroli, and B. Leoncini

Temozolomide (TMZ) 1 week on/1 week off as initial treatment for progressive low grade oligodendroglial tumors: A phase II AINO study
J Clin Oncol (Meeting Abstracts) 2008 26: 2019. [Abstract]  

J. F. De Groot, P. Y. Wen, K. Lamborn, S. Chang, T. F. Cloughesy, A. P. Chen, L. M. DeAngelis, M. P. Mehta, M. R. Gilbert, W. K. Yung, and M. D. Prados

Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601
J Clin Oncol (Meeting Abstracts) 2008 26: 2020. [Abstract]  

S. A. Wagner, A. Desjardins, D. A. Reardon, J. Marcello, J. E. Herndon, II, J. A. Quinn, J. N. Rich, S. Sathornsumetee, H. S. Friedman, and J. J. Vredenburgh

Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas
J Clin Oncol (Meeting Abstracts) 2008 26: 2021. [Abstract]  

J. N. Rich, A. Desjardins, S. Sathornsumetee, J. J. Vredenburgh, J. A. Quinn, S. Gururangan, A. H. Friedman, H. S. Friedman, and D. A. Reardon

Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma
J Clin Oncol (Meeting Abstracts) 2008 26: 2022. [Abstract]  

P. Nghiemphu, C. Graham, W. Liu, T. Than, A. Lai, R. Green, R. M. Elashoff, and T. F. Cloughesy

A retrospective single institutional analysis of bevacizumab and chemotherapy versus non-bevacizumab treatments for recurrent glioblastoma
J Clin Oncol (Meeting Abstracts) 2008 26: 2023. [Abstract]  

K. A. Jaeckle, W. Wu, M. Kosel, P. J. Flynn, and J. C. Buckner

Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials
J Clin Oncol (Meeting Abstracts) 2008 26: 2024. [Abstract]  

J. L. Clarke, L. E. Abrey, S. Karimi, and A. B. Lassman

Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2008 26: 2025. [Abstract]  

A. Desjardins, D. P. Barboriak, J. E. Herndon, II, J. Marcello, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, H. S. Friedman, and J. J. Vredenburgh

Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients
J Clin Oncol (Meeting Abstracts) 2008 26: 2026. [Abstract]  

A. Tosoni, E. Franceschi, V. Blatt, F. Ruggeri, F. Benevento, S. Bartolini, L. Morandi, L. Scopece, V. Mazzocchi, and A. A. Brandes

Recurrence pattern after concomitant radio-chemotherapy in newly diagnosed glioblastoma patients: Correlation with MGMT promoter methylation status
J Clin Oncol (Meeting Abstracts) 2008 26: 2027. [Abstract]  

A. B. Lassman, F. M. Iwamoto, P. H. Gutin, and L. E. Abrey

Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM)
J Clin Oncol (Meeting Abstracts) 2008 26: 2028. [Abstract]  

A. Korfel, L. Fischer, P. Martus, M. Weller, H. Klasen, B. Rohden, A. Röth, B. Storek, M. Hummel, and E. Thiel

Prospective evaluation of meningeal involvement in primary CNS lymphoma (PCNSL)
J Clin Oncol (Meeting Abstracts) 2008 26: 2029. [Abstract]  

K. Jahnke, A. Korfel, N. E. Bechrakis, G. Willerding, D. F. Kraemer, L. Fischer, and E. Thiel

Ifosfamide or trofosfamide in patients with intraocular lymphoma: Final report
J Clin Oncol (Meeting Abstracts) 2008 26: 2030. [Abstract]  

E. T. Wong, M. Yu, S. Song, S. Jeyapalan, M. Groves, K. D. Swanson, and S. Gautam

Vascular endothelial growth factor and matrix metalloprotease in lymphomatous meningitis
J Clin Oncol (Meeting Abstracts) 2008 26: 2031. [Abstract]  

M. Danova, E. Bajetta, L. Crinò, S. Del Prete, S. Cascinu, S. Salvagni, and S. Siena

Multicenter phase II study of temozolomide therapy for brain metastases in patients with malignant melanoma, breast cancer, or non-small cell lung cancer: Final results
J Clin Oncol (Meeting Abstracts) 2008 26: 2032. [Abstract]  

L. E. Abrey, P. Wen, R. Govindan, H. Reimers, J. R. Rigas, H. I. Robins, E. Allen-Freda, B. Gao, J. Ko, and A. Johri

Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study
J Clin Oncol (Meeting Abstracts) 2008 26: 2033. [Abstract]  

M. B. Streiff, S. A. Grossman, X. Ye, T. S. Kickler, G. J. Lesser, T. T. Batchelor, J. T. Jani, and S. Desideri

Elevated factor VIII activity is common in patients with newly diagnosed high-grade gliomas
J Clin Oncol (Meeting Abstracts) 2008 26: 2035. [Abstract]  

Y. Lin, T. Jiang, and S. Song

Plasma IGFBP-2 for prediction of clinical outcomes of patients with gliomas
J Clin Oncol (Meeting Abstracts) 2008 26: 2036. [Abstract]  

C. Balañá, C. Carrato, J. Ramírez, M. Berdiel, D. Kaen, J. Sánchez, M. Tarón, C. Hostalot, A. Ariza, and R. Rosell

Concordance and clinical value of the MGMT promoter methylation pattern in tissue with paired serum and MGMT protein expression in a series of glioblastoma (GB) patients
J Clin Oncol (Meeting Abstracts) 2008 26: 2037. [Abstract]  

F. M. Iwamoto, A. F. Hottinger, S. Karimi, E. Riedel, K. Panageas, B. Gu, J. Rao, M. Fleisher, E. Holland, L. M. DeAngelis, and A. Hormigo

A longitudinal prospective study of YKL-40 and matrix metalloproteinase-9 (MMP-9) as serum tumor markers in gliomas
J Clin Oncol (Meeting Abstracts) 2008 26: 2038. [Abstract]  

P. Z. New, D. Baskin, T. Trask, R. Cavaliere, A. R. Chaudhury, S. Bell, L. K. Aguilar, E. Aguilar-Cordova, A. Chiocca, and K. Wong

Radiographic and immunologic responses to adjuvant immunotherapy for malignant gliomas
J Clin Oncol (Meeting Abstracts) 2008 26: 2039. [Abstract]  

M. J. van den Bent, W. Wick, A. M. Liepa, V. K. Puduvalli, A. F. Carpentier, L. Cher, W. P. Mason, M. J. Taphoorn, S. Hong, and H. A. Fine

Time to deterioration in dimensions of health-related quality of life (HRQL) for patients with recurrent glioblastoma multiforme (GBM): Results from the randomized, phase III trial of enzastaurin (ENZ) versus lomustine (CCNU)
J Clin Oncol (Meeting Abstracts) 2008 26: 2040. [Abstract]  

M. J. Taphoorn, L. Claassens, N. K. Aaronson, C. Coens, M. Mauer, D. Osoba, R. Stupp, R. Mirimanoff, M. J. Van den Bent, and A. Bottomley

The EORTC QLQ-BN20 questionnaire for assessing the health-related quality of life (HRQoL) in brain cancer patients: A phase IV validation study on behalf of the EORTC QLG, BCG, ROG, NCIC-CTG
J Clin Oncol (Meeting Abstracts) 2008 26: 2041. [Abstract]  

D. Mitchell, G. E. Archer, D. D. Bigner, H. S. Friedman, D. Lally-Goss, J. E. Herndon, II, S. McGehee, R. McLendon, D. A. Reardon, and J. H. Sampson

Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM
J Clin Oncol (Meeting Abstracts) 2008 26: 2042. [Abstract]  

T. T. Batchelor, G. J. Lesser, and S. A. Grossman

Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma
J Clin Oncol (Meeting Abstracts) 2008 26: 2043. [Abstract]  

M. Weiler, C. Hartmann, D. Wiewrodt, U. Herrlinger, J. Schuth, M. Bamberg, A. von Deimling, M. Weller, and W. Wick

Radiochemotherapy with daily concomitant and adjuvant one week on/one week off temozolomide plus indomethacin in newly diagnosed glioblastoma: A phase II trial
J Clin Oncol (Meeting Abstracts) 2008 26: 2044. [Abstract]  

S. R. Plotkin, C. F. Halpin, M. J. McKenna, T. T. Batchelor, J. S. Loeffler, and F. G. Barker, II

Treatment of progressive neurofibromatosis type 2-related vestibular schwannoma with erlotinib
J Clin Oncol (Meeting Abstracts) 2008 26: 2045. [Abstract]  

J. O. Blakeley, K. Redmon, E. Ford, E. Dunbar, K. Singh, M. Armour, S. A. Grossman, and L. Kleinberg

Impact of preradiation versus postoperative MRI changes in T1w contrast enhanced and FLAIR images on radiation treatment planning
J Clin Oncol (Meeting Abstracts) 2008 26: 2046. [Abstract]  

E. D. Hager, H. Sahinbas, D. H. Groenemeyer, and F. Migeod

Prospective phase II trial for recurrent high-grade gliomas with capacitive coupled low radiofrequency (LRF) hyperthermia
J Clin Oncol (Meeting Abstracts) 2008 26: 2047. [Abstract]  

G. Dresemann, C. Hosius, J. Lilienthal, E. Schleyer, U. Bogdan, M. Weller, and W. Paulus

Treatment failure due to intracerebral stem cell-like behavior of glioblastoma (GBM) cells: A reason for targeted maintenance therapy with imatinib (I) and hydroxyurea (H)? An analysis of study DE21 and DE40 (Ambrosia)
J Clin Oncol (Meeting Abstracts) 2008 26: 2048. [Abstract]  

D. Dutta, N. Shah, T. Gupta, A. Munshi, and R. Jalali

Prospective analysis of endocrine function in children with residual/recurrent low-grade brain tumours treated with high-precision stereotactic conformal radiotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 2049. [Abstract]  

A. E. Sturdza, A. Bezjak, G. R. Pond, K. Brrows, B. Millar, C. Garraway, N. Laperriere, L. Dawson, and R. K. Wong

A phase II prospective study of standardized steroid dosing for patients with brain metastases undergoing whole brain radiotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 2050. [Abstract]  

D. A. Reardon, T. F. Cloughsey, J. J. Raizer, J. Laterra, D. Schiff, X. Yang, E. Loh, and P. Y. Wen

Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2008 26: 2051. [Abstract]  

L. Bauchet, V. Rigau, H. Mathieu-Daude, P. Fabbro-Peray, M. Fabbro, O. L. Chinot, L. Taillandier, D. Figarella-Branger, F. Labrousse, H. Duffau, and J. Honnorat

Patterns of care for 952 patients with newly diagnosed glioblastoma
J Clin Oncol (Meeting Abstracts) 2008 26: 2052. [Abstract]  

E. J. Wuthrick, W. J. Curran, Jr., M. Werner-Wasik, A. Lin, R. A. Axelrod, A. Pereira-Rico, H. Murphy, M. Machtay, and A. P. Dicker

A phase I trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 2053. [Abstract]  

G. B. Roldán, A. E. Sijben, J. B. McIntyre, J. C. Easaw, E. Yan, P. A. Forsyth, I. F. Parney, A. M. Magliocco, H. Bernsen, and J. G. Cairncross

Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2008 26: 2054. [Abstract]  

M. R. Rosenfeld, M. C. Chamberlain, S. A. Grossman, D. M. Peereboom, G. J. Lesser, T. T. Batchelor, S. Desideri, A. M. Salazar, X. Ye, and New Approaches to Brain Tumor Therapy Consortium

A phase II trial of radiation plus temozolomide followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma multiforme (NABTT #0501)
J Clin Oncol (Meeting Abstracts) 2008 26: 2055. [Abstract]  

U. Lassen, B. Hasselbalch, M. Sørensen, M. Holmberg, S. Hansen, M. Kosteljanetz, H. Laursen, and H. S. Poulsen

A phase II trial with cetuximab, bevacizumab, and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolamide
J Clin Oncol (Meeting Abstracts) 2008 26: 2056. [Abstract]  

J. P. Kirkpatrick, J. N. Rich, J. J. Vredenburgh, A. Desjardins, J. A. Quinn, S. Gururangan, S. Sathornsumetee, M. J. Egorin, H. S. Friedman, and D. A. Reardon

Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG)
J Clin Oncol (Meeting Abstracts) 2008 26: 2057. [Abstract]  

U. Bode, M. Windelberg, M. Massimino, E. Khuhlaeva, M. Warmuth-Metz, R. D. Kortmann, F. Bach, and G. Fleischhack

Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents
J Clin Oncol (Meeting Abstracts) 2008 26: 2058. [Abstract]  

J. A. Haas, M. R. Witten, J. R. Matera, E. P. Montchal, J. A. Brown, M. Brisman, N. Epstein, J. Lauritano, K. Episcopia, and A. J. Katz

Spinal reirradiation using the Cyberknife-preliminary efficacy from a single institution
J Clin Oncol (Meeting Abstracts) 2008 26: 2059. [Abstract]  

R. DeBoer, S. A. Grimm, J. Chandler, L. Gallot, S. Kennedy, K. Burns, L. Rice, C. Cabreza, K. Muro, and J. J. Raizer

A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas
J Clin Oncol (Meeting Abstracts) 2008 26: 2060. [Abstract]  

L. M. Núñez, A. Muggeri, E. Arias, A. L. Taratuto, G. Sevlever, B. Diez, and H. Martinetto

EGFR/AKT pathways alterations in gliomas
J Clin Oncol (Meeting Abstracts) 2008 26: 2061. [Abstract]  

H. S. Friedman, A. Desjardins, J. J. Vredenburgh, J. N. Rich, S. Sathornsumetee, S. Gururangan, J. A. Quinn, and D. A. Reardon

Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2008 26: 2062. [Abstract]  

B. Ingold, P. Schraml, S. Stopatschinskaja, F. L. Heppner, and H. Moch

Frequent MGMT gene promoter methylation in brain metastases of melanoma, lung, breast and renal carcinoma
J Clin Oncol (Meeting Abstracts) 2008 26: 2063. [Abstract]  

T. Y. Kang, A. Thomas, L. Tsao, D. M. Peereboom, and E. Hsi

Correlation of tumor infiltrating lymphocytes and outcome in primary central nervous system lymphomas
J Clin Oncol (Meeting Abstracts) 2008 26: 2064. [Abstract]  

N. Panakis, C. Offiah, A. Azizan, A. Roy, and P. N. Plowman

Sorafenib therapy and CNS hemangioblastomas in individuals with Von Hippel Lindau syndrome
J Clin Oncol (Meeting Abstracts) 2008 26: 2065. [Abstract]  

J. Engh, A. Mintz, F. Lieberman, and A. B. Kassam

Completely endoscopic resection of glioblastomas using a transparent conduit: Proof of concept
J Clin Oncol (Meeting Abstracts) 2008 26: 2066. [Abstract]  

C. Kim, J. Han, C. Park, S. Lee, D. Kim, S. Paek, D. Kim, D. Heo, I. Kim, and H. Jung

Pre-radiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: A retrospective analysis
J Clin Oncol (Meeting Abstracts) 2008 26: 2067. [Abstract]  

O. L. Chinot, M. Sanson, M. Barrié, M. Fabbro, L. Taillandier, J. Honnorat, D. Figarella-Branger, K. Mokhtari, R. Guillevin, and K. Hoang-Xuan

Phase II study of combination BCNU and temozolomide (TMZ) prior to radiotherapy in newly diagnosed anaplastic oligodendroglial tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2068. [Abstract]  

K. Scheinemann, U. Bartels, A. Huang, C. Hawkins, E. Bouffet, and U. Tabori

Feasibility and efficacy of second-line chemotherapy at recurrence for pediatric low-grade gliomas: A comparative population-based study
J Clin Oncol (Meeting Abstracts) 2008 26: 2069. [Abstract]  

L. M. DeAngelis, J. L. Clarke, and H. R. Perez

Retrospective analysis of patients with leptomeningeal disease (LMD) in the MRI era
J Clin Oncol (Meeting Abstracts) 2008 26: 2070. [Abstract]  

M. E. Salacz, A. Desjardins, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, S. Sathornsumetee, K. Goli, H. S. Friedman, and D. A. Reardon

Treatment of adults with recurrent progressive low-grade glioma using imatinib mesylate and hydroxyurea
J Clin Oncol (Meeting Abstracts) 2008 26: 2071. [Abstract]  

S. Shen, R. Lustig, K. D. Judy, J. B. Fiveash, and J. S. Shan

Open-label, dose confirmation and dosimetry study of Interstitial ¹³¹I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2008 26: 2072. [Abstract]  

G. Vassal, N. Hamelin, P. Opolon, R. Versace, and B. Geoerger

The topoisomerase I inhibitor gimatecan exhibits synergistic antitumor activity in combination with imatinib mesylate and everolimus against malignant glioma xenografts
J Clin Oncol (Meeting Abstracts) 2008 26: 2073. [Abstract]  

R. Maron, J. J. Vredenburgh, A. Desjardins, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Gururangan, S. A. Wagner, M. E. Salacz, and H. S. Friedman

Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2008 26: 2074. [Abstract]  

J. K. Altman, C. Tellez, J. Chandler, R. M. Levy, C. Getch, R. Cohn, L. Gallot, M. Marymont, S. A. Grimm, and J. J. Raizer

Phase II trial of recurrent primary CNS lymphoma (PCNSL) treated with pemetrexed
J Clin Oncol (Meeting Abstracts) 2008 26: 2075. [Abstract]  

U. Bogdahn, A. K. Mahapatra, V. Olyushin, V. Parfenov, G. Stockhammer, S. Ludwig, G. Wuerth, H. Heinrichs, and K. H. Schlingensiepen

Results of a phase Iib active-controlled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma
J Clin Oncol (Meeting Abstracts) 2008 26: 2076. [Abstract]  

S. E. Combs, D. Schulz-Ertner, C. Hartmann, T. Welzel, C. Timke, K. Herfarth, A. von Deimling, L. Edler, M. Platten, W. Wick, and J. Debus

Phase I/II study of cetuximab plus temozolomide as radiochemotherapy for primary glioblastoma (GERT)—Eudract number 2005–003911–63; NCT00311857
J Clin Oncol (Meeting Abstracts) 2008 26: 2077. [Abstract]  

C. E. Murray, R. D’Agostino, Jr., and G. J. Lesser

Retreatment with a prolonged temozolomide (TMZ) dosing schedule in patients (pts) with recurrent malignant gliomas (MG)
J Clin Oncol (Meeting Abstracts) 2008 26: 2078. [Abstract]  

A. A. Brandes, A. Tosoni, E. Franceschi, E. Mazza, A. Santoro, M. Faedi, R. Labianca, R. Bertorelle, T. Perrone, and E. Pesenti

A phase II multicentric trial of fotemustine (FTM) in patients (pts) with recurrent/progressive glioblastoma after radiotherapy plus concomitant and/or adjuvant temozolomide: A GICNO (Gruppo Italiano Cooperativo di Neuro-Oncologia) study
J Clin Oncol (Meeting Abstracts) 2008 26: 2079. [Abstract]  

C. Colavolpe, E. Guedj, J. Mancini, C. Bequet-Boucard, P. Metellus, M. Barrie, D. Taieb, D. Figarella-Branger, O. Mundler, and O. L. Chinot

Pretherapeutic prognostic impact of FDG-PET in high-grade gliomas: A multivariate analysis including all consensual prognostics factors
J Clin Oncol (Meeting Abstracts) 2008 26: 2080. [Abstract]  

M. C. Chamberlain and M. J. Glantz

-interferon for recurrent WHO grade 1 meningioma
J Clin Oncol (Meeting Abstracts) 2008 26: 2081. [Abstract]  

A. S. Desai and S. A. Grossman

Association of melanoma with glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2008 26: 2082. [Abstract]  

A. Silvani, A. Fiumani, V. Scaioli, E. Lamperti, P. Gaviani, M. Eoli, C. Falcone, A. Salmaggi, and A. Boiardi

A phase II study evaluating systemic sagopilone (ZK-EPO) treatment in patients with recurrent malignant gliomas
J Clin Oncol (Meeting Abstracts) 2008 26: 2083. [Abstract]  

J. A. Quinn, X. S. Jiang, J. N. Rich, A. Desjardins, J. J. Vredenburgh, D. A. Reardon, S. Gururangan, A. R. Walker, R. Birch, A. H. Friedman, and H. S. Friedman

Phase I trial of temozolomide plus O⁶-benzylguanine on three different 5-day temozolomide regimens for patients with progressive glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2008 26: 2084. [Abstract]  

P. N. Shah, V. A. Kumar, E. Jung, E. A. Knopp, J. S. Babb, G. Johnson, M. L. Gruber, D. Zagzag, S. Raza, and A. Narayana

Comparison of dynamic susceptibility contrast MRI with conventional MRI in evaluating tumor response following bevacizumab therapy in recurrent high-grade gliomas
J Clin Oncol (Meeting Abstracts) 2008 26: 2085. [Abstract]  

K. Ogawa, Y. Yoshii, N. Shikama, K. Nakamura, T. Uno, H. Onishi, J. Itami, Y. Shioyama, H. Ito, and S. Murayama

Risk factors and treatment outcomes of spinal recurrence from intracranial germinoma
J Clin Oncol (Meeting Abstracts) 2008 26: 2086. [Abstract]  

D. E. Ney and L. E. Abrey

Maintenance rituximab for CNS lymphoma
J Clin Oncol (Meeting Abstracts) 2008 26: 2087. [Abstract]  

S. Phuphanich, J. Rudnick, R. Chu, J. S. Yu, and K. L. Black

A phase I trial of gefitinib and sirolimus in adults with recurrent glioblastoma multiforme (GBM)
J Clin Oncol (Meeting Abstracts) 2008 26: 2088. [Abstract]  

A. Narayana, S. Raza, J. G. Golfinos, G. Johnson, E. A. Knopp, D. Zagzag, I. Fischer, P. Medabalmi, P. Eagan, and M. L. Gruber

Bevacizumab therapy in recurrent high grade glioma: Impact on local control and survival
J Clin Oncol (Meeting Abstracts) 2008 26: 13000. [Abstract]  

C. Chaskis, J. Sadones, A. Michotte, M. Dujardin, H. Everaert, and B. Neyns

A phase II trial of sunitinib in patients with recurrent high-grade glioma
J Clin Oncol (Meeting Abstracts) 2008 26: 13001. [Abstract]  

D. Nass, S. Rosenwald, E. Sitbon, G. Lithwick, E. Elyakim, H. Cholakh, Y. Spector, N. Rosenfeld, R. Aharonov, I. Barshack, and Z. Bentwich

MicroRNAs as specific biomarkers for distinguishing between primary and metastatic brain tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 13002. [Abstract]  

T. Ryken, T. Carlisle, J. Buatti, P. Kirby, J. Maley, R. Hohl, B. J. Smith, J. Greenlee, M. Frees, and M. Rogers

Treatment of adults with newly diagnosed glioblastoma multiforme or anaplastic astrocytoma with surgery, gliadel wafers and limited field radiation plus concomitant temozolomide followed by adjuvant temozolomide
J Clin Oncol (Meeting Abstracts) 2008 26: 13003. [Abstract]  

D. F. Kraemer, L. Angelov, N. D. Doolittle, T. Siegal, D. M. Peereboom, K. Jahnke, S. Bell, G. Barnett, J. McGregor, and E. A. Neuwelt

The importance of total dose intensity in the treatment of primary central nervous system lymphoma
J Clin Oncol (Meeting Abstracts) 2008 26: 13004. [Abstract]  

H. K. Gan, L. Cher, A. Benson, A. Dowling, and M. Rosenthal

A phase II trial of temolozomide in patients with untreated high grade oligodengroglial brain tumours
J Clin Oncol (Meeting Abstracts) 2008 26: 13005. [Abstract]  

J. D. Schiffman, Y. Wang, S. R. Vandenberg, P. G. Fisher, J. M. Ford, H. Ji, and J. G. Hodgson

Molecular inversion probes (MIPs) identify novel copy number changes in pediatric gliomas
J Clin Oncol (Meeting Abstracts) 2008 26: 13006. [Abstract]  

A. Dresemann, A. Hobbold, and G. Dresemann

Bevacizumab (B) plus irinotecan (I) in progressive multiple pretreated and temozolomide (T) refractory glioblastoma multiforme (GBM): A single center experience using a low dose regimen
J Clin Oncol (Meeting Abstracts) 2008 26: 13007. [Abstract]  

S. Sathornsumetee, J. J. Vredenburgh, J. N. Rich, A. Desjardins, J. A. Quinn, A. E. Mathe, S. Gururangan, A. H. Friedman, H. S. Friedman, and D. A. Reardon

Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2008 26: 13008. [Abstract]  

J. Hu, S. G. Groshen, D. D. Tsao-Wei, and M. C. Chamberlain

Conditional survival of malignant glioma patients
J Clin Oncol (Meeting Abstracts) 2008 26: 13009. [Abstract]  

T. M. Mayer, J. Lacy, and J. Baehring

A single institution’s experience with bevacizumab and cytoxic chemotherapy in progressive malignant glioma
J Clin Oncol (Meeting Abstracts) 2008 26: 13010. [Abstract]  

M. J. Gil Gil Sr., M. Martinez-Garcia, G. Reynes, E. Costas, C. Fernández-Chacón, S. Pernas, M. Benavides, A. Herrero, J. Perez-Martin, C. Balañá, and Grupo Español de Neuro-Oncología Médica

Combination of bevacizumab plus irinotecan in recurrent malignant gliomas (MG): A retrospective study of efficacy and safety
J Clin Oncol (Meeting Abstracts) 2008 26: 13011. [Abstract]  

C. Nieder, A. Pawinski, and S. T. Astner

Disease presentation and course in patients with a high number of multiple brain metastases
J Clin Oncol (Meeting Abstracts) 2008 26: 13012. [Abstract]  

R. M. Zuniga, R. Torcuator, T. Doyle, J. Anderson, R. Jain, J. Orley, M. Rosenblum, and T. Mikkelsen

Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan
J Clin Oncol (Meeting Abstracts) 2008 26: 13013. [Abstract]  

D. N. Korones, M. Milano, and P. Okunieff

Accelerated radiotherapy and temozolomide in adults with newly diagnosed glioblastoma multiforme: A pilot study
J Clin Oncol (Meeting Abstracts) 2008 26: 13014. [Abstract]  

M. M. Abdel Wahab, K. M. Maher, and M. A. Osman

The prognostic value of radiological bio-markers for detection of cerebral glioma grades and early evaluation of tumor response to radiation therapy using MRI perfusion and spectroscopy
J Clin Oncol (Meeting Abstracts) 2008 26: 13015. [Abstract]  

H. M. Strik, J. H. Buhk, C. Bock, A. L. Hoffmann, A. Wrede, C. Marosi, U. Kaiser, M. Christmann, B. Kaina, and M. Bähr

Tegwondo: Development of a novel near-continuous dose-dense temozolomide regimen for the treatment of recurrent brain tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 13016. [Abstract]  

R. Nishikawa

Efficacy and safety of long-term administration of temozolomide monotherapy in patients with anaplastic astrocytoma at first relapse
J Clin Oncol (Meeting Abstracts) 2008 26: 13017. [Abstract]  

M. Glas, T. Hundsberger, M. Stuplich, D. Wiewrodt, D. Kurzwelly, B. Nguyen-Huu, K. Rasch, and U. Herrlinger

Nimustine plus teniposide in recurrent glioblastoma
J Clin Oncol (Meeting Abstracts) 2008 26: 13018. [Abstract]  

K. Elandt, M. R. Hassler, S. Oberndorfer, T. Brücke, C. C. Zielinski, and C. Marosi

Severe thrombocytopenia after the first cycle of temozolomide: Who is at risk?
J Clin Oncol (Meeting Abstracts) 2008 26: 13019. [Abstract]  

K. Reiss, K. Urbanska, L. DelValle, and P. J. Mencel

PPAR agonist fenofibrate inhibits IGF-I - mediated growth and DNA repair responses and sensitizes human glioblastoma cells to cisplatin
J Clin Oncol (Meeting Abstracts) 2008 26: 13020. [Abstract]  

M. Martinez Garcia, A. Tortosa, X. Maldonado, S. Gonzalez, C. Balañá, O. Gallego, N. Viñolas, R. Fuentes, V. Navarro, and M. Gil

MGMT promoter methylation status in newly diagnosed glioblastomas: Retrospective analysis from a clinical series of patients
J Clin Oncol (Meeting Abstracts) 2008 26: 13021. [Abstract]  

Developmental Therapeutics: Cytotoxic Chemotherapy:

R. M. Strother, D. Jones, L. Li, A. Younger, L. H. Einhorn, S. Williams, and C. J. Sweeney

Effect of the C3435T genetic polymorphism in MDR1 on etoposide pharmacokinetics
J Clin Oncol (Meeting Abstracts) 2008 26: 2500. [Abstract]  

J. R. Infante, J. L. Spratlin, R. Kurzrock, S. G. Eckhardt, H. A. Burris, III, T. A. Puchalski, J. Li, K. Wu, J. Ochs, and R. S. Herbst

Clinical, pharmacokinetic (PK), pharmacodynamic findings in a phase I trial of weekly (wkly) intravenous AZD4877 in patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2501. [Abstract]  

K. T. Flaherty, L. Gore, A. N. Avadhani, J. L. Spratlin, K. Harlacker, Z. Zhong, R. G. Johnson, A. L. Hannah, P. J. O’Dwyer, and S. G. Eckhardt

First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or Q
J Clin Oncol (Meeting Abstracts) 2008 26: 2502. [Abstract]  

A. Elfiky, M. W. Saif, M. Beeram, S. O' Brien, N. Lammanna, J. E. Castro, J. Woodworth, R. Perea, C. Storgard, and D. D. Von Hoff

BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience
J Clin Oncol (Meeting Abstracts) 2008 26: 2503. [Abstract]  

I. Puzanov, W. Lee, J. D. Berlin, M. W. Calcutt, D. L. Hachey, W. L. Vermeulen, V. J. Spanswick, J. A. Hartley, A. P. Chen, and M. L. Rothenberg

Final results of phase I and pharmacokinetic trial of SJG-136 administered on a daily x 3 schedule
J Clin Oncol (Meeting Abstracts) 2008 26: 2504. [Abstract]  

D. Sarker, D. Anderson, V. J. Spanswick, S. Davies, R. Agarwal, G. Aitken, D. J. Kerr, J. A. Hartley, I. Judson, and M. R. Middleton

Preliminary results of a Cancer Research UK phase I trial combining the dinitrobenzamide prodrug CB1954 (tretazicar) and the NQO2 substrate EP-0152R (caricotamide) intravenously (IV) every 3 weeks
J Clin Oncol (Meeting Abstracts) 2008 26: 2505. [Abstract]  

J. M. van der Bol, R. H. Mathijssen, J. Verweij, A. S. Planting, G. M. Creemers, A. Sparreboom, and F. A. de Jong

CYP3A phenotype-based individualized dosing of irinotecan to reduce interindividual variability in pharmacokinetics and toxicity: Results from a randomized trial
J Clin Oncol (Meeting Abstracts) 2008 26: 2506. [Abstract]  

B. C. Goh, R. A. Soo, S. Lim, J. Zhang, T. Furuie, P. D. Urrea, and L. S. Rosen

Inter-ethnic variability of S-1 pharmacokinetics (PK) and correlation with CYP2A6 phenotyping
J Clin Oncol (Meeting Abstracts) 2008 26: 2507. [Abstract]  

H. Arkenau, J. Barriuso, D. Olmos, C. Barlow, J. S. De Bono, I. Judson, S. Stapelton, J. Hanwell, S. Ashley, and S. B. Kaye

Prospective validation of a prognostic score to improve patient selection for phase I trials
J Clin Oncol (Meeting Abstracts) 2008 26: 2508. [Abstract]  

S. C. Postel-Vinay, H. Arkenau, S. Ashley, J. Barriuso, D. Olmos, H. Shaw, M. Wright, I. Judson, J. De-Bono, and S. B. Kaye

Clinical benefit in phase I trials of novel molecularly targeted agents: Does dose matter?
J Clin Oncol (Meeting Abstracts) 2008 26: 2509. [Abstract]  

J. Ang, H. Arkenau, D. Olmos, J. Barriuso, S. Ashley, A. Little, S. Pacey, J. S. De Bono, I. Judson, and S. B. Kaye

90-day mortality rate in cancer patients treated within the context of phase I trials: Can we identify patients who should not go on trial?
J Clin Oncol (Meeting Abstracts) 2008 26: 2510. [Abstract]  

A. Roy, H. Zhu, M. Cohen, L. Zhang, and M. Pfister

Analysis of ixabepilone exposure-response for neutropenia in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 2511. [Abstract]  

M. M. Woo, Clinical investigators TBD, J. Zhang, F. Rocha, A. Fandi, and H. F. Schran

Clinical pharmacokinetics (PK) of two oral dosing schedules of gimatecan in a phase I study: Implications for safety and efficacy
J Clin Oncol (Meeting Abstracts) 2008 26: 2512. [Abstract]  

J. Y. Bruce, D. Geary, B. de las Heras, A. Soto, P. Garcia Paramio, A. Yovine, R. L. Schilsky, S. D. Undevia, and M. J. Ratain

Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations
J Clin Oncol (Meeting Abstracts) 2008 26: 2513. [Abstract]  

M. W. Saif, L. S. Rosen, J. Zhang, C. Zergebel, L. Ravage-Mass, P. D. Urrea, and M. S. Gordon

A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics (PK) of 5-fluorouracil (5-FU)
J Clin Oncol (Meeting Abstracts) 2008 26: 2514. [Abstract]  

J. M. Vainshtein, M. H. Ghalib, M. Kumar, I. Chaudhary, M. Maniar, D. R. Taft, S. Cosenza, E. P. Reddy, S. Goel, and S. Mani

Phase I study of ON 01910.Na, a novel polo-like kinase 1 pathway modulator, administered as a weekly 24-hour continuous infusion in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 2515. [Abstract]  

J. J. Stephenson, N. Lewis, J. C. Martin, A. Ho, J. Li, K. Wu, L. Pace, J. P. Eder, and G. K. Schwartz

Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 2516. [Abstract]  

S. F. Jones, H. A. Burris, III, H. Dumez, J. R. Infante, C. Fowst, P. Gerletti, H. Xu, J. Jakubczak, N. Mellaerts, and P. Schöffski

Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results
J Clin Oncol (Meeting Abstracts) 2008 26: 2517. [Abstract]  

J. M. Foran, F. Ravandi, S. M. O'Brien, G. Borthakur, M. Rios, P. Boone, J. Worrell, K. H. Mallett, M. Squires, L. H. Fazal, and H. M. Kantarjian

Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia
J Clin Oncol (Meeting Abstracts) 2008 26: 2518. [Abstract]  

E. R. Plummer, H. Calvert, H. Arkenau, K. H. Mallett, M. Squires, D. Smith, S. Lewis, and I. Judson

A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours
J Clin Oncol (Meeting Abstracts) 2008 26: 2519. [Abstract]  

R. B. Cohen, S. F. Jones, M. von Mehren, J. Cheng, D. M. Spiegel, B. Laffranchi, M. Mariani, R. Spinelli, D. Magazzu, and H. A. Burris, III

Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2520. [Abstract]  

M. Cohen, D. Mould, A. Roy, M. Mandava, and M. Pfister

A population pharmacokinetic analysis of ixabepilone in patients with cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 2521. [Abstract]  

M. A. Amantea, B. E. Houk, and C. Bello

Population pharmacokinetics of sunitinib in Japanese and Western healthy volunteers, solid tumor, metastatic renal cell carcinoma (MRCC) and imatinib-resistant or -intolerant gastrointestinal stromal tumors (GIST) patients
J Clin Oncol (Meeting Abstracts) 2008 26: 2522. [Abstract]  

P. Schaiquevich, J. C. Panetta, S. Throm, N. C. Daw, J. R. Geyer, W. L. Furman, and C. F. Stewart

Population pharmacokinetic (PK) analysis of gefitinib in pediatric cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 2523. [Abstract]  

D. Yin, M. L. Paccagnella, M. Q. Lacy, J. S. De Bono, P. Haluska, A. Gualberto, and A. Sharma

Population pharmacokinetics of CP-751,871, a monoclonal antibody against IGF-I receptor, in patients with multiple myeloma or solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2524. [Abstract]  

Y. Xin, T. M. Tohnya, R. S. Herbst, D. S. Mendelson, S. G. Eckhardt, P. J. O'Dwyer, W. Novotny, D. E. Allison, B. L. Lum, and N. Jumbe

Population pharmacokinetic (PPK) analysis of recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a Phase 1a Study in advanced cancer and lymphoma
J Clin Oncol (Meeting Abstracts) 2008 26: 2525. [Abstract]  

E. Chatelut, A. Pétain, J. Azard, D. Kattygnarath, C. Delbaldo, B. Geoerger, M. Barrois, S. Séronie-Vivien, A. Lecesne, and G. Vassal

Population pharmacokinetics of imatinib in children and adults
J Clin Oncol (Meeting Abstracts) 2008 26: 2526. [Abstract]  

B. S. Choi, K. D. Holen, D. Alberti, W. Schelman, J. Kolesar, J. P. Thomas, W. Antholine, R. Marnocha, J. Eickhoff, and G. Wilding

The maximum tolerated dose and biologic effects of 3-amino-pyridine-2-carboxaldehyde thiosemicarbazone (T) in combination with irinotecan (I) for patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2527. [Abstract]  

B. Y. Wong, G. I. Shapiro, M. S. Gordon, M. J. Borad, J. P. Eder, R. Tibes, D. S. Mendelson, E. Wasserman, T. Kawabe, and S. Sharma

Phase I studies of CBP501, a novel G2 checkpoint abrogator, alone and combined with cisplatin (CDDP) in advanced solid tumor patients (pts)
J Clin Oncol (Meeting Abstracts) 2008 26: 2528. [Abstract]  

G. K. Dy, G. A. Croghan, Y. Qi, J. Glockner, L. Hanson, M. Roos, A. D. Tan, J. R. Molina, and A. A. Adjei

Phase I trial of the mTOR inhibitor RAD001 (R) in combination with two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 (P) in patients (pts) with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2529. [Abstract]  

P. Witteveen, M. Langenberg, H. M. Verheul, J. Roodhart, M. Roelvink, J. van der Sar, E. Brendel, N. Laferriere, J. H. Schellens, and E. E. Voest

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2530. [Abstract]  

S. P. Anthony, W. Read, P. J. Rosen, R. Tibes, D. Park, D. Everton, B. Tseng, J. Whisnant, and D. D. Von Hoff

Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity
J Clin Oncol (Meeting Abstracts) 2008 26: 2531. [Abstract]  

S. M. O'Brien, N. Vey, D. A. Rizzieri, H. M. Kantarjian, T. Prebet, F. Ravandi, T. F. Jacobsen, B. I. Nilsson, K. Staudacher, and F. J. Giles

A phase I study with CP-4055 in patients with hematologic malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 2532. [Abstract]  

C. Mueller, S. Al-Batran, E. Jaeger, B. Schmidt, M. Bausch, C. Unger, and N. Sethuraman

A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2533. [Abstract]  

S. Fu, L. Chintala, D. Madoff, D. S. Hong, A. Naing, S. L. Moulder, J. J. Wheler, C. S. Ng, J. Lim, M. Patterson, and R. Kurzrock

A phase I study of hepatic arterial infusion of oxaliplatin plus intravenous fluorouracil, leucovorin, and bevacizumab in patients with predominant hepatic metastases
J Clin Oncol (Meeting Abstracts) 2008 26: 2534. [Abstract]  

Y. Ogata, Sr., Y. Akagi, T. Sasatomi, S. Mori, N. Ishibashi, K. Shiouzu, T. Tanaka, Y. Tsuji, S. Sueyoshi, and M. Isobe

Phase I/II study of metronomic chemotherapy using S-1 and irinotecan in patients with advanced colorectal cancer (KSCOG CR-01)
J Clin Oncol (Meeting Abstracts) 2008 26: 2535. [Abstract]  

S. Silberman, J. H. Hwang, J. L. Marshall, T. Ahmed, M. Basche, A. L. Cohn, M. R. Modiano, G. Tapolsky, S. Yancik, and L. Pugliese

A phase I study of TPI 287, a novel taxane, administered weekly in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 2536. [Abstract]  

M. E. Bonneterre, N. Penel, T. Bachelot, L. Pascal, J. Y. Blay, J. Delord, A. Adenis, and J. Bonneterre

Development and validation of a prediction model for early death among cancer patients participating in phase I clinical trials of new cytotoxic agents
J Clin Oncol (Meeting Abstracts) 2008 26: 2537. [Abstract]  

H. A. Burris, III, J. R. Infante, D. R. Spigel, F. A. Greco, D. S. Thompson, S. Matsumoto, S. Kawamura, and S. F. Jones

A phase I dose-escalation study of NK012
J Clin Oncol (Meeting Abstracts) 2008 26: 2538. [Abstract]  

B. H. Kim, T. P. Bradley, J. Y. Tai, and D. R. Budman

Five-year analysis of hypersensitivity to oxaliplatin (OXP): Determination of incidence and identification of risk factors
J Clin Oncol (Meeting Abstracts) 2008 26: 2539. [Abstract]  

M. K. Gibson, R. P. Smith, D. E. Heron, R. L. Ferris, S. Y. Lai, S. W. Kim, T. Boyer, J. T. Johnson, J. R. Grandis, and A. E. Argiris

Phase I trial of pemetrexed, cetuximab, and concurrent radiotherapy (RT) in head and neck cancer (HNC)
J Clin Oncol (Meeting Abstracts) 2008 26: 2540. [Abstract]  

A. Omori, A. C. Hoffmann, M. M. Shi, H. J. Lenz, C. O. Michie, C. M. Gourley, J. Cooc, J. S. Clark, K. D. Danenberg, and P. V. Danenberg

Use of ERCC1 gene expression to predict the effectiveness of platin-based therapy in colorectal, ovarian and lung cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 2541. [Abstract]  

J. De Castro, C. Belda-Iniesta, R. Machado-Pinilla, P. Cejas, V. Rodriguez-Fanjul, E. Casado Sáenz, J. Feliú, L. G. Paz-Ares, M. González-Barón, and R. Perona

Use of global expression profile from non-small cell lung carcinoma (NSCLC) surgical samples to predict response to pemetrexed (P)
J Clin Oncol (Meeting Abstracts) 2008 26: 2542. [Abstract]  

M. E. Menefee, H. Huang, M. Edgerly, H. Kotz, M. Merino, F. M. Balis, C. C. Chen, R. Robey, S. E. Bates, and A. T. Fojo

Effects of the P-glycoprotein (Pgp) antagonist tariquidar (XR-9576; TQD) on Pgp function as well as the toxicity and efficacy of combined chemotherapy in patients with metastatic adrenocortical cancer (mACC)
J Clin Oncol (Meeting Abstracts) 2008 26: 2543. [Abstract]  

L. Rodriguez-Rodriguez, N. Muthukumaran, S. Goodin, G. Frenkel, P. Caffrey, D. G. Gibbon, W. Nieves-Neira, A. Vaidya, W. J. Shih, and E. H. Rubin

Serum CD44 levels and response to selenium-based therapy in patients with gynecologic cancers
J Clin Oncol (Meeting Abstracts) 2008 26: 2544. [Abstract]  

T. Gangadhar, E. E. Cohen, L. Janisch, L. K. House, S. D. Undevia, G. F. Fleming, M. L. Maitland, J. Ramirez, and M. J. Ratain

A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 2545. [Abstract]  

W. Zamboni, J. J. Hwang, S. Strychor, B. J. Sidone, B. A. Zamboni, S. M. Malik, K. Catley, K. Grafton, and J. L. Marshall

Pharmacokinetic (PK) and pharmacodynamic (PD) study of the combination of docetaxel (Doc) and oxaliplatin (Ox) in patients (Pts) with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2546. [Abstract]  

B. A. Sparano, M. J. Egorin, R. A. Parise, J. Walters, K. A. Komazec, R. L. Redner, and J. H. Beumer

Effect of antacid co-medication on imatinib disposition: A healthy volunteer study
J Clin Oncol (Meeting Abstracts) 2008 26: 2547. [Abstract]  

C. H. Takimoto, S. Fu, N. Dhillon, M. M. Mita, A. C. Mita, W. Cheung, Y. Xu, A. Ali, A. Johri, and R. Kurzrock

Evaluation of pharmacokinetics (PK) and pharmacodynamics (PD) of patupilone and warfarin in patients (pts) with advanced solid tumors: An open-label, phase I study
J Clin Oncol (Meeting Abstracts) 2008 26: 2548. [Abstract]  

L. S. Schwartzberg, C. F. Stewart, P. Schaiquevich, P. Legenne, K. Bhatt, A. Johns, and M. S. Walker

Phase I dosage-finding and pharmacokinetic (PK) study of intravenous topotecan and oral erlotinib in patients (pts) with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2549. [Abstract]  

D. E. Cole, F. M. Balis, N. Grant, T. White, K. Dunleavy, J. E. Janik, L. Whalen, W. Goodspeed, and W. H. Wilson

Pharmacokinetics (pk) and tolerance of infusional vincristine (vcr) for aggressive lymphomas indicate dose reductions for excretory organ dysfunction are not necessary
J Clin Oncol (Meeting Abstracts) 2008 26: 2550. [Abstract]  

G. A. Milano, T. Besnard, N. Renée, M. Etienne-Grimaldi, J. Mouroux, L. Brouchet, D. Pop, R. Garraffo, and N. Venissac

A novel intra-thoracic hyperthermic schedule combining gemcitabine (Gem) and cisplatin (Pt) in patients with pleural mesothelioma: A pharmacokinetic analysis
J Clin Oncol (Meeting Abstracts) 2008 26: 2551. [Abstract]  

J. Zhang, M. R. Lichinitser, M. Abramov, E. Borisova, A. Lud, P. Scigalla, C. Zergebel, P. D. Urrea, and M. S. Gordon

A phase I study evaluating the effect of oxonic acid (Oxo) as a component of S-1 on the pharmacokinetics (PK) of 5-fluorouracil (5-FU)
J Clin Oncol (Meeting Abstracts) 2008 26: 2552. [Abstract]  

M. J. Dooley, S. G. Poole, and E. Stathakopoulos

Implications on chemotherapy dose selection of the 4-variable Modification of Diet in Renal Disease equation (MDRD) for estimating renal function
J Clin Oncol (Meeting Abstracts) 2008 26: 2553. [Abstract]  

Q. Liu, R. Madabushi, C. Garnett, and B. Booth

Experience in QT evaluation of oncology drug products since ICH E14 guidance
J Clin Oncol (Meeting Abstracts) 2008 26: 2554. [Abstract]  

N. J. Dickgreber, I. Díaz Padilla, L. G. Paz-Ares, L. C. Musib, Z. Yuan, and J. E. Latz

The safety and pharmacokinetics (PK) of pemetrexed (PEM) in patients with third-space fluid (TSF)
J Clin Oncol (Meeting Abstracts) 2008 26: 2555. [Abstract]  

Z. Guo, J. J. Wheler, A. Naing, S. Mani, S. Goel, M. Mulcahy, F. Gamza, C. Longley, A. Buchbinder, and R. Kurzrock

Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: A phase I, first-in-human, dose-escalation study
J Clin Oncol (Meeting Abstracts) 2008 26: 2556. [Abstract]  

T. R. Reid, C. H. Takimoto, C. F. Verschraegen, J. Sarantopoulos, W. Cheung, E. Allen-Freda, J. Li, Y. Xu, J. Ko, and A. Johri

Evaluation of safety, tolerability and pharmacokinetics (PK) of patupilone in patients (pts) with advanced solid tumors and varying degrees of hepatic function: An open-label phase I study
J Clin Oncol (Meeting Abstracts) 2008 26: 2557. [Abstract]  

A. Frost, M. Buechert, C. Unger, O. Christensen, A. Wagner, R. A. Heinig, M. E. Scheulen, D. Strumberg, U. Fasol, and K. Mross

Phase I study of BAY 73–4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study
J Clin Oncol (Meeting Abstracts) 2008 26: 2558. [Abstract]  

A. Iasonos, E. R. Riedel, and D. R. Spriggs

Is the Continual Reassessment Method superior to the standard 3+3 dose escalation scheme?
J Clin Oncol (Meeting Abstracts) 2008 26: 2559. [Abstract]  

C. Sessa, D. Hess, J. Bauer, C. Droege, E. Gallerani, M. Miani, A. Tinazzi, O. Krieter, R. Angst, and C. Nay

Phase I study of the oral platinum agent satraplatin (S) in sequential combination with capecitabine (C) in patients with advanced solid tumours
J Clin Oncol (Meeting Abstracts) 2008 26: 2560. [Abstract]  

G. Saulnier Sholler, W. Ferguson, B. Laurent, G. Johnson, B. Heath, P. Bingham, A. Taka, B. Kamen, and A. Homans

A phase I study of nifurtimox in patients with relapsed/refractory neuroblastoma
J Clin Oncol (Meeting Abstracts) 2008 26: 2561. [Abstract]  

M. B. Jameson, D. Rischin, M. Pegram, J. C. Gutheil, A. Patterson, W. Denny, and W. Wilson

A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2562. [Abstract]  

T. H. Luu, W. A. Chow, D. Lim, M. Koczywas, P. Frankle, M. Cristea, G. Somlo, and R. J. Morgan

Phase I of fixed-dose-rate gemcitabine in combination with bortezomib in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2563. [Abstract]  

R. Bahleda, E. Felip, R. S. Herbst, N. H. Hanna, S. A. Laurie, F. A. Shepherd, J. P. Armand, C. J. Sweeney, E. Calvo-Aller, and J. C. Soria

Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 2564. [Abstract]  

L. Chen, T. Chang, A. Cheng, C. Yang, H. Shiah, J. Chang, and G. Yeh

Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients
J Clin Oncol (Meeting Abstracts) 2008 26: 2565. [Abstract]  

D. Hochhauser, T. Meyer, P. Loadman, V. J. Spanswick, M. Cobb, R. H. Begent, J. Wu, P. H. Clingen, J. A. Hartley, and D. Jodrell

Phase I study of the DNA minor groove binding pyrrolobenzodiazepine dimer (SJG 136) administered every 21 days in patients with advanced solid tumours
J Clin Oncol (Meeting Abstracts) 2008 26: 2566. [Abstract]  

H. H. Doss, S. F. Jones, J. R. Infante, D. R. Spigel, N. Willcutt, R. Lamar, J. Barton, M. Keegan, and H. A. Burris, III

A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2567. [Abstract]  

D. S. Dizon, F. Maluf, C. A. Aghajanian, A. I. Daud, P. Sabbatini, S. Pezzulli, S. Soignet, and D. R. Spriggs

Final results of a phase I study of picoplatin and pegylated liposomal doxorubicin in advanced solid tumor malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 2568. [Abstract]  

S. Kumar, R. S. Marks, R. Richardson, F. Quevedo, G. A. Croghan, S. N. Markovic, R. Qin, A. D. Tan, J. R. Molina, C. E. Erlichman, and A. A. Adjei

A phase I study of the raf kinase/VEGF-R inhibitor sorafenib in combination with bortezomib in patients with advanced malignancy
J Clin Oncol (Meeting Abstracts) 2008 26: 2569. [Abstract]  

T. B. Leal, G. Wilding, J. Eickhoff, D. McNeel, D. Alberti, and G. Liu

Phase I study of satraplatin and docetaxel in solid malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 2570. [Abstract]  

T. D. Tillmanns, R. Buller, C. F. Stewart, J. MacEachern, P. Schaiquevich, M. S. Walker, and E. J. Stepanski

Daily oral topotecan: Utilization of a metronomic dosing schedule to treat recurrent or persistent solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2571. [Abstract]  

F. Fiore, C. D. Gadaleta, C. Granetto, M. Middleton, R. Sorio, R. Labianca, O. Valota, R. N. Pirotta, R. Battaglia, and F. Izzo

Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC)
J Clin Oncol (Meeting Abstracts) 2008 26: 2572. [Abstract]  

R. H. Wilson, R. Plummer, J. Adam, M. M. Eatock, A. V. Boddy, M. Griffin, R. Miller, Y. Matsumura, T. Shimizu, and H. Calvert

Phase I and pharmacokinetic study of NC-6004, a new platinum entity of cisplatin-conjugated polymer forming micelles
J Clin Oncol (Meeting Abstracts) 2008 26: 2573. [Abstract]  

J. Pander, J. Tol, H. Gelderblom, N. F. Antonini, R. J. van der Straaten, C. J. Punt, and H. Guchelaar

Pharmacogenetic (PGx) analysis of toxicity after oxaliplatin (Ox), capecitabine (Cap), bevacizumab (Bev) and cetuximab (Cet) therapy for advanced colorectal cancer (ACC): First results from the Dutch Colorectal Cancer Group (DCCG)-CAIRO2 trial
J Clin Oncol (Meeting Abstracts) 2008 26: 2574. [Abstract]  

G. Del Conte, D. Tosi, A. Fasolo, C. Chiesa, P. Erba, C. M. Grana, H. D. Menssen, G. Mariani, E. Bombardieri, and L. Gianni

A phase I trial of antifibronecitin ¹³¹I-L19-small immunoprotein (L19-SIP) in solid tumors and lymphoproliferative disease
J Clin Oncol (Meeting Abstracts) 2008 26: 2575. [Abstract]  

A. L. Thomas, A. Anthoney, E. Scott, S. Ahmed, A. S. Lundberg, A. Major, R. L. Capizzi, and C. J. Twelves

C-1311, a novel inhibitor of FLT3 and topoisomerase II: A phase 1 trial of a once every three week schedule in patients with advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 2576. [Abstract]  

K. K. Sankhala, C. H. Takimoto, A. C. Mita, H. Xiong, J. Rodon, R. Adinin, K. Burns, T. Toko, K. Arakawa, and S. Kopetz

Two phase I, pharmacokinetic (PK) and pharmacodynamic (PD) studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules
J Clin Oncol (Meeting Abstracts) 2008 26: 2577. [Abstract]  

R. Khosravan, M. Toh, J. LaFargue, G. Ni, and C. Bello

Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis
J Clin Oncol (Meeting Abstracts) 2008 26: 2578. [Abstract]  

J. Brody, W. Z. Ai, D. Czerwinski, R. Advani, S. J. Horning, K. N. Ganjoo, and R. Levy

Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909
J Clin Oncol (Meeting Abstracts) 2008 26: 3003. [Abstract]  

I. D. Davis, B. Brady, R. Kefford, M. J. Millward, B. K. Skrumsager, U. Mouritzen, P. E. Kristjansen, and G. A. McArthur

Activity of recombinant human interleukin-21 (rIL-21) in patients (pts) with stage IV malignant melanoma (MM) without prior treatment: Clinical data from a phase IIa study
J Clin Oncol (Meeting Abstracts) 2008 26: 3042. [Abstract]  

B. R. Tan, B. Zehnbauer, J. Picus, C. Fournier, J. James, A. Brower, and H. McLeod

UGT1A1 genotype-based dose modification of irinotecan regimens: Impact on hematologic toxicities
J Clin Oncol (Meeting Abstracts) 2008 26: 13500. [Abstract]  

E. Sandanaraj, R. Savic, S. Lal, Z. W. Wong, C. S. Ang Peter, N. S. Wong, N. Holford, M. O. Karlsson, and B. Chowbay

Population pharmacokinetics of doxorubicin and doxorubicinol in Asian breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 13501. [Abstract]  

D. G. Power, N. Wu, W. Qin, D. Sully, C. Cisek, J. Randazzo, P. S. Ritch, M. P. Jhawer, D. P. Kelsen, and M. A. Shah

Docetaxel clearance and cisplatin administration: Implications for toxicity of docetaxel, cisplatin, and fluorouracil (DCF) in gastric cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 13502. [Abstract]  

M. Y. Biakhov, D. Kirsanov, G. Kononova, and S. Loibl

A phase I study of nab-paclitaxel in patients (pts) with advanced solid tumors and hepatic dysfunction
J Clin Oncol (Meeting Abstracts) 2008 26: 13503. [Abstract]  

E. G. Feigal, N. Parikh, G. Kottayil, and D. Fisher

Pharmacokinetic profile of fentanyl sublingual (SL) spray
J Clin Oncol (Meeting Abstracts) 2008 26: 13505. [Abstract]  

O. D. Roe, E. Anderssen, E. Helge, C. Hild Hakvaag Pettersen, H. Sandeck, E. Larsson, and S. Lundgren

Overexpression of a set of genes in mesothelioma versus parietal pleura may explain its chemo- and radio-resistance
J Clin Oncol (Meeting Abstracts) 2008 26: 13506. [Abstract]  

M. Kundranda, P. Fu, L. Patrick, S. Manda, J. Gibbons, and A. Dowlati

Shifting of patient characteristics enrolled on phase I clinical trials
J Clin Oncol (Meeting Abstracts) 2008 26: 13507. [Abstract]  

U. Shah, H. K. Sanoff, B. H. O’Neil, T. E. Stinchcombe, K. Keller, D. Carrizosa, C. M. Walko, L. Buie, W. Chiu, and E. C. Dees

A phase I trial of pemetrexed and vinflunine (VFL)
J Clin Oncol (Meeting Abstracts) 2008 26: 13508. [Abstract]  

S. Attia, J. Eickhoff, K. D. Holen, H. Bailey, D. Alberti, G. Wilding, and G. Liu

Phase I study of fixed-dose rate (FDR) gemcitabine with capecitabine in advanced solid malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 13509. [Abstract]  

M. R. Modiano, P. Plezia, M. Basche, A. L. Cohn, Y. Baram, G. Tapolsky, S. Yancik, L. Pugliese, and S. Silberman

A phase I study of TPI 287, a novel taxane, administered every 21 days in patients (pts) with advanced cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 13510. [Abstract]  

Z. Wang, S. Lal, E. Sandanaraj, W. T. Lim, S. S. Leong, E. H. Tan, and B. Chowbay

Phase I dose finding study of Genexol-PM (G-PM) in Asian cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 13512. [Abstract]  

M. Ono, K. Tsuta, K. Yonemori, C. Shimizu, S. Shibui, T. Kouno, M. Ando, K. Tamura, N. Katsumata, and Y. Fujiwara

Existence of blood brain barrier in brain metastases with breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 13513. [Abstract]  

M. Ando, Sr., K. Yonemori, M. Yunokawa, E. Nakano, T. Kouno, C. Shimizu, N. Katsumata, K. Tamura, H. Arioka, and Y. Fujiwara

Phase II study of carboplatin (CBDCA) and irinotecan (CPT-11) for patients with cancer of unknown primary (CUP)
J Clin Oncol (Meeting Abstracts) 2008 26: 13514. [Abstract]  

H. Sayar, C. F. Verschraegen, H. Smith, I. Rabinowitz, F. C. Lee, and Z. Shen

Phase I study of capecitabine (C) in combination with cisplatin (DDP) and irinotecan (IRI) in patients (pts) with advanced solid malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 13515. [Abstract]  

I. Duran, L. L. Siu, A. Jimeno, D. Panisko, and L. Seymour

Development of core competencies in drug development in medical oncology: An unexplored field
J Clin Oncol (Meeting Abstracts) 2008 26: 13516. [Abstract]  

D. P. Petrylak, K. Hood, R. Xu, J. F. Gill, and S. J. Nicol

Phase I trial of pemetrexed (P) plus docetaxel (D) in advanced malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 13517. [Abstract]  

M. J. Borad, J. T. Hamm, L. S. Rosen, G. S. Jameson, J. Utz, M. Mulay, M. Eldon, S. Dhar, L. Acosta, and D. D. Von Hoff

Phase I dose finding and pharmacokinetic study of NKTR-102 (PEGylated irinotecan): Early evidence of anti-tumor activity
J Clin Oncol (Meeting Abstracts) 2008 26: 13518. [Abstract]  

P. B. Murphy, E. Raefsky, H. A. Burris, III III, J. R. Infante, S. F. Jones, D. R. Spigel, N. Dickson, M. Lawton, J. S. Dicksey, and W. P. Peters

A phase I study evaluating a novel schedule of oral eniluracil (EU) combined with escalating doses of oral 5-fluorouracil (5- FU)
J Clin Oncol (Meeting Abstracts) 2008 26: 13519. [Abstract]  

E. Bölke, C. Matuschek, M. Peiper, C. Giro, M. Pelzer, W. Budach, and S. Gripp

Cystatin-C a sensitive diagnostic marker for evaluation of the renal function in patients with cisplatin based chemotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 13520. [Abstract]  

S. Cascinu, R. Labianca, V. Catalano, F. Ferraù, F. Pucci, R. R. Silva, G. Luppi, R. Berardi, and G. D. Beretta

Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: A randomised phase II trial
J Clin Oncol (Meeting Abstracts) 2008 26: 13521. [Abstract]  

F. Nakhl, R. Elsoueidi, F. Forte, J. Lowry, and J. Burton

A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for first-line or greater treatment of selected advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 13522. [Abstract]  

R. A. Hilger, H. Richly, M. Grubert, M. Libicher, D. Strumberg, J. Ebert, D. Hecker, and M. Zähringer

Pharmacokinetics of intra-arterial applied liposomal encapsulated doxorubicin in liver metastases or hepatocellular carcinoma: A phase I study
J Clin Oncol (Meeting Abstracts) 2008 26: 13523. [Abstract]  

R. O’Cearbhaill, A. Barry, D. Griffin, M. Keane, P. Donnellan, and H. Grimes

Evaluation of carboplatin dosage based on a body surface area adjusted 4-variable modification of diet in renal disease (MDRD) equation
J Clin Oncol (Meeting Abstracts) 2008 26: 13524. [Abstract]  

S. G. Holtan, N. R. Foster, C. E. Erlichman, M. Aubry, M. M. Ames, S. Safgren, P. D. Steen, R. F. Morton, D. Graham, and M. P. Goetz

Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial
J Clin Oncol (Meeting Abstracts) 2008 26: 13525. [Abstract]  

F. W. Harper, E. I. Heath, M. E. Gleason, P. M. LoRusso, and T. L. Albrecht

Objective versus subjective predictors of patient clinical benefit from phase I treatment
J Clin Oncol (Meeting Abstracts) 2008 26: 13526. [Abstract]  

Y. Goto, I. Sekine, K. Yamada, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, and T. Tamura

Differences in the toxicity and efficacy in phase I studies between cytotoxic and molecular-targeted therapies
J Clin Oncol (Meeting Abstracts) 2008 26: 13527. [Abstract]  

R. D. Pentz, Z. Xu, S. Lonial, J. S. Kauh, R. M. O’Regan, E. K. Waller, D. M. Shin, H. Fu, and F. Khuri

Research participants’ views of nontherapeutic biopsies
J Clin Oncol (Meeting Abstracts) 2008 26: 13529. [Abstract]  

C. Ho, A. M. Davies, P. N. Lara, H. K. Chew, L. Beckett, R. S. Sangha, P. C. Mack, and D. R. Gandara

Phase I trial of combination nab-paclitaxel and pemetrexed in advanced solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 13530. [Abstract]  

M. Airoldi, L. Cattel, P. Milla, R. Passera, F. Pedani, and A. Crova

Parmacokinetics (PK) of oral vinorelbine (VNR) in association with pegylated liposomal doxorubicin (PLD) in metastatic ovarian carcinoma
J Clin Oncol (Meeting Abstracts) 2008 26: 13531. [Abstract]  

H. Russell, M. S. Cairo, S. M. Blaney, P. C. Adamson, A. M. Ingle, and S. Berg

Phase I trial and pharmacokinetics (PK) of lenalidomide in pediatric patients with relapsed/refractory solid tumors or MDS: A Children’s Oncology Group phase I consortium study
J Clin Oncol (Meeting Abstracts) 2008 26: 13532. [Abstract]  

J. M. Brell, J. A. Bokar, M. M. Cooney, S. S. Krishnamurthi, J. Gibbons, C. J. Nock, P. Savvides, E. Batts, S. P. Ivy, and A. Dowlati

Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 13533. [Abstract]  

P. Marchetti, I. Paris, G. Antonini Cappellini, A. Romiti, P. Malaguti, A. Viterbo, A. De Blasi, A. M. Lostia, L. Lionetto, and M. Simmaco

Dihydropyrimidine dehydrogenase (DPD) evaluation in 5-fluorouracil (5FU)-based therapies for gastrointestinal (GIC) and breast cancer (BC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2008 26: 13535. [Abstract]  

A. S. Lundberg, M. R. Baer, M. Chau, H. P. Erba, A. L. Dressel, A. M. Ajami, and R. L. Capizzi

Blast cells from patients treated for secondary AML (sAML) show less P-glycoprotein (Pgp)-mediated efflux of amonafide compared to daunorubicin: Implications for therapy
J Clin Oncol (Meeting Abstracts) 2008 26: 13536. [Abstract]  

E. Prasad

Maximum tolerated dose–Results of a phase I trial of paclitaxel and cisplatin with radiation therapy in carcinoma of the cervix
J Clin Oncol (Meeting Abstracts) 2008 26: 13537. [Abstract]  

M. Q. Baggstrom, A. Ravaud, and P. M. Fracasso

Patupilone combined with carboplatin in patients (pts) with advanced solid tumors: Preliminary safety and activity results
J Clin Oncol (Meeting Abstracts) 2008 26: 13538. [Abstract]  

L. I. Chap, I. Laux, A. Van Vugt, A. M. Silva, A. Khashi, J. Zhang, C. Zergebel, P. D. Urrea, and L. S. Rosen

A phase I study of S-1 GI toxicity with and without oxonic acid (Oxo)
J Clin Oncol (Meeting Abstracts) 2008 26: 13539. [Abstract]  

J. Lyandres, M. M. Moasser, M. Melisko, A. Goga, J. W. Park, and H. S. Rugo

Phase I study of sunitinib (S) in combination with metronomic dosing of cyclophosphamide and methotrexate (CM) in patients with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 13540. [Abstract]  

T. Cil, A. Altintas, S. Pasa, M. A. Kaplan, S. Alan, and A. Isikdogan

NT-Probnp levels to perspectively assess acut cardiac failure after adjuvant doxorubicine therapy in early breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 13541. [Abstract]  

R. Yoshikawa, T. Hashimoto-Tamaoki, M. Gega, T. Yagyu, M. Noda, and H. Yanagi

Effect of setting of drug holidays on the efficacy of weekly higher shorter plus lower continuous (metronomic) five-fluorouracil (5-FU) concentration regimen in colorectal cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 13542. [Abstract]  

J. Ma, J. Zhang, S. Zhou, J. L. Hubbs, R. J. Foltz, D. R. Hollis, K. L. Light, T. Z. Wong, C. R. Kelsey, and L. B. Marks

The association between RT-induced changes in lung density and global lung function
J Clin Oncol (Meeting Abstracts) 2008 26: 13543. [Abstract]  

P. M. Fracasso, A. Ravaud, M. Q. Baggstrom, P. M. LoRusso, D. V. Jones, C. Sguotti, P. Urban, B. Gao, and J. Medioni

Patupilone combined with carboplatin in patients (pts) with advanced solid tumors: preliminary safety and activity results
J Clin Oncol (Meeting Abstracts) 2008 26: 13544. [Abstract]  

L. C. Pagliaro, N. M. Tannir, S. Tu, B. Moomey, C. M. Carter, N. Bekele, and P. Mathew

A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer with prior taxane therapy
J Clin Oncol (Meeting Abstracts) 2008 26: 13545. [Abstract]  

Z. Atassi, V. Heilmann, N. Hauser, P. C. Hartmann, R. Kreienberg, and C. Kurzeder

Pharmacokinetics, safety and efficacy of pegfilgrastim in dose-dense, sequential adjuvant chemotherapy for patients with breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2008 26: 13546. [Abstract]  

R. A. Nagourney, J. Blitzer, D. McConnell, R. Shuman, S. Grant, K. Azaren, I. Shbeeb, T. Ascuito, B. Sommers, and M. Paulsen

Clinical application of functional profiling in advanced NSCLC and colorectal cancers
J Clin Oncol (Meeting Abstracts) 2008 26: 13547. [Abstract]  

M. Kawahara, A. Kubo, K. Komuta, M. Fukushima, T. Daimon, K. Furuse, and T. Mio

A phase I study of amrubicin (AMR) and irinotecan (CPT-11) in relapsed small cell lung cancer(SCLC)
J Clin Oncol (Meeting Abstracts) 2008 26: 13548. [Abstract]  

J. Schupp, L. P. Lopez, J. M. Robbins, L. Arboit, H. Requejo, G. Arroyo, C. Blajman, L. Fein, M. Chacón, and P. Quintana

Tolerability and incidence of infusion site reactions with emulsion formulation of vinorelbine (ANX-530) compared to vinorelbine solution
J Clin Oncol (Meeting Abstracts) 2008 26: 13549. [Abstract]  

M. S. Gonzalez, J. Rebollo, V. Escudero, B. Valenzuela, R. Nalda, M. Duart, and A. Brugarolas

Pharmacokinetic (pk) guide for dose adjustments in cancer patients (pts) treated with 5-fluoruracil (5-fu) infusions. Preliminary results
J Clin Oncol (Meeting Abstracts) 2008 26: 13550. [Abstract]  

K. K. Curtis, R. C. Jewell, J. T. Hartney, P. P. Griffin, T. R. Fitch, and D. W. Northfelt

Phase I study to characterize pharmacokinetics (PK) of topotecan (T) at 4 mg/m² administered weekly as a 30-minute IV infusion
J Clin Oncol (Meeting Abstracts) 2008 26: 13551. [Abstract]  

N. H. Yamaguchi, M. T. Arruda, S. M. Nikaedo, F. K. Ikan, T. Takagaki, and J. R. Pereira

An exploratory analysis of gemcitabine/vinorelbine/cisplatin in 83 patients with advanced NSCLC in a single brazilian institution
J Clin Oncol (Meeting Abstracts) 2008 26: 13552. [Abstract]  

H. Rubie, D. Frappaz, A. Defachelles, A. Ndiaye, N. Dias, I. Aerts, J. Gentet, L. Djafari, M. Jaworski, G. Vassal, and B. Geoerger

Phase I study of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed malignant tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 13553. [Abstract]  

K. Wisinski, M. Mulcahy, T. M. Kuzel, A. B. Benson, III, M. Agulnik, G. R. MacVicar, D. Desai, S. Yun, M. Petrone, and W. Gradishar

A phase I study of the oral platinum agent satraplatin (S) in with capecitabine (C) in patients (pts) with advanced solid malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 13554. [Abstract]  

J. Bennouna, J. B. Vermorken, H. Senellart, C. Valverde, S. Altintas, V. Aslanis, M. Brandely, and E. Calvo-Aller

Phase I dose-escalation study of oral vinflunine given twice a day for 2 consecutive days every week in patients with solid tumours
J Clin Oncol (Meeting Abstracts) 2008 26: 13555. [Abstract]  

E. Assenat, A. Kramar, P. Senesse, E. Samalin, F. Portales, and M. Ychou

A phase I trial of a bi-weekly combination of capecitabine/irinotecan (XELIRI) in solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 13556. [Abstract]  

B. Chen, Sr., J. Wang, C. Gao, J. Ding, Y. Sun, F. Gao, J. Cheng, G. Zhao, and N. Chen

Reversal of P-glycoprotein-dependent resistance to adriamycin by 5-bromotetrandrine in K562/A02 cell line
J Clin Oncol (Meeting Abstracts) 2008 26: 13557. [Abstract]  

Developmental Therapeutics: Immunotherapy:

S. Parsons, P. X. Murawa, P. Koralewski, E. Kutarska, O. O. Kolesnik, M. A. Stroehlein, A. Lahr, M. Jaeger, and M. M. Heiss

Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study
J Clin Oncol (Meeting Abstracts) 2008 26: 3000. [Abstract]  

R. J. Kreitman, W. H. Wilson, M. Stetler-Stevenson, P. Noel, D. J. FitzGerald, and I. Pastan

Pharmacokinetics of recombinant immunotoxin BL22 during phase II testing in chemo-resistant hairy cell leukemia
J Clin Oncol (Meeting Abstracts) 2008 26: 3001. [Abstract]  

S. Shusterman, W. B. London, S. D. Gillies, J. A. Hank, S. Voss, R. C. Seeger, T. Hecht, R. A. Reisfeld, J. M. Maris, and P. M. Sondel

Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children’s Oncology Group (COG) phase II study
J Clin Oncol (Meeting Abstracts) 2008 26: 3002. [Abstract]  

H. L. Kaufman, S. Kim-Schulze, D. Kim, D. Moroziewicz, G. DeRaffele, J. Mitcham, W. H. Shingler, R. Harrop, and S. Naylor

Correlation of effector and regulatory T cell responses with clinical outcome in metastatic renal cell carcinoma patients treated with MVA-5T4 vaccine and high-dose interleukin-2
J Clin Oncol (Meeting Abstracts) 2008 26: 3004. [Abstract]  

R. A. Madan, J. L. Gulley, W. L. Dahut, K. Y. Tsang, S. M. Steinberg, J. Schlom, and P. M. Arlen

Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): Implications for clinical trial design
J Clin Oncol (Meeting Abstracts) 2008 26: 3005. [Abstract]  

J. R. Brahmer, S. Topalian, I. Wollner, J. D. Powderly, J. Picus, C. Drake, J. Covino, A. Korman, D. Pardoll, and I. Lowy

Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 3006. [Abstract]  

M. Sznol, F. S. Hodi, K. Margolin, D. F. McDermott, M. S. Ernstoff, J. M. Kirkwood, C. Wojtaszek, D. Feltquate, and T. Logan

Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)
J Clin Oncol (Meeting Abstracts) 2008 26: 3007. [Abstract]  

F. S. Hodi, A. Hoos, R. Ibrahim, K. Chin, H. Pehamberger, K. Harmankaya, S. O'Day, O. Hamid, R. Humphrey, and J. Wolchok

Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody
J Clin Oncol (Meeting Abstracts) 2008 26: 3008. [Abstract]  

L. A. Emens, J. M. Asquith, J. M. Leatherman, M. M. Daphtary, S. Petrik, J. H. Fetting, M. L. Disis, S. Piantadosi, N. E. Davidson, and E. M. Jaffee

Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine
J Clin Oncol (Meeting Abstracts) 2008 26: 3009. [Abstract]  

T. M. Clay, A. Hobeika, T. Osada, D. Serra, D. Niedzwiecki, H. K. Lyerly, and M. A. Morse

Depletion of human regulatory T cells (Treg) and antigen-specific immune responses to cancer vaccines
J Clin Oncol (Meeting Abstracts) 2008 26: 3010. [Abstract]  

A. Naing, J. M. Reuben, C. F. Verschraegen, L. H. Camacho, S. Stephen, D. S. Hong, J. J. Wheler, S. Fu, M. Martinez, L. Akinsanmi, and R. Kurzrock

Phase I dose-escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon-alfa for patients with solid tumors
J Clin Oncol (Meeting Abstracts) 2008 26: 3011. [Abstract]  

H. Loibner, H. Eckert, W. Stoiber, F. Groiss, and E. Stoelben

Randomized double-blind placebo-controlled phase II/III trial in adjuvant NSCLC patients with the candidate cancer vaccine IGN101
J Clin Oncol (Meeting Abstracts) 2008 26: 3012. [Abstract]  

M. B. Faries, R. Essner, X. Ye, M. Hoban, and D. L. Morton

Humoral shift and increased early recurrence with GM-CSF + vaccine versus vaccine alone
J Clin Oncol (Meeting Abstracts) 2008 26: 3013. [Abstract]  

P. Filipazzi, L. Pilla, R. Patuzzo, C. Castelli, A. Maurichi, G. Tragni, M. Maio, G. Parmiani, M. Santinami, and L. Rivoltini

Adjuvant multipeptide vaccination in high-risk early melanoma patients
J Clin Oncol (Meeting Abstracts) 2008 26: 3014. [Abstract]  

M. L. Disis, J. H. Strickler, D. Wallace, V. Goodell, L. G. Salazar, D. Higgins, J. Childs, K. Tietje, Y. Dang, and M. Slota

Cellular immune parameters associated with improved long-term survival in advanced stage breast cancer patients after active immunization with a HER2-specific vaccine
J Clin Oncol (Meeting Abstracts) 2008 26: 3015. [Abstract]  

L. C. Benavides, J. P. Holmes, J. D. Gates, M. G. Carmichael, M. T. Hueman, E. A. Mittendorf, E. von Hofe, S. Ponniah, and G. E. Peoples

Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03
J Clin Oncol (Meeting Abstracts) 2008 26: 3016. [Abstract]  

S. M. Schmidt, M. Haentschel, M. R. Mueller, J. Wierecky, L. Kanz, O. Maksimovic, A. Stenzl, W. Brugger, S. Pascolo, and P. Brossart

Vaccinations with RNA coding for tumor associated antigens in advanced RCC patients—A phase I/II study
J Clin Oncol (Meeting Abstracts) 2008 26: 3017. [Abstract]  

W. J. Urba, J. S. Weber, S. J. O'Day, J. D. Powderly, M. J. Yellin, G. Nichol, and E. M. Hersh

Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing)
J Clin Oncol (Meeting Abstracts) 2008 26: 3018. [Abstract]  

A. Sharabi, M. Aldrich, and S. Chen

Function of Twist-2 as an antigen presentation attenuator and effect on potency of dendritic cells for immunotherapy
J Clin Oncol (Meeting Abstracts) 2008 26: 3019. [Abstract]  

J. D. Wolchok, R. Ibrahim, V. DePril, M. Maio, P. Queirolo, K. Harmankaya, L. Lundgren, A. Hoos, R. Humphrey, and O. Hamid

Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment
J Clin Oncol (Meeting Abstracts) 2008 26: 3020. [Abstract]  

F. Ghiringhelli, C. Menard, C. Mateus, S. Horn, L. Zitvogel, and C. Robert

Effect of CTLA-4 blockade on lymphocyte resistance to regulatory T cells in advanced melanoma and use as a surrogate marker of efficacy of tremelimumab
J Clin Oncol (Meeting Abstracts) 2008 26: 3021. [Abstract]  

D. Berman, S. M. Parker, S. D. Chasalow, J. Siegel, Z. Tsuchihashi, D. Wu, K. Bennett, S. Alaparthy, A. Ronczka, and S. Galbraith

Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide
J Clin Oncol (Meeting Abstracts) 2008 26: 3022. [Abstract]  

N. Lewis, L. S. Rosen, C. Rocha Lima, J. L. Marshall, S. F. Jones, R. B. Cohen, L. Kunkel, S. Stewart, and H. A. Burris, III

Phase I experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2008 26: 3023. [Abstract]  

G. Deng, H. L. Smith-Jones, A. D. Seidman, M. Fornier, G. D'Andrea, K. Wesa, S. Cunningham-Rundles, K. S. Yeung, A. Vickers, and B. R. Cassileth

A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2008 26: 3024. [Abstract]  

A. M. Scott, R. A. Herbertson, F. T. Lee, B. Chappell, N. Micallef, S. T. Lee, T. Saunder, W. Hopkins, F. E. Smyth, and N. C. Tebbutt

Phase I biodistribution study of Le^y targeting immunoconjugate in advanced epithelial cancers
J Clin Oncol (Meeting Abstracts) 2008 26: 3025. [Abstract]  

M. A. Castro, G. Cinat, M. Guthmann, M. R. Gabri, D. F. Alonso, and L. Fainbom

A phase II trial of N-Acetyl-GM3/VSSP vaccine in high-risk resected melanoma patients (pts). Does vaccination modify melanoma outcome after relapse?
J Clin Oncol (Meeting Abstracts) 2008 26: 3026. [Abstract]  

S. Motohashi, K. Nagato, T. Fujisawa, M. Taniguchi, I. Yoshino, and T. Nakayama

A phase I/II study of Galactosylceramide-pulsed dendritic cells in patients with advanced or recurrent non-small cell lung cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 3027. [Abstract]  

K. S. Anderson, N. Ramachandran, J. Wong, E. Hainsworth, G. Dranoff, and J. LaBaer

Immune monitoring of antibody responses to complex immunotherapies using custom protein microarrays
J Clin Oncol (Meeting Abstracts) 2008 26: 3028. [Abstract]  

H. Ueno, L. Bourdery, J. Blanck, J. W. Fay, J. Banchereau, and A. K. Palucka

Induction of broad repertoire of melanoma associated antigen-specific CD4+ T cells by dendritic cell vaccine loaded with killed allogeneic melanoma cells in patients with metastatic melanoma
J Clin Oncol (Meeting Abstracts) 2008 26: 3029. [Abstract]  

A. Kotsakis, K. Vetsika, N. Christou, M. Drogaris, N. Pantazopoulos, D. Aggouraki, G. Konsolakis, K. Kosmatopoulos, D. Mavroudis, and V. Georgoulias

Clinical and immunologic response of patients with advanced solid tumors vaccinated with an optimized cryptic hTERT peptide (Vx-001)
J Clin Oncol (Meeting Abstracts) 2008 26: 3030. [Abstract]  

M. Noguchi, S. Todo, H. Yanagimoto, R. Yamanaka, T. Kamura, K. Matsumoto, T. Mine, A. Yamada, and K. Itoh

Immunologic and clinical effects of personalized selection of peptide vaccines in HLA-A2 positive patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 3031. [Abstract]  

M. R. Theoret, C. J. Cohen, M. E. Dudley, R. A. Morgan, and S. A. Rosenberg

In vitro and in vivo studies of human lymphocytes genetically engineered to express T cell receptors that recognize a p53 antigenic epitope
J Clin Oncol (Meeting Abstracts) 2008 26: 3032. [Abstract]  

X. Liang, J. Tolar, J. S. Miller, T. W. LeBien, B. R. Blazar, and W. Chen

Toll-like receptor 7 agonist induces apoptosis of human B-lineage acute lymphocytic leukemia cells in vitro and in vivo
J Clin Oncol (Meeting Abstracts) 2008 26: 3033. [Abstract]  

L. G. Lum, Z. Al-Kadhimi, C. Skuba, R. Sandborg, R. Rathore, Q. Liu, J. P. Uberti, and V. Ratanatharathorn

Phase I immunotherapy in women with metastatic breast cancer with activated T cells targeted with anti-CD3 x anti-Her2/neu bispecific antibody
J Clin Oncol (Meeting Abstracts) 2008 26: 3034. [Abstract]  

M. Mohebtash, R. A. Madan, J. L. Gulley, J. Jones, M. Pazdur, M. Rauckhorst, J. Schlom, and P. M. Arlen

PANVAC vaccine alone or with docetaxel for patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 3035. [Abstract]  

L. G. Salazar, R. Swensen, V. Markle, A. Coveler, B. Royer, Y. Dang, M. Slota, J. Childs, D. Wallace, and M. L. Disis

Phase I study of intraperitoneal (IP) denileukin diftitox in patients with advanced ovarian cancer (OC)
J Clin Oncol (Meeting Abstracts) 2008 26: 3036. [Abstract]  

D. G. Bebb, A. M. Brade, C. Smith, S. Rorke, and I. Sherman

Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy
J Clin Oncol (Meeting Abstracts) 2008 26: 3037. [Abstract]  

R. Digumarti, P. P. Bapsy, and J. S. Shan

A phase Ib safety and pharmacokinetic study of bavituximab plus chemotherapy in patients with refractory advanced solid tumor malignancies
J Clin Oncol (Meeting Abstracts) 2008 26: 3038. [Abstract]  

I. Pastan, W. H. Wilson, M. Stetler-Stevenson, P. Noel, D. J. Fitzgerald, and R. J. Kreitman

Early phase I results of recombinant immunotoxin HA22 in patients with B-cell leukemia
J Clin Oncol (Meeting Abstracts) 2008 26: 3039. [Abstract]  

N. Wallis, C. A. Bulanhagui, P. C. Dorazio, D. I. Healey, M. A. Marshall, J. Q. Liang, D. Pavlov, and J. Gomez-Navarro

Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 3040. [Abstract]  

H. Schmidt, P. Selby, U. Mouritzen, U. H. Thelin, P. E. Kristjansen, and P. Geertsen

Subcutaneous (SC) dosing of recombinant human interleukin-21 (rIL-21) is safe and has clinical activity: Results from a dose-escalation study in stage 4 melanoma (MM) or renal cell cancer (RCC)
J Clin Oncol (Meeting Abstracts) 2008 26: 3041. [Abstract]  

D. M. Goldenberg, C. Chang, E. A. Rossi, T. M. Cardillo, W. A. Wegener, N. Teoh, J. P. Leonard, L. E. Fayad, B. Coiffier, and F. Morschhauser

Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab
J Clin Oncol (Meeting Abstracts) 2008 26: 3043. [Abstract]  

M. Skoberne, A. Yewdall, K. S. Bahjat, E. Lemmens, W. Liu, P. Lauer, W. Luckett, T. W. Dubensky, D. G. Brockstedt, and N. Bhardwaj

Use of KBMA Listeria monocytogenes as an antigen loading platform for dendritic cell-mediated induction of antitumor immunity
J Clin Oncol (Meeting Abstracts) 2008 26: 3044. [Abstract]  

R. J. Brentjens, D. Hollyman, M. Weiss, J. Stefanski, M. Przybylowski, S. Bartido, O. Borquez-Ojeda, C. Taylor, M. Heaney, I. Riviere, and M. Sadelain

A phase I trial for the treatment of purine analog-refractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specific antigen CD19
J Clin Oncol (Meeting Abstracts) 2008 26: 3045. [Abstract]  

J. C. Becker, M. Wobser, V. Hofmeister, B. Bauer, E. B. Broecker, P. thor Straten, and M. H. Andersen

Safety, immunogenicity, and clinical response of a survivin-based peptide vaccine in therapy-resistant advanced cancer: Results from a phase I/II trial
J Clin Oncol (Meeting Abstracts) 2008 26: 3046. [Abstract]  

N. R. Murray, C. Butts, C. Smith, P. M. Ellis, K. Jasas, A. Maksymiuk, G. Goss, G. Ely, and D. Soulieres

A multicenter, open-label, phase I/II study in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with L-BLP25: 2-year survival and safety results
J Clin Oncol (Meeting Abstracts) 2008 26: 3047. [Abstract]  

M. N. Jure-Kunkel, G. Masters, E. Girit, G. Dito, and F. Y. Lee

Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in combination with ixabepilone in preclinical tumor models
J Clin Oncol (Meeting Abstracts) 2008 26: 3048. [Abstract]  

A. K. Palucka, E. Akagawa, H. Ueno, J. Fay, and J. Banchereau

LPS activated dendritic cell vaccine in combination with immunomodulatory dose of cyclophosphamide in patients with stage IV melanoma: Preliminary report from the phase I/IIa clinical trial
J Clin Oncol (Meeting Abstracts) 2008 26: 3049. [Abstract]  

A. Jakobovits, J. Gudas, Z. An, N. Ganguly, K. R. Morrison, K. J. Morrison, A. B. Raitano, D. Satpaev, X. Jia, and S. B. Kanner

AGS-16M18: A novel therapeutic human monoclonal antibody for the treatment of kidney and liver cancers
J Clin Oncol (Meeting Abstracts) 2008 26: 3050. [Abstract]  

A. B. Brown, L. M. Krug, P. Maslak, L. P. James, T. Dao, L. Tyson, S. M. Chanel, S. Bekele, and D. A. Scheinberg

Pilot trial of a Wilms tumor-1 (WT1) peptide vaccine in patients with thoracic and myeloid neoplasms
J Clin Oncol (Meeting Abstracts) 2008 26: 3051. [Abstract]  

E. P. Hui, B. B. Ma, S. L. Chan, R. Ho, W. L. Wong, G. S. Taylor, N. M. Steven, A. B. Rickinson, and A. T. Chan

Therapeutic vaccination with modified vaccinia Ankara (MVA) encoding Epstein-Barr virus (EBV) target antigens in EBV+ nasopharyngeal carcinoma (NPC)
J Clin Oncol (Meeting Abstracts) 2008 26: 3052. [Abstract]  

R. Harrop, C. Macdermott, A. Shablak, C. Hamer, F. Thistlethwaite, N. L. Drury, P. Chikoti, W. H. Shingler, S. Naylor, and R. Hawkins Prof

Vaccination of renal cell cancer patients with TroVax (modified vaccinia Ankara delivering the tumor antigen 5T4) plus IFN: A phase II trial
J Clin Oncol (Meeting Abstracts) 2008 26: 3053. [Abstract]  

A. Letsch, O. Elisseeva, C. Scheibenbogen, A. Asemissen, D. Stather, A. Busse, Y. Oka, U. Keilholz, H. Sugiyama, and E. Thiel

Effect of vaccination of leukemia patients with a MHC class I peptide of Wilms tumor gene 1 (WT1) peptide with unspecific T helper stimulation on WT1-specific IgM responses and on IgG responses
J Clin Oncol (Meeting Abstracts) 2008 26: 3054. [Abstract]  

C. Wiltschke, U. Wiedermann, R. Zurbriggen, K. Elandt, K. Brämswig, J. Jasinska, H. Pehamberger, O. Scheiner, and C. C. Zielinski

A phase I study to evaluate safety, immunogenicity and antitumor activity of a HER2 multi-peptide virosome vaccine in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2008 26: 3055. [Abstract]  

P. Ginopoulos, J. Giannios, E. Seraj, J. Peristeris, and N. Alexandropoulos

Eradication of osteolytic and osteoblastic metastases of HRBC with pegylated trispecific disulfide linked Fv (sdFv) targeting epitopes of EGFr, PTHrP, and RANKL conjugated to vinorelbine
J Clin Oncol (Meeting Abstracts) 2008 26: 3056. [Abstract]  

C. A. Bulanhagui, J. Gomez-Navarro, S. Antonia, J. A. Sosman, J. M. Kirkwood, B. G. Redman, T. F. Gajewski, A. Ribas, L. H. Camacho, and D. Pavlov

Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma
J Clin Oncol (Meeting Abstracts) 2008 26: 3057. [Abstract]  

L. Wu, M. Adams, P. Schafer, G. Muller, D. Stirling, and B. Bartlett

Effect of lenalidomide and pomalidomide combined with IgG1-isotype antibodies on antibody-dependent cellular cytotoxicity (ADCC) via cytokine signaling and effector cell granzyme B and FasL expression
J Clin Oncol (Meeting Abstracts) 2008 26: 3058. [Abstract]